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Abstract 
The thiazolidinediones rosiglitazone and pioglitazone were introduced in 2000 for the 
treatment of type 2 diabetes. They have a novel n1ode of action as peroxiso1ne 
proliferator-activated receptor-y agonists and reduce insulin resistance. There is 
evidence frmn previous work that although rosiglitazone and pioglitazone have shnilar 
effects on blood glucose and glycosylated haemoglobin their effect on sermn lipid 
concentrations is different. Rosiglitazone increases total and LDL-cholesterol, both 
drugs increase HDL-cholesterol and pioglitazone reduces triglyceride. This difference 
remains to be explained and has implications for clinical usage. 
The aim of this study was to compare the effect of pioglitazone and rosiglitazone on 
lipoprotein 1netabolisn1. 24 subjects with type 2 diabetes of more than 6 months duration 
were randomised to 3 months treatlnent with rosiglitazone 8mg, pioglitazone 30mg or 
placebo. Before and after treatment, fractional secretion and catabolic rates of VLDL, 
IDL and LDL apo BlOO was measured using a 10 hour infusion ofl-13C leucine. 
Subjects were middle-aged/elderly (tnean age 62.75 years ± 1.93), mostly male (18 
male, 6 female), overweight/obese (mean Bl\III 30.92kg!tn2 ± 0.82) with well controlled 
diabetes (mean HbAlc 7.02% ± 0.15), and lipids (mean total cholesterol 4.9hnmol/l ± 
0.17, tnean HDL cholesterol 1.21mmolll ± 0.06, median triglyceride 1.61mmol/l [1.22, 
1.97]) at baseline. Following treatment there was a significant reduction in HbA1c in the 
rosiglitazone (-0.48%, p < 0.05) and the pioglitazone group (-0.71%, p < 0.05), a 
significant reduction in :fi:ee fatty acids in both active treatment groups but no change in 
any other lipid variable. There was a significant reduction in VLDL apo B absolute 
secretion rate in the rosiglitazone group (-2.19tng/kg/day, p = 0.017) but no change in 
catabolic rate in any group and no change in IDL or LDL metabolistn. These results 
were not as expected and reasons for this are discussed. 
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Introduction 
Diabetes Mellitus 
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycaetnia 
resulting :fi·om defects in insulin secretion, insulin action, or both. The chronic 
hyperglycaemia of diabetes is associated with long-tenn damage, dysfunction, and 
failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels 
(American Diabetes Association, 2004). Diabetes mellitus was probably first described 
by the Ancient Egyptians in 1500 B.C. The word diabetes comes from the Greek word 
for siphon and was first used by Aretaeus of Cappadocia (A.D. 81-138). The word 
mellitus derives :fi·om the word for 'honey sweet' and was added by Cullen (1710-1790) 
referring to the sweet taste of serum and urine from people with diabetes. The cardinal 
symptoms of the disease; polyuria, thirst, polydipsia and weight loss were described by 
Celsus (30 B.C.-A.D. 50) and in Chinese writings (A.D. 200-600) (Hazlett, 2000). Two 
early Hindu physicians, Sushruta and Charaka (1000 B.C.) described syndromes 
interpreted to represent 2 forms of diabetes, one was associated with emaciation, 
dehydration, polyuria and lassitude and the other associated with stout build, gluttony, 
obesity and sleepiness. 
Nowadays the American Diabetes Association criteria for diagnosis of diabetes mellitus 
are a fasting plasma glucose greater than or equal to 7.0mmoVL, a random plastna 
glucose of greater than or equal to ll.hnmol/L with symptoms, or a plasma glucose 
greater than or equal to 11.1mmol/L 2 hours after a 75g oral glucose tolerance test 
(Davidson, 2000). The vast majority of cases of diabetes fall into two broad groups. In 
the first, type 1 diabetes, the cause is an absolute deficiency of insulin secretion due to 
immune tnediated destruction of pancreatic P-cells. Individuals at increased risk of 
developing this type of diabetes can often be identified by the presence of circulating 
auto-antibodies directed against the islet cells of the pancreas and by genetic markers. In 
the other, much more prevalent category, type 2 diabetes, the cause is a combination of 
resistance to insulin action and an inadequate compensatory insulin secretory response 
(American Diabetes Association, 2004). The classification of diabetes is summarised in 
Table 1. 
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Table 1 Classification of Diabetes Mellitus 
I. Type 1 diabetes (8-cell destruction, usually leading to absolute insulin 
deficiency) 
A. ltmnune tnediated 
B. Idiopathic 
n. Type 2 diabetes (may range from predominantly insulin resistance with 
relative insulin deficiency to a predominantly secretory defect with insulin 
resistance) 
ill. Other specific types 
A. Genetic defects of B-cell function 
B. Genetic defects in insulin action 
c. Diseases ofthe exocrine pancreas 
D. Endocrinopathies 
E. Drug- or chetnical-induced 
F. Infections 
G. Uncommon forms of immune-mediated diabetes 
H. Other genetic syndron1es sometimes associated with diabetes 
IV Gestational diabetes mellitus 
Epidemiology of Diabetes 
In the UK the cmnulative risk of developing type 1 diabetes by the age of 20 years is 
0.3-0.4% (Lambert and Bingley, 2002). Type 2 diabetes is much more co1m11on, with a 
prevalence of about 2% in the UK, undiagnosed type 2 diabetes probably affects another 
2% of the population over 40. 
Type 2 diabetes typically affects adults over the age of 40 years and is strongly 
associated with obesity, inactivity, fatnily history of diabetes and ethnic background 
(Nolan, 2002). There is also geographical variation in the prevalence o£type 2 diabetes. 
The prevalence is lowest in rural areas of developing countries, ｩｮｴ･ｲｮＱ･､ｩ｡ｴｾ＠ in 
developed countries and is highest in certain ethnic groups who have adopted western 
lifestyle patterns. The populations with the highest prevalence are the Pima Indians in 
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Arizona in the USA and the Nauruans in Micronesia, populations which also have a high 
prevalence of obesity (Wareham, 2002). 
The prevalence of type 2 diabetes is increasing dramatically throughout the world 
because of increasing obesity, sedentary lifestyle and population ageing (Winer and 
Sowers, 2004). In 1985 it was estimated that there were approxitnately 30 million people 
with diabetes worldwide, by 1995 this had risen to 135 million and by 2025 it is 
estimated that it will have increased to 300 tnillion people, 5.4% of the world population 
(Winer and Sowers, 2004). Type 2 diabetes is increasingly being diagnosed in people 
under the age of 40 and this is linked to a parallel rise in obesity. 
Pathophysiology of type 1 diabetes 
Type 1 diabetes is caused by destruction of the beta cells of the pancreatic islets 
resulting in insulin deficiency. Beta cell destruction is mediated by an autoimmune 
process but a single trigger for this immunological destruction has yet to be discovered 
(Chessler and Lerrunark, 2000). It is thought that a number of different factors interact to 
cause the disease. These include genetic factors, environmental factors and infection. 
Pathophysiology of type 2 diabetes 
The aetiology of type 2 diabetes is only partly understood and susceptibility is both 
genetically and environmentally determined (Nolan, 2002). Individuals with type 2 
diabetes usually have insulin resistance and relative (rather than absolute) insulin 
deficiency. Type 2 diabetes cmrunonly results from progressive failure of pancreatic 
beta cells in a situation where there is insulin resistance (Buchanan et al, 2002), Figure 
1. Established type 2 diabetes is characterised by a combination of increased glucose 
production by the liver, decreased insulin-stimulated peripheral glucose uptake by 
n1uscle and adipose tissue, high circulating insulin concentration but inadequate 
response ofthe ｾＭ｣･ｬｬ＠ to hyperglycaetnia, Figure 2 (Nolan, 2002; Stmnvoll and Haring, 
2002). 
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Figure 1 Natural History of Type 2 Diabetes 
Adapted from Henry 1998 (Henry, 1998) 
Figure 2 Pathogenesis ofType 2 Diabetes 
Adapted from www.medscape.com 
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Insulin secretion 
Insulin secretion from the pancreatic beta cell occurs as a result of the interplay of a 
number of factors. The intracellular metabolism of glucose generates ATP. A rise in the 
intracellular concentration of ATP closes the ATP sensitive potassium channel of the 
pancreatic beta cell which leads to membrane depolarisation. This causes voltage gated 
calcium channels to open and the resulting influx of calcium leads to insulin release, 
(O'Rahilly and Savill, 1997), Figure 3. Although people with type 2 diabetes may have 
insulin levels that appear normal or elevated, the higher blood glucose levels in these 
patients would be expected to result in even higher insulin values had their 13-cell 
function been normal. Thus, insulin secretion is defective in these patients and 
insufficient to compensate for insulin resistance. 
Figure 3 Insulin Secretion from the Beta Cell 
ｔｨ･ｾ＠ cell Regulator of ATP sensitive channel 
(sulphonylurea receptor) 
p ium control 
./ 
ATP sensiti:Jv 
ｾｾ＠
ｾ ｩｴｯ｣ｨｯｮ､ｲｩ｡ｬ＠
oxidative 
phosphorylation 
Release of granules 
containing stored insulin 
I 
Voltage sensitive 
calcium channel 
Adpated from O'Rahilly and Savill, 1997 
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In those with normal glucose tolerance oral and intravenous glucose cause an hnmediate 
insulin secretion response made up of 2 phases. The early phase response peaks at 3-5 
minutes and is over in 1 0 minutes and in the later phase insulin concentrations rise 
steadily to a lower peak. The significance of the early phase of insulin secretion is 
unclear. In type 2 diabetes it has been established that there is a loss or attenuation of 
early phase insulin secretion. The lack of increase in insulin levels after a tneal results in 
inadequate suppression of endogenous glucose production (Dornhorst, 2001). 
This decline in P-cell function begins many years before diabetes is diagnosed 
(American Diabetes Association, 2004). Defective insulin secretion may be exacerbated 
by hyperglycaemia and hyperlipidaemia (Nolan, 2002). 
Insulin resistance 
Insulin resistance can be defined as a state of reduced responsiveness to normal 
circulating levels of insulin (Savage et al, 2005). It is the best predictor of the 
development of diabetes in high risk individuals and can be demonstrated to be present 
years before the onset of diabetes (Lillioja et al, 1993; Petersen et al, 2004). Type 2 
diabetes develops when insulin production and secretion by the beta cells is no longer 
able to increase enough to counter insulin resistance. 
Insulin sensitivity is related to glucose disposal which occurs mainly in muscle and 
adipose tissue, and endogenous glucose production by the liver and to a lesser extent by 
the kidney. The n1ost cmmn<:m factor resulting in insulin resistance is excessive fat mass, 
particularly if the excess fat mass is deposited in visceral rather than peripheral 
subcutaneous areas (O'Rahilly and Savill, 1997). 
Insulin acts on cells in tnuscle and adipose tissue by binding to its receptor and 
triggering a series of intracellular protein phosphorylation steps resulting in glucose 
uptake, effects on fatty acid and protein metabolistn and gene expression in all cells 
(Nolan et al, 1994). The insulin molecule arid the insulin receptor are normal in most 
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people with type 2 diabetes, however several defects have been demonstrated in 
downstream metabolic pathways. 
Studies using nuclear magnetic resonance spectroscopy (NMR) have shown that muscle 
glycogen synthesis is a tnajor pathway for glucose metabolism. In people with type 2 
diabetes this pathway is defective. Defective muscle glycogen synthesis has also been 
demonstrated in the insulin resistant offspring of parents with type 2 diabetes (Shulman, 
2000). Defective muscle glycogen synthesis is thought to play an impmiant role in 
insulin resistance. Further studies using N:MR have suggested that this defect reflects 
abnormalities in glucose transpm1 across the cell membrane (Shulman, 2000). 
Abnormalities oftriglyceride storage and lipolysis in insulin sensitive tissues are seen in 
insulin resistant subjects long before the development of hyperglycaetnia. The insulin 
resistant offspring of people with type 2 diabetes have been shown to have increased 
plasma free fatty acid (FF A) levels and intramuscular lipid content suggesting that 
dysregulation of fatty acid tnetabolistn 1nay also play a role in tnediating insulin 
resistance (Petersen et al, 2004). It has been demonstrated that there is an accumulation 
of intracellular triglyceride in muscle and liver in type 2 diabetes {Taylor, 2004). Lipid 
accumulation tnay lead to insulin resistance and the increased intracellular lipid stores 
may predate the onset of clinical diabetes by many years. It is hypothesised that 
increases in the intramyocellular concentration of fatty acid metabolites activate a serine 
kinase cascade which decreases the insulin stimulated activity of insulin receptor 
substratel-assoicated phosphatidylinositol 3-kinase resulting in reduced glucose 
transport and glycogen synthesis (Petersen et al, 2004). Until recently the mechanism 
behind the association between insulin resistance and fat accmnulation in muscle and 
liver was not completely understood. However recent work (Petersen et al, 2004) 
suggests that mitochondrial abnormalities may be involved. The insulin resistant 
offspring of people with type 2 diabetes were found to have a reduction in tnitochondrial 
content in muscle which may result in a reduced rate of mitochondrial oxidative 
phosphorylation and contribute to increased intramyocellular lipid content. 
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Fasting plasma FF As are generally elevated in individuals with type 2 diabetes, obesity 
and insulin resistance (Lewis et al, 2002) and have been shown to be an independent 
predictor of progression to type 2 diabetes in Caucasians and Pilna Indians. Insulin has a 
potent suppressive effect on hormone-sensitive lipase (HSL), the enzytne which is the 
tnain regulator ofFF A release fi·otn adipose tissue. Impaired suppression of lipolysis has 
been reported in individuals with type 2 diabetes in most but not all studies (Lewis et al, 
2002; Stmnvoll and Haring, 2002), and this may contribute to the increase in circulating 
FFAs. 
It has been well established that FFAs itnpair glucose metabolism in insulin sensitive 
tissues such as tnuscle and liver (Lewis et al, 2002). They have been shown to impair 
cellular glucose uptake, and it has also been hypothesised that they inhibit glucose 
oxidation (Lewis et al, 2002). This was hypothesised to occur as a result of substrate 
competition by Randle et al (Randle et al, 1963). In this hypothesis increased fatty 
oxidation causes an increase in the mitochondrial acetyl coenzyme A (CoA):CoA and 
NADH:NAD+ ratios leading to inhibition of pyruvate dehydrogenase. This induces a 
rise in intracellular citrate levels causing inhibition of phosphofructokinase and glucose-
6-phosphate accmnulation. Because glucose-6-phosphatase inhibits hexokinase activity 
this results in intracellular glucose accumulation and decreased glucose uptake. More 
recently this hypothesis has been challenged by the finding that elevating fi·ee fatty acid 
levels reduces intracellular glucose-6-phosphate levels (rather than the increase 
predicted by the Randle hypothesis). Further work has shown that FF As impair insulin 
signalling (Lewis et al, 2002; Shulman, 2000), and this may result frmn serine 
phosphorylation of insulin receptor substrate- I, mediated through a FF A induced 
increase in fatty acyl-CoA and diacylglycerol (Savage et al, 2005; Yu et al, 2002). FFAs 
acutely increase glucose mediated insulin secretion but prolonged elevation in FFAs 
results in reduced glucose mediated insulin secretion (Lewis et al, 2002). 
To sumn1arise although insulin resistance is not fully understood it is likely that it partly 
results frmn fat accumulation, particularly in visceral areas. This fat accumulation and 
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dysregulation of fat metabolism interferes with glucose metabolis1n resulting in insulin 
resistance and possible progression to type 2 diabetes. 
Maturity Onset Diabetes of the Young 
A subtype of type 2 diabetes characterised by early onset (classically before the age of 
25), a strong family history with autosomal dominant inheritance and insulin 
independence has been recognised for many years (Tattersall, 1998). The term maturity 
onset diabetes ofthe young (MODY) was coined to describe this subgroup in the 1970s. 
MODY is clinically heterogeneous and to date mutations of 6 genes have been 
described. One of these genes encodes the enzyme glucokinase (MODY2), and the other 
5 encode transcription factors: hepatocyte nuclear factor (HNF) 4a. (MODY1) 
(Yatnagata et al, 1996a), HNF-1a. (MODY3) (Yamagata et al, 1996b), ｈｎｆＭＱｾ＠
(MODY5) (Horikawa et al, 1997), insulin promoter factor 1 (MODY 4) and neurogenic 
differentiation factor (MODY6) (Fajans et al, 2001). 
MODY is rare accounting for less than 2% of all diabetes. Diabetes in MODY is 
prilnarily due to beta cell dysfunction. In MODY2 due to glucokinase tnutations 
hyperglycaemia results :fi·mn a reduction in sensitivity of the pancreatic beta cells to 
glucose as well as a defect in post-prandial glycogen synthesis in the liver. Glucokinase 
catalyses the conversion of glucose to glucose-6-phosphate so it can be used in 
glycolysis. It has the critical features of a rate determining enzyme, it has a low affinity 
for glucose and exhibits a lack of inhibition by its product, it therefore acts as the 
pancreatic glucose sensor (Pearson et al, 2001). Mutations ofthe glucokinase gene cause 
tnild fasting hyperglycaemia and patients do not develop microvascular cmnplications of 
diabetes (Fajans et al, 2001; Hattersley, 1998). 
In contrast diabetes in transcription factor MODY is less well understood. The 
transcription factors probably function in the nucleus of the beta cell and affect the 
transcription of genes involved in the transpmt and metabolism of glucose (Fajans et al, 
2001). Patients with transcription factor diabetes may have mild fastil1g hyperglycaemia 
but in particular show a decreased insulin response to a glucose load and therefore 
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increased 2 hour glucose on oral glucose tolerance tests. In contrast to glucokinase 
mutations the diabetes tends to be progressive over time and can be associated with 
tnicrovascular complications (Fajans et al, 2001). 
There is no evidence that mutations in the MODY genes are responsible for diabetes in 
the majority of patients with type 2 diabetes. However sunilar defects in glucose 
metabolisn1 and insulin secretion may be important in some patients with type 2 
diabetes. Ongoing studies in MODY patients are helping to further our understanding of 
the aetiology of type 2 diabetes. 
Morbidity and mortality in type 2 diabetes 
The cmnplications that result frmn diabetes are a significant cause of mortality and 
tnorbidity. Diabetes was the fifth leading cause of death in the United States in the year 
2000 (Winer and Sowers, 2004). It is among the cmrunonest causes of blindness in 
middle aged and elderly people, a leading cause of renal failure resulting in the need for 
dialysis or renal transplant and the most common non-traumatic cause of lower limb 
amputation (O'Rahilly and Savill, 1997). In addition it is associated with a considerable 
increase in the risk of ischaemic heart disease and cerebrovascular disease. 
Diabetes and cardiovascular disease 
Diabetes is a major risk factor for the development of cardiovascular disease. Up to 70% 
of people with type 2 diabetes will die of coronary heart disease. The risk of 
cardiovascular 1nort:ality in men with diabetes is 2 to 3 tunes higher than men without 
diabetes and in wotnen the risk is 3 to 5 tunes higher (HOPE study investigators, 2000). 
People with type 2 diabetes develop cardiovascular disease at a younger age and have 
more severe, multi-vessel disease. They are tnore likely to die following myocardial 
infarction in the acute phase and in the following years, they are more likely to have a 
further infarct and to develop left ventricular dysfunction (Valabhji and Elkeles, 2002). 
People with diabetes are as likely to have a myocardial infarction as people without 
diabetes who have already had an u1farct (Haf:fuer et al, 1998). Cardiovascular mortality 
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is decreasing in the developed world except in people with diabetes and it is actually 
increasing among w01nen with diabetes (Colwell, 2001). 
This increase in tnacrovascular disease is not totally understood but is thought to occur 
for a number of reasons. Type 2 diabetes is associated with several cardiovascular risk 
factors, namely obesity, hypertension and dyslipidaemia (Gerstein et al, 2001). The 
insulin resistance of type 2 diabetes tnay also play a role in cardiovascular risk. This 
cluster of risk factors has been described as the insulin resistance syndrome, the 
metabolic syndron1e or syndr01ne X and can occur before the developtnent of diabetes. 
However these factors do not explain fully the increased cardiovascular risk seen in 
diabetes (Valabhji and Elkeles, 2002) and other factors such as oxidative stress, 
alterations in coagulation and endothelial cell dysfunction are nnplicated (Calles-
Escandon and Cipolla, 2001). There now follows a short discussion of factors known to 
be altered in type 2 diabetes and the metabolic syndrome and to contribute to the 
increased risk of macrovascular disease. Diabetic dyslipidaemia will be discussed in 
more detail later as it is fundamental to the present work. 
Hypertension 
The prevalence of hypertension in type 2 diabetes is higher than in the general 
population. Around 40% of people with type 2 diabetes of 45 years are hypertensive and 
this increases to 60% by age 75. The presence of hypertension leads to a 
disproportionate rise in the risk of a cardiovascular event (Taylor, 2001). The increased 
incidence of hypertension in diabetes is thought to be partly due to a derangement in the 
production of vasoconstrictor and vasodilator substances such as nitric oxide by the 
endotheliutn of blood vessels. There is a relative overproduction of vasoconstrictor 
substances causing a rise in vascular tone and hence blood pressure. However 
hypertension in people with diabetes is often multifactorial and other tnechanisms 
involved include diabetic neplu·opathy, altered sodium homeostasis and protein 
glycation (Taylor, 2001). 
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There is evidence that treatment of hypertension is as, if not more impmtant than the 
treatment of hyperglycaemia in type 2 diabetes in the prevention of macrovascular 
complications. The UKPDS was the largest study oftype 2 diabetes and ran fi·om 1977-
1997. It included more than 5000 patients with newly diagnosed type 2 diabetes (UK 
Prospective Diabetes Study (UKPDS) Group, 1998a). Embedded within this study was 
the hypertension in diabetes study, a multi-centre randomised controlled trial. Patients 
with hypertension were allocated to a tight blood pressure (BP) control group (target BP 
< 150/85mmHg) or less tight control group (target BP < 180/1 05nunHg). Patients 
randomised to the tight BP control group had a highly significant 24% risk reduction in 
developing any end-point related to diabetes cmnpared to the less tightly controlled 
group. This included a significant reduction in death related to diabetes, stroke, heart 
failure, combined macrovascular end-points and microvascular complications. This 
reduction was more than was seen with intensive blood glucose control in the same 
study (UK Prospective Diabetes Study (UKPDS) Group, 1998b ). 
Hyperglycaemia 
Type 2 diabetes frequently goes undiagnosed for many years because the 
hyperglycaetnia develops gradually and at earlier stages is often not severe enough for 
the patient to notice any of the classic symptoms of diabetes. Therefore at diagnosis 
patients tnay have had a long exposw·e time to hyperglycaemia. Hyperglycaemia may 
accelerate vascular disease by a number of tnechanisms including glycation of proteins, 
glycation of lipoproteins, formation of advanced glycosylation end products, increased 
oxidative stress, increased reactive oxygen species, increased oxidized lipoproteins, 
increased protein kinase C, diacylglycerol and increased activation of the coagulation 
cascade (Calles-Escandon and Cipolla, 2001). 
The association between microvascular complications of diabetes and hyperglycaetnia 
has been consistently demonstrated but evidence associating hyperglycaetnia and 
macrovascular disease is less persuasive. In the UKPDS, reduction in the risk of 
myocardial infarction of borderline significance was seen with intensive treatment 
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compared to standard treat1nent whereas there was a substantial reduction in 
microvascular complications (UK Prospective Diabetes Study (UKPDS) Group, 1998a). 
The relative risk of macrovascular disease seems to increase with any increase in 
glycaetnia above the normal range whereas microvascular complications occur with 
more extreme hyperglycaemia. This is illustrated by the EPIC-Norfolk trial, a 
prospective cohort study of residents of Norfolk (Khaw et al, 2001). In this trial 
glycosylated haemoglobin concentration (HbAlc) significantly predicted mortality frmn 
cardiovascular and other causes in men. The predictive value was stronger than that for 
cholesterol concentration, body mass index and blood pressure. The effect was present 
even at low concentrations of HbAlc, below the range for diabetes suggesting a 
continuous relationship with cardiovascular risk rather than a threshold. The lowest 
death rates were in people with HbAlc less than 5o/o. About 70% ofthe population had 
an HbAlc between 5 and 6.9% and this group accounted for 1nore than 80% of the 
excess cardiovascular mortality. 
Diabetes as a procoagulant state 
In order to explain the excess cardiovascular risk diabetes has been conceptualised as a 
pro coagulant state with increased activity of the coagulation cascade, decreased activity 
ofthe fibrinolytic pathway and altered platelet function. There is evidence that diabetes 
is associated with increases in fibrinogen and factor VII activity and decreases in 
antithrmnbin III and protein C. Diabetes also affects the fibrinolytic pathway. 
Plasminogen-activator inhibitor 1 (PAI-l) is the major inhibitor of tissue plasminogen 
activator (tP A) which is responsible for the conversion of plasminogen to plasmin. The 
balance between tPA levels and PAI-l levels determines whether clot is formed or 
broken down. Increased PAI-l levels tip the balance to a procoagulant state. PAI-l 
levels are increased in type 2 diabetes but normal in type 1 diabetes. They are also 
increased in the metabolic syndrome (Colwell, 2001). 
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Oxidative Stress 
There is evidence that people with diabetes have increased production of reactive 
oxygen species and that this is linked to the vascular abnormalities (Ammar Jr et al, 
2000). There is also an increase in substances such as hnmunoreactive prostanoids, 
depletion of NADPH and decreased nitric oxide formation which leads to decreased 
endothelimn dependent relaxation (Tesfamariam and Cohen, 1992). In vitro studies have 
detnonstrated that the impainnent in endothelium dependent relaxation seen in animal 
models of diabetes can be reversed by free radical scavengers such as superoxide 
dismutase (Ammar Jr et al, 2000; Tesfamariam and Cohen, 1992). 
Endothelial dysfunction 
It is now understood that in addition to providing a barrier between blood and tissues 
endothelial cells also have a critical role in homeostasis. The function of the 
endothelium includes vasoconstriction and vasodilation, growth and changes in vascular 
smooth muscle, role in inflammation and maintenance of blood flow while preventing 
bleeding. Endothelial dysfunction has been suggested as the final common pathway 
whereby the previously discussed abnormalities cause accelerated atherosclerosis and 
hence tnacrovascular disease in diabetes. Endothelial dysfunction has been demonstrated 
in individuals with type 2 diabetes, individuals with type 1 diabetes especially those with 
tnicroalbuminuria, and also those with impaired glucose tolerance, insulin resistance and 
previous gestational diabetes (Calles-Escandon and Cipolla, 2001; Taylor, 2001). 
Treatment of type 2 diabetes 
The UKPDS provides a wealth of evidence on the natural history of type 2 diabetes as 
well as rationale for treatment. Subjects were randomised to conventional or intensive 
treatment. In the conventional treatment ann the aim oftherapy was to maintain fasting 
plastna glucose less than 15tntnol/L without symptoms of hyperglycaetnia. The ahn in 
the intensive treatment group was to achieve a fasting plastna glucose less than 61nmol/L 
and in insulin treated patients pre-n1eal glucose concentrations of 4-7trunol/L. Patients in 
the intensive treatment group were randmnly assigned to treatment with insulin or 
sulphonylureas. In addition overweight patients were randomly assigned metformin. 
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One of the main findings was that all patients exhibited a marked deterioration in 
glycaetnia over time manifest as an increasing requirement for pharmacological therapy 
(UK Prospective Diabetes Study (UKPDS) Group, 1998a). This is thought to represent a 
progressive decline in beta cell function over tune and provides a framework for the 
necessary stepwise treatment of type 2 diabetes. The majority of patients will need a 
progressive increase in their treatment over titne in order to try and maintain glycaemic 
control. 
Diet and exercise 
It was noted more than a century ago that overweight people with diabetes became 
aglucosuric coincidental to the food shortage and weight loss that occurred during the 
siege of Paris during the Franco-Prussian war (Davidson and DiGirolamo, 2000). This 
led to the first introduction of reduced calorie intake, exercise and weight loss to treat 
type 2 diabetes. Sitnilarly during both world wars when food was rationed in England 
and Wales there was a parallel decrease in sugar (and calorie) consumption and diabetes 
mortality indices (Davidson and DiGirolamo, 2000). Supervised exercise programmes 
produce significant reductions in HbAlc, insulin resistance and weight in individuals 
with type 2 diabetes but the satne benefit is not seen with unsupervised progratmnes 
(Alatn et al, 2004). Weight reduction and calorie restriction re1nain the cornerstone of 
managetnent of type 2 diabetes. In the UKPDS every patient received an initial 3 month 
period of dietary advice with monthly visits to a dietician and doctor. At the end of this 
run-in period only 17% of subjects had a fasting plasma glucose of less than 6tnmol/L 
despite this intensive therapy. This illustrates that although lifestyle change can remove 
the need for pharmacological therapy for type 2 diabetes it unfortunately rarely does. 
Sulphonylureas 
Sulphonylureas have been in use since the early 1950s and exert their effect by 
stimulating endogenous it1sulin secretion (Pieber, 2002). They bind to the sulphonylurea 
receptor, a subunit of the ATP sensitive potassium channel in the tnembrane of the 
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pancreatic beta cell. Binding leads to depolarisation of the cell, an influx of calcimn ions 
and insulin secretion (Dornhorst, 2001). The most common side effect is hypoglycaemia 
and they also cause weight gain. Typically they reduce HbA1 c by 1-2%. Since the 1970s 
there has been concern about their safety particularly in view of their action in 
increasing insulin levels. However the UKPDS (UK Prospective Diabetes Study 
(UKPDS) Group, 1998a) did not show any increase in risk attached to their use 
compared to insulin or conventional treatment. 
Metformin 
Metformin has been widely used worldwide for more than 30 years but has only been 
available in the USA since 1995 (Einhorn et al, 2000). The mechanistn of action of 
tnetformin is poorly understood. It was shown in 2001 that in rats tnetformin activates 
AMP-activated protein kinase in liver cells. This leads to inhibition of lipogenesis, a 
decrease in hepatic steatosis and inhibition of hepatic glucose production (Zhou et al, 
2001). Clinically metformin is an insulin sensitiser. It probably has its effect by reducing 
hepatic glucose production and also possibly by improving the action of insulin in 
muscle (Pieber, 2002). It also reduces triglyceride levels, circulating FFAs and 
diminishes very low density lipoprotein (VLDL) production (Tiikkainen et al, 2004; 
Witters, 2001). It does not increase insulin secretion, therefore it has a complimentary 
action to sulphonylureas. It does not cause hypoglycaemia or weight gain but its use can 
be limited by gastrointestinal side effects. In the UKPDS overweight patients who were 
randotnised to receive tnetformin showed less weight gain and a lower risk of diabetes 
related end-points, diabetes related death and n1yocardial infarction than other treatment 
groups (Pieber, 2002). Metformin is therefore first line therapy for overweight people 
with type 2 diabetes. 
Alpha-glucosidase Inhibitors 
Acarbose is the most cotrunonly prescribed drug in this group. It works by inhibiting the 
activity of a.-glucosidase in the lun1en intestinal border. This leads to a delay in 
carbohydrate absorption and therefore a reduction in post-prandial glucose levels. 
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Unfortunately it also leads to gastrointestinal side-effects that limit the tolerability of this 
drug (Pieber, 2002). If tolerated it can reduce HbA1c by up to 1%. 
Meglitinides 
Repaglinide was the first meglitinide analogue to become available. It works by closing 
the ATP sensitive potassimn channel in the beta cell, depolarising the cell and hence 
causing insulin secretion. It has a 1nore rapid onset of action and shorter duration of beta 
cell stimulation than sulphonylureas which should decrease the risk of hypoglycaemia 
and weight gain (Dornhorst, 2001 ). The other agent in this group, nateglinide, again 
inhibits the ATP sensitive potassium channel in the presence of increased glucose 
concentrations leading to rapid onset of insulin release. 
Insulin 
The UKPDS showed that insulin was safe in the treatment of type 2 diabetes and since 
then it has been increasingly prescribed to try and optimise control. Many different 
regimes are used and the regimen of choice is currently the subject of 1nuch research. 
Proble1ns with insulin use are hypoglycaemia and weight gain. 
Thiazolidinediones 
This relatively new class of drugs for the treatlnent of type 2 diabetes are the subject of 
this work. They will be discussed in more detail later. 
Cardiovascular risk reduction 
In type 2 diabetes vascular disease accounts for n1uch of the excess mortality and 
n1orbidity. The UKPDS showed that intensive treatment of hyperglycaetnia decreased 
the risk of microvascular complications but did not affect diabetes related and all cause 
mortality (UK Prospective Diabetes Study (UKPDS) Group, 1998a). Therefore 
management of cardiovascular risk factors is as important as the treatment of 
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hyperglycaemia. This includes treatment of hypertension, treattnent of dyslipidaemia 
and prescription of aspirin. 
Prevention of type 2 diabetes 
There is now evidence from randomized, controlled trials that lifestyle interventions can 
decrease the incidence of diabetes in people at high risk of developing the disease. In the 
Diabetes Prevention Program (Diabetes Prevention Research Group, 2002) subjects with 
impaired glucose tolerance were randomised to intensive lifestyle counselling, 
metformin or placebo. After an average follow-up period of2.8 years there were 11, 7.8 
and 4.8 cases of diabetes per 100 person years in the placebo, tnetfonnin and lifestyle 
groups respectively. There was a relative reduction in the progression to diabetes of 58% 
in the lifestyle group and a 31% reduction in the metfonnin group cmnpared to control 
subjects. Similarly a Finnish study (Tuomilehto et al, 2001) detnonstrated that after an 
average follow-up of 3.2 years, cotnpared to standard treatment, an intensive lifestyle 
intervention led to a 58% reduction in the incidence of diabetes in a group of tniddle-
aged obese men with unpaired glucose tolerance 
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Lipids 
The tnajor lipids present in plasma are fatty acids, triglycerides, cholesterol and 
phospholipids. Lipids have an essential role in health and abnormalities of the lipid 
system are an important cause of morbidity and mortality. Cholesterol is essential for 
tnembrane formation and is also the precursor of bile acids and hormones such as 
adrenal steroids and sex hormones. Triglycerides are made up of glycerol esterified with 
three long chain fatty acids. They are used as an energy store and are utilized in times of 
starvation. They can be oxidised by tissues when required or stored by adipose tissue in 
titnes of plenty. Lipid is mobilized frmn adipose tissue as free fatty acid (FFA) and 
circulates bound to serun1 albmnin (Ginsberg, 1998). 
Cholesterol and triglyceride are insoluble and therefore cit·culate in the plasma bound to 
lipoproteins. This allows thetn to become soluble and be transpmied around the body. In 
the circulation the lipoproteins are linked in a cascade and undergo a series of 
modifications which alter their composition, structure and biological function. 
Lipoprotein structure 
Lipoproteins share a sitnilar basic structure, Figure 4. They have a non-polar lipid core 
mostly made up of triglyceride and cholesterol esters. Surrounding this is a monolayer of 
polar lipids, (phospholipids and free cholesterol) and proteins known as apolipoproteins. 
Apolipoproteins are impmiant in the structure and the metabolisn1 of lipoproteins. The 
polar layer allows the transport of highly insoluble lipids and regulates interactions 
between lipoproteins and cell membranes (Ginsberg, 1998). 
Classification of lipoproteins 
Lipoproteins con1prise a continuum of particles differing gradually in density and in 
lipid and apoprotein cotnposition. However there are accumulations of various relatively 
distinct subclasses which can be classified by density after separation by 
ultracentrifugation (Ginsberg, 1998). In order of increasing density these are 
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chylomicrons, very low density lipoprotein (VLDL), intermediate density lipoprotein 
(IDL), low density lipoprotein (LDL) and high density lipoprotein (HDL). 
Figure 4 Basic structure of a lipoprotein 
Structure of a Lipoprotein 
Adapted from www.medscape.com 
Apollpoprotein 
A·(HDL))C 
S. (LDL))ft 
Cholesterol 
Phospholipid 
The composition of circulating lipoproteins is not static, they are in a dynamic state with 
constant exchange between the different components. Lipoproteins may also be 
separated according to their electrophoretic properties and identified by 
immunoelectrophoresis, Table 2, Table 3, Table 4. 
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Table 2 Characteristics of plasma lipoproteins 
Source 
VLDL 0.95- ｐｲ･Ｍｾ＠ Liver 
1.006 
IDL 1.006- Slow ｰｲ･Ｍｾ＠ Catabolism 
1.019 ofVLDLand 
ch !omicrons 
LDL 1.019- 2.3 X 10 18-25 Catabolism 
1.063 ofVLDL and 
direct 
s nthesis 
HDL 1.063- 1.7-3.6 X 5-12 al Liver and 
1.21 106 intestine, 
catabolism of 
VLDL and 
ch }omicrons 
Table 3 Composition of the major lipoprotein subclasses 
Phospholipids 
(%) 
Chylomicrons 1-2 88 3 8 
VLDL 7-10 56 8 15 20 
IDL 11 29 9 34 26 
LDL 21 13 10 48 28 
HDL 55 4 2 15 24 
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Table 4 Characteristics ofthe major apolipoproteins 
Apo A-II 17 414 HDL, chylomicrons Unknown 
Apo A-IV 46,465 HDL, chylomicrons Unknown 
Apo B-48 264 000 Chylomicrons Assembly and secretion of 
chylomicrons in the small 
intestine 
Apo B-100 540,000 VLDL, IDL and LDL Assembly and secretion of 
VLDL from the liver, 
structural protein ofVLDL, 
IDL and LDL, ligand for 
LDL 
Apo C-1 6630 Unclear 
Apo C-11 8900 
Apo C-111 8800 
e 
ApoE 34,145 Chy !omicrons, Ligand for binding to the 
VLDL, HDL LDL 
Tables 2, 3 and 4 adapted from Ginsberg 1998 and Mayes 2003. 
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Apolipoprotein B 
Apolipoprotein B has 2 forms, BlOO and B48. Apolipoprotein B48 (apo B48) is 
transcribed from the gene for apolipoprotein B100 (apo BlOO). However in the intestine 
the translation of mRNA stops earlier hence apo B48 rather than apo B100 is secreted. 
This occurs because of RNA editing, the process whereby a RNA sequence is tnodified 
:fi:otn that of the genomic sequence. In this case cytidine to uridine editing ofthe gene in 
the intestine converts a glutamine codon (CAA) to a stop codon (UAA) resulting in the 
production of apo B48 (Chester et al, 2000). Apo B48 is necessary for the intestinal 
assetnbly and secretion of chylomicrons. 
Apo B100 is a large hydrophobic protein of 4563 amino acids with a tnolecular weight 
of approximately 540kD. It is synthesised in the liver. It is the tnajor apoprotein of 
VLDL, IDL and LDL and cmnprises approximately 30%, 60% and 95% ofthe protein in 
these lipoproteins respectively. Unlike other apoproteins apo B 100 does not exchange 
between lipoproteins. It is necessary for the assembly and secretion of VLDL by the 
liver (Ginsberg, 1998). The hepatic secretion of apo B100 determines VLDL secretion 
and therefore plasma lipid concentrations. 
Apo BIOO contains hydrophobic areas that are important in lipid binding and lipoprotein 
assetnbly and hydrophilic areas which interact with plasma. It also has a LDL receptor 
binding domain that is involved in the uptake of plasma LDL and possibly IDL and 
VLDL by tissues (Ginsberg, 1998). Because of the central role of apo BIOO, studies of 
this apoprotein can provide further understanding of lipoprotein tnetabo lism. 
Chylomicrons 
Cholesterol and triglyceride are present in dietary fat. Following consumption of fat 
triglyceride and cholesterol are absorbed by the intestinaltnucosa and incorporated into 
chylomicrons. Chylotnicrons enter the lytnphatic system and then enter the systetnic 
circulation through the thoracic duct. Hence chylomicrons are the tnajor transport form 
of exogenous fat and the n1ost important triglyceride rich lipoprotein in the post-prandial 
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state. Their main constituent is triglyceride. Triglyceride is removed frm11 chylomicron 
by the enzyme lipoprotein lipase (LPL) which is on the lmninal surface of endothelium 
of adipose tissue, skeletal and cardiac 1nuscle and the lactating breast. In this way FF As 
are delivered to the tissues where they can be used directly for energy or they can be re-
esterified to form triglyceride and used as an energy store. The residual lipoprotein, 
chylomicron remnant enriched with cholesterol esters is removed by hepatic LDL 
receptors and receptors that recognise apo E. 
Very low density lipoprotein 
Chylomicrons are the most abundant triglyceride rich lipoprotein in the post-prandial 
state whereas VLDL particles are the major triglyceride rich lipoprotein in the fasting 
state. They are asse1nbled and secreted by the liver (Ginsberg, 1998). Apo B 100 is 
formed in the endoplasmic reticulum and 1natures in the Golgi apparatus of hepatocytes 
(Ginsberg, 1998). Microsomal transfer protein (MTP) 1nediates the addition of lipid to 
apo B100 to fonn a nascent VLDL particle (Millar and Packard, 1998). Triglyceride is 
synthesised in the liver de novo or by re-esterification of fi·ee fatty acids. VLDL particles 
also contains some cholesterol, apo C-I, apo C-II, apo C-III and apo E. Cholesterol is 
synthesised frmn acetate or delivered to the liver by other lipoproteins such as 
chylmnicron remnant and LDL. 
Triglyceride rich VLDL is released from the liver and initially triglyceride is hydrolysed 
by the action of LPL. Apo C-II is a necessary activator of LPL and apo C-III inhibits 
LPL action (Ginsberg, 1998). The VLDL particles become smaller and phospholipids, 
free cholesterol and apoproteins C and E are released from the surface and taken up by 
HDL. Hence VLDL is converted to the denser IDL. 
Intermediate density lipoprotein 
Under normal circumstances there is not n1uch IDL in the circulation. This is because it 
is either rapidly removed by the liver by LDL receptors or converted to LDL. 
Conversion of IDL to LDL is the result of removal of further triglyceride. Apo E 
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interacts with receptors in the liver including the LDL receptor and has a critical role in 
the retnoval ofretmmnt lipoproteins fi:om plasma. 
Low density lipoprotein 
LDL is the main carrier of cholesterol, mainly in the form of cholesterol ester. LDL also 
contains apo B100 and phospholipids. It is formed mainly by the catabolism ofVLDL 
and IDL but there is smne evidence that the liver may also directly secrete LDL 
(Ginsberg, 1998). LDL can pass tln·ough the junctions between capillary endothelial 
cells and attach to specific LDL receptors on cell surfaces. The LDL receptor is a 
glycoprotein with a n1olecular weight of approxitnately 160,000kD. It is present on the 
cell surface of nearly all the tissues of the body and recognises apo BlOO (Ginsberg, 
1998). After interaction with its receptor LDL is internalised and degraded by lysosomes 
and cholesterol is released. Cholesterol esters can be hydrolysed, incorporated into cell 
metnbranes, stored or they can exit the cells. Intracellular cholesterol regulates 
cholesterol metabolism by inhibiting the transcription of the genes for LDL receptors 
and the rate-limiting enzyn1e in cholesterol synthesis, 3-hydroxy-3-methylglutary-
Coenzyme A reductase (HMG-CoA-reductase) (Brown and Goldstein, 1984; Packard et 
al, 2000). These lipoprotein pathways are summarised in Figure 5. 
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Figure 5 Summary of lipoprotein pathways 
Adapted from www.med.usf.edu/2005/firstsemester.html (University of Southern 
Florida Medical school teaching page) 
Therefore it can be seen that VLDL is the precursor ofiDL and IDL is the precursor of 
LDL. Only one molecule of apo BlOO is present in each of these lipoprotein particles 
and this is conserved during the transformations. Thus each LDL particle is derived from 
one VLDL particle (Mayes, 2003). This principle is of fundamental importance when 
understanding the methodology behind the cunent work. 
Regulation of apo BlOO secretion 
Regulation of apo BlOO secretion is mainly at the post-translational stage (Ginsberg 
1998). Between 50 and 80% of newly synthesised apo BlOO may be degraded in liver 
cells. Availability of cholesterol and particularly triglyceride has been shown to be 
important in determining whether newly formed apo BlOO is secreted or degraded 
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(Ginsberg, 1998). In addition MTP activity also regulates apo B secretion (Ginsberg, 
2000; Taskinen, 2003). Stimulation of triglyceride synthesis appears to be the 
tnechanistn for the stitnulation of apo B secretion by fatty acids (Ginsberg, 1996). 
Availability of newly synthesised triglyceride can accelerate the translocation of apo B 
across the membrane of the endoplasmic reticulum so it avoids degradation. 
The HDL pathway 
HDL is an extretnely cmnplex class of lipoproteins. They act to transpmt excess cellular 
cholesterol, the so-called reverse cholesterol transport system. The 1nost abundant 
proteins in HDL are apolipoprotein A-I and apolipoprotein A-II with small amounts of 
apolipoprotein C, D and E. HDL does not contain apo B. The intestine and the liver 
secrete apoproteins with a stnall atnount of phospholipid. These stnall cholesterol-poor 
HDL discs can then adsorb cholesterol from celltnembranes and other lipoproteins. The 
:fi:ee cholesterol in the HDL disc is esterified by lecithin-cholesterol acyltransferase 
(LCAT) which increases the capacity of HDL for further :fi·ee cholesterol. Triglyceride 
also accumulates :fi:om triglyceride rich lipoproteins mediated by cholesterol ester 
transfer protein (CETP). Accumulation of cholesterol and triglyceride transforms the 
disc of HDL into small spheres (HDL3). HDL3 enlarges further, accommodating more 
cholesterol and apo C and phospholipids :fi:om chylomicrons and VLDL forming HDL2. 
Then HDL cholesterol can be directly taken up by the liver through interaction with the 
scavenger receptor, class B, type I (SRB 1) (Brewer, 2004). Alternatively HDL2 can have 
the cholesterol removed and transferred to chylmnicrons, VLDL and LDL in exchange 
for triglyceride, mediated by CETP. The excess ｾｨｯｬ･ｳｴ･ｲｰｬ＠ is then returned to the liver 
and taken up by the LDL receptor (Ginsberg, 1998). HDL cholesterol that is taken up by 
the liver can be excreted in the form of bile acids or cholesterol cotnpleting the process 
of reverse cholesterol transpot1 (Brewer, 2004). Alternatively HDL2 can be converted 
back to HDL3 by hydrolysis of triglyceride by hepatic lipase. 
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Clinical importance of lipids 
Lipids are essential for energy hmneostasis, reproductive and organ physiology and 
many aspects of cell biology. However they are also linked to tnany pathological 
processes. Abnormalities of the tnetabolism of apo B containing lipoproteins may be 
ilnplicated in tnany hyperlipidaemic states, the associated risk of atherosclerosis and 
hence cardiovascular disease. Evidence for the itnportance of lipids in disease, 
particularly cardiovascular comes frmn a number of sources. 
Familial hypercholesterolaemia 
The existence of a dominantly inherited form of hypercholesterolaetnia causing tendon 
xanthomata has been recognised for 70 years (Durrington, 2004). It was recognised in 
the 1970s that this condition results frotn diminished expression of the functional LDL 
receptor (Goldstein and Brown, 1977). Mutations prevent the LDL receptor being 
transported to the cell surface, LDL binding to the receptor and then the internalisation 
and release of LDL. This leads to an increase in the amount of time spent in the 
circulation by LDL. Fatnilial hypercholesterolaetnia affects about 1 in 500 people in the 
heterozygous fonn. It is tnuch more common in certain co1111nunities where the 
community is descended from small numbers of early settlers, (the founder effect), for 
example South Africans of Dutch descent. Serum cholesterol concentration in 
heterozygous familial hypercholesterolaen1ia is raised from birth and by adulthood is 
normally in the range of9-14mmol/L i11 the UK. 
People with fatnilial hypercholesterolaemia have a marked increase in coronary heart 
disease (Slack, 1969). If untreated more than half of male heterozygotes and 15% of 
female heterozygotes will die before the age of 60. The pattern of coronary heart disease 
shows variability between families possibly due to the effect of different tnutations or to 
changes in HDL cholesterol. Although hon1ozygosity is rare the prognosis is very poor. 
Sennn cholesterol is usually higher than 15tnmoVL and can be up to 30nunoVL. Angina 
can develop in childhood and myocardial infarction has been recorded as early as 2 
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years old, life expectancy does not normally extend beyond the third decade 
(Durrington, 2004; Slack, 1969). 
Epidemiological studies 
Epidemiological studies show that countries with high coronary heart disease (CHD) 
mortality are those in which the typical cholesterol concenn·ation of their inhabitants is 
higher than in countries with lower CHD mortality (Durrington, 2004). For example the 
rate of cardiovascular death is greatly increased in developed countries such as the 
United States, Scotland and Finland and 1nuch lower in Asia, Africa, Central and South 
America. Death rates :fi:om ischaemic heat1 disease in the United States are 6 times those 
in Japan (Con·an et al, 1994). 
Further epidemiological evidence comes frmn the Framinghatn Heart Study. This was a 
prospective cohmt study started in 1948 that followed 5,209 men and wotnen between 
the ages of30 and 62 from the town ofFramingham, Massachusetts, USA every 2 years. 
This study was the first to establish a relationship between cholesterol and 
cardiovascular disease and to demonstrate a positive association between LDL 
cholesterol and coronary artery disease (Cotran et al, 1994). 
Studies of lipid lowering drugs 
There is evidence from double-blinded randomised placebo controlled trials that 
lowering LDL-cholesterol decreases cardiovascular disease. Landmark trials with 
clinical endpoints den10nstrate decreased risk of CHD and stroke of about a third among 
men and women using statins as pritnary or secondary prevention (Downs et al, 1998; 
Heart Protection Study Collaborative Group, 2002; Sacks et al, 1996; Scandinavian 
Simvastatin Survival Study Group, 1994; Shepherd et al, 1995; The Long-tenn 
Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group, 1998). A 1% 
decrease in LDL cholesterol produces roughly a 1.25% decrease in CHD risk 
(Durrington, 2004). This effect is seen in people with diabetes (Heart Protection Study 
Collaborative Group, 2003), the elderly (Shepherd et al, 2002) and people without 
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marked hypercholesterolaetnia at baseline (1nean cholesterol concentration 5.4trunol/L) 
(Sacks et al, 1996). 
Triglyceride and HDL 
It can be seen that cardiovascular risk is strongly related to LDL cholesterol levels. 
However the other lipoproteins are also hnportant in cardiovascular risk. The role of 
HDL as a carrier of excess cellular cholesterol in the reverse cholesterol transport 
pathway is believed to provide protection against atherosclerosis (Brewer, 2004) and 
there are several lines of evidence detnonstrating the protective effect of HDL. 
Epidemiological studies show an inverse correlation between HDL cholesterol levels 
and cardiovascular disease (Castelli, 1988; Gordon et al, 1977). In fact there is evidence 
from the Framinghatn study that of all the lipid parameters studied HDL cholesterol had 
the strongest relationship to coronary artery disease. In-vitro research in rabbits has 
shown that increasing HDL levels by infusing apolipoprotein A-I reduces the 
development of atherosclerosis (Badimon et al, 1990; Brewer, 2004). HDL also 
decreases atherosclerosis by protecting LDL from oxidation (Brewer, 2004) and there is 
evidence that this may partly be due to the retnoval of seeding particles (reactive oxygen 
species which 'seed' LDL before it is oxidised) from LDL by HDL and its components 
(Navab et al, 2000). Oxidised LDL is readily taken up by the macrophage scavenge 
receptor SR-A or CD36 leading to the formation of foam cells. 
HDL concentrations vary reciprocally with plasma triglyceride concentrations and 
directly with the action of LPL (Mayes, 2003). This may be due to surplus surface 
constituents of VLDL and chylomicrons such as phospholipids and apo A-I being 
released during hydrolysis contributing to the formation ofHDL. 
There is less evidence of a direct independent relationship between triglyceride and 
coronary at1ery disease (Gordon et al, 1977). In the Framingham study there was a 
significant relationship between triglyceride and risk of coronary artery disease in 
tnultivariate analysis in women but not in men. Interestingly men and women with the 
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highest triglycerides had the highest blood glucoses and the people with the highest 
triglycerides eventually ran about twice the risk of developing diabetes (Castelli, 1988). 
This led the author to describe a syndrome associated with an increased risk of 
cardiovascular disease characterised by high triglyceride, low HDL cholesterol, high 
uric acid and raised blood glucose, an early description of the metabolic syndrome. It 
can be seen that it is difficult to separate the effect of high triglyceride from the other 
associated abnonnalities. 
There is evidence from interventional studies that reducing triglyceride concentration is 
associated with a decrease in cardiovascular morbidity and mortality but again it is 
difficult to separate from the effect of raising HDL-cholesterol. The VA-HIT study 
showed that treatment with the fibrate gemofibrozilled to a significant reduction in the 
cmnbined incidence of non fatal myocardial infarction and CHD death compared to 
placebo. Subjects were tnen with known CHD and low HDL cholesterol and LDL 
cholesterol levels. The drug treatment led to an average 6% increase in HDL-cholesterol, 
a 3lo/o decrease in triglycerides and no change in LDL-cholesterol (Robins et al, 2001). 
Sitnilar results were found in the Helsinki Heart Study. Treatment with a fibrate drug for 
5 years led to a 34% reduction in CHD in dyslipidaemic men compared to placebo 
(Manninen et al, 1988). In this study there was a 14% increase in HDL, a 35% decrease 
in triglyceride but also an II% decrease in LDL cholesterol. Further statistical analysis 
using the Cox proportional hazard tnodel showed that the association between CHD and 
triglyceride was insignificant, the relationship between HDL and LDL cholesterol and 
CHD was significant (Manninen et al, 1988). 
There is some evidence that lowering triglyceride levels 1nay slow the progression of 
angiographic coronary artery disease in people with type 2 diabetes. Treatment with a 
fibrate drug led to a significant reduction in total cholesterol, LDL cholesterol and 
triglyceride and a significant hnprovement in HDL cholesterol. The reduction in 
triglyceride was approxiinately 30% and the reduction in total cholesterol was 
approximately I 0%. The group treated with a fibrate showed a reduction in the 
42 
progression of angiographic coronary artery disease compared to those on placebo 
(Diabetes Atherosclerosis Intervention Study Investigators, 2001 ). 
More recently there has been interest in the 'atherogenic lipoprotein phenotype' 
characterised by a normal cholesterol concentration, raised triglyceride levels, low HDL 
cholesterol levels and a shift in the size of LDL particles towards small dense species 
(Packard et al, 2000). This profile has been shown to associated with a high risk of 
coronary artery disease and is prevalent in people with insulin resistance and type 2 
diabetes (Sacks, 2002). 
Small dense LDL has properties that are thought to enhance its atherogenicity such as 
binding to LDL receptors less well (Packard et al, 2000). Packard et al (Packard et al, 
2000) suggest a 1nodel accounting for the formation of small dense LDL. CETP 
mediates the exchange of cholesterol ester for triglyceride in LDL. The key step in 
reducing LDL size is the action of hepatic lipase (HL) which removes core triglyceride 
and surface phospholipids from LDL. Normally there is not enough time for LDL to lose 
cholesterol and acquire triglyceride before it is cleared by receptors. The fonnation of 
stnall dense LDL occurs if LDL has a residence time of greater than 3 days and is 
exposed to high levels of VLDL. In contrast if VLDL is low and HDL cholesterol is 
high CETP can transfer HDL associated cholesterol to LDL to maintain its composition. 
In situations where there is high VLDL or prolonged residence time of LDL the 
formation of small dense LDL is favoured. 
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Lipids and diabetes 
The dyslipidaetnia of type 2 diabetes is characterised by hypertriglyceridaemia and 
decreased HDL cholesterol often in the presence of normal LDL cholesterol (Krauss, 
2004). In addition increased VLDL, IDL and small dense LDL are observed. This 
particular pattern of abnormalities can also be seen in insulin resistant individuals and 
there is evidence that this is linked to the increased incidence of cardiovascular disease 
seen in individuals with type 2 diabetes and insulin resistance (Krauss, 2004). 
Abnormalities of apo BlOO pathway 
Multiple abnormalities in lipoprotein metabolisn1 have been observed in patients with 
type 2 diabetes and it is thought that these contribute to the risk of cardiovascular disease 
(Duvillard et al, 2000). People with type 2 diabetes generally have an increased plasma 
concentration of VLDL contributing to hypertriglyceridaemia. Cummings et al 
(Cutnmings et al, 1995b) used stable isotope techniques to compare VLDL apo B 
metabolistn in people with type 2 diabetes to age and weight tnatched controls. Patients 
with diabetes had significantly higher VLDL triglyceride and VLDL triglyceride/apo B 
ratios than controls. In addition individuals with type 2 diabetes had a significantly 
higher rate of hepatic VLDL apo B secretion than controls. Similar increases in hepatic 
VLDL apo B secretion rates have been found in patients with type 2 diabetes in other 
studies done using stable isotopes (Ouguerran1 et al, 2003) and most studies using 
radioactive isotopes (Kissebah et al, 1982; Taskinen et al, 1986). 
Cmmnings et al (Cummings et al, 1995b) found no significant difference in fi·actional 
catabolic rate of VLDL apo B between people with diabetes and controls. However 
smne studies have found that people with diabetes have a decreased catabolic rate of 
VLDL apo B and triglycerides (Duvillard et al, 2000; Kissebah et al, 1982; Ouguerram 
et al, 2003; Taskinen et al, 1986). Kissebah (Kissebah et al, 1982) studied patients with 
diabetes with normal and abnormal plasma lipids. They found both groups had an 
increased secretion rate ofVLDL apo Band triglyceride. People with normal lipid levels 
had an increased fractional catabolic rate whereas those with abnonnal plasma lipids had 
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a normal catabolic rate ofVLDL apo B. This suggests that the hypertriglyceridaemia of 
type 2 diabetes is predominately due to VLDL overproduction with reduced clearance 
playing a role in smne instances, for exatnple when there is tnarked insulin deficiency or 
poor glycaemic control (Lewis et al, 2002). Reduced catabolism of VLDL may reflect 
decreased activity of LPL, the enzyme which hydrolyses triglyceride frmn VLDL. The 
concentration of LPL at the endothelial surface of adipose tissue and tnuscle is largely 
controlled by insulin (Snidennan et al, 2001). There is evidence that poorly controlled 
diabetes may be associated with decreased LPL action (Taskinen, 2003). 
VLDL can be subdivided by density into large, buoyant VLDLl and smaller, denser 
VLDL2 (Millar and Packard, 1998; Packard et al, 2000). The availability of triglyceride 
affects the size of the VLDL particles which are secreted. In the presence of excess 
triglyceride large triglyceride-rich VLDL1 is secreted (Ginsberg, 1998) as opposed to 
cholesterol ester rich VLDL 2. 
It has been proposed that the production of increased amounts ofVLDLl is tnore likely 
to lead to the formation of small dense LDL through enhanced CETP mediated 
triglyceride and cholesterol ester exchange between VLDL and LDL (Millar and 
Packard, 1998; Packard et al, 2000). There may be a threshold of 1.5mmol/L for 
triglyceride above which there is an increase in the propmtion of small dense LDL. This 
explains the presence of small dense LDL in type 2 diabetes and other insulin resistant 
states. 
Increased hepatic VLDL secretion in type 2 diabetes and other states of insulin 
resistance probably occurs for a number of reasons. There is increased fatty acid flux to 
the liver because of defective esterification and re-esterification of fatty a9ids in adipose 
tissue and possibly reduced insulin mediated suppression of hormone sensitive lipase 
(Lewis et al, 2002). Increased FF A flux to the liver increases the hepatocyte fatty acid 
pool size and esterification of fatty acids is favoured over oxidation. Esterified fatty 
acids are stored as triglyceride or directed towards VLDL synthesis increasing the 
VLDL secretion rate. 
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Clu·onic hyperinsulinaemia was assumed to have a direct role in causing increased 
VLDL secretion (Lewis et al, 1993). However in clinical situations insulin treatment 
generally has a beneficial effect on the dyslipidaemia associated with type 2 diabetes. 
Hypertriglyceridaetnia is reduced with an associated reduction in VLDL and IDL and a 
decreased triglyceride content of VLDL. Conversely LDL cholesterol concentration is 
not normally affected by insulin (Duvillard et .al, 2000). 
It may be predicted that insulin therapy would reduce apo B secretion rate because 
insulin suppresses plasma FFAs due to its anti-lipolytic effect on adipose tissue. This 
reduces the flow of FFA to the liver and hence the substrate for ｖｌｄｾ＠ production. As 
expected most in vitro studies have shown an acute suppressive effect of insulin on 
VLDL apo B production (Mahnstrom et al, 1998). In vivo studies in normal volunteers 
have also shown that hyperinsulinaemia acutely suppresses VLDL production (Lewis et 
al, 1994; Watts et al, 1996). Siinilar results have been found in patients with type 2 
diabetes (Cummings et al, 1995a). This study showed that during a hyperinsulinaemic 
euglycaetnic clatnp VLDL apo B secretion rate decreased cmnpared with a control 
(saline) infusion. There was no effect on catabolic rate ofVLDL apo B. 
Insulin may have a direct effect on VLDL apo B production as well as the indirect effect 
through reduction in FF As. Acipimox is a drug which reduces the availability of FF As. 
The effects of insulii1 and acipin1ox on VLDL apo B production were compared in 
healthy tnen using a stable isotope tnethodology. Acipimox did not suppress VLDL 
apoB production to the satne degree as an insulin infusion despite similar suppression of 
FFAs. Interestingly insulin markedly reduced the production ofVLDLl particles but did 
not change the production of smaller and tnore dense VLDL2 particles (Malmstrmn et 
al, 1998). These authors suggest that this is evidence for the independent regulation of 
the secretion ofVLDLl and 2 particles. 
Previous work using radio-isotopes had shown that people with type 2 diabetes failed to 
suppress VLDLl apo B production in response to acute hyperiilstllinaetnia compared to 
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controls. Si.tnilar results were found in group of obese people cotnpared to controls 
(Lewis et al, 1993). However this group used a lower dose of insulin compared with 
Cmrunings (Cummings et al, 199Sa) and the patients who were studied had lower 
triglyceride levels. 
Duvillard et al (Duvillard et al, 2000) studied the effect of chronic insulin treatment on 
kinetics of VLDL, IDL and LDL metabolistn. They looked at six patients before and 2 
months after the introduction of insulin therapy for poorly controlled type 2 diabetes 
(mean HbA1c before insulin 9.3%). Kinetic studies were done in the fed state. Food 
i.t1take was fi:actionated into stnall portions which were consumed every 2 hours to 
attempt to avoid variations in hepatic apo B 100 secretion. Compared to unmatched 
controls patients with type 2 diabetes had an increased VLDL apo B plasma 
concentration, an increased production rate of VLDL apo B and a decreased 
transformation rate of VLDL into IDL and LDL. Insulin therapy led to a 35% reduction 
in plasma triglycerides (non-significant) and no significant change in HDL or LDL 
cholesterol concentration. Insulin did lead to a significant reduction in triglyceride/apo B 
ratio in the VLDL particles and a decrease in VLDL apo B plastna concentration related 
to a significant increase in VLDL apo B fractional catabolic rate towards IDL and LDL. 
Insulin did not decrease VLDL apo B production rate. In keeping with these studies, 
Lewis et al (2002) have shown that rat hepatocytes incubated with high concentrations 
of insulin for 3 days no longer responded to insulin suppression of VLDL apo B 
secretion but had higher basal levels of VLDL apo B secretion. Therefore the evidence 
suggests that acute hyperinsulinaetnia suppresses VLDL apo B production by the liver in 
normal individuals. Those with chronic insulin resistance or hyperinsuli.t1aemia are 
resistant to this effect and have i.t1creased secretion of VLDL. However, high doses of 
insulin can suppress VLDL secretion i.t1 those with insulin resistance. 
Therefore it seems that hypermsulinaetnia per sae is not the cause of the lipid 
abnormalities in type 2 diabetes. Rather it seems that i.t1creased flux of fatty acids to the 
liver associated with insulin resistance increases hepatic triglyceride synthesis and 
secretion and cholesterol ester synthesis (Sniderman et al, 2001). The availability of 
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these lipids influences the post-translationaltnetabolism of apo B and hence its secretion 
rate (Ginsberg, 1996). This appears to be one ofthe factors in the increase in secretion of 
VLDL particles in type 2 diabetes. Another factor tnay be increased expression of MTP 
which contributes to decreased degradation of apo B (Taskinen, 2003). In an animal 
model of insulin resistance and dyslipidaetnia, the fructose fed Golden Hatnster, 
hamsters that were fructose-fed developed VLDL over-secretion compared to controls. 
In addition they showed a significant increase in the amount of newly synthesised apo B 
that was secreted rather than broken down. There was a 2 fold increase in MTP in 
insulin resistant animals and the authors speculate that this may be the mechanism 
behind the over-secretion ofVLDL apo B seen in insulin resistant humans (Taghibiglou 
et al, 2000). 
Although people with type 2 diabetes often have a normal or only moderately raised 
LDL concentration there is evidence that LDL apo B metabolism may be impaired. The 
LDL apo B production rate has been reported to be normal or increased whereas LDL 
apo B catabolic rate is reported to be decreased (Duvillard et al, 2000; Ouguerratn et al, 
2003), contributing to a prolonged residence titne for LDL. This prolonged residence 
time increases the risk of oxidation and glycation of LDL particles. The uptake of 
oxidised LDL by tnacrophages is an important step in the development of 
atherosclerosis. The glycation of LDL can promote its subsequent . oxidation and also 
renders it more prone to be taken up by macrophages (Duvillard et al, 2000). 
Hyperglycaemia may induce an increase in glycation of proteins such as LDL (Sobenin 
et al, 1996). 
Individuals with type 2 diabetes tend to have low levels of HDL cholesterol (Ginsberg, 
1996). This is thought to be tnultifactorial but an in1portant factor is increased transfer of 
cholesterol ester from HDL to triglyceride rich lipoproteins with reciprocal transfer of 
triglyceride to HDL (Krauss, 2004). Triglyceride rich HDL particles are hydrolysed by 
hepatic lipase and the stnaller denser HDL are rapidly catabolised and cleared from 
plasma. Typically in type 2 diabetes the reduction in HDL levels is seen in HDL2 with 
relative or absolute increases in the concentration ofthe smaller and more dense HDL3. 
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In summary it can be seen that the typical dyslipidaemia of type 2 diabetes stems from 
increased VLDL secretion. Hence studies ofVLDL apo BlOO secretion are fundamental 
to our understanding of the increased macrovascular risk of individuals with type 2 
diabetes. 
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Thiazolidinediones 
History of development 
The thiazolidinediones (TZDs) are a relatively new class of drugs for the treatment of 
type 2 diabetes. Their introduction was met with tnuch excitement as they were the first 
new agents for the treatment of type 2 diabetes for several decades. In addition they have 
a novel mode of action targeting insulin resistance. Ciglitazone was the ftrst ofthe TZDs 
to be described (Day, 1999; Gale, 2001). It is a clofibrate analogue and was initially 
screened as a potential lipid-lowering agent. It was found to have a glucose lowering 
effect but was abandoned due to liver toxicity (Gale, 2001). 
Troglitazone was the first TZD to be introduced for clinical use in 1997 (Day, 1999; 
Gale, 2001). It was withdrawn by the UK Medicines Control Agency with the support of 
the pharmaceutical company that was marketing it in the UK (GlaxoWellcmne) in 
Decetnber 1997. This was 6 weeks after it was launched and followed concerns about 
liver toxicity (Day, 1999; Gale, 2001). At this time there had been 135 cases of serious 
hepatotoxicity and 6 deaths attributed to troglitazone. It was not withdrawn in the USA 
until March 2000 by which time 60 patients had-died of liver problems and 10 patients 
had received liver transplants (Gale, 2001). 
Rosiglitazone and pioglitazone are the 2 TZDs which are currently licensed for the 
treatment of type 2 diabetes. They were launched in the USA in 1999 and in the UK in 
2000 (Gale, 2001). 
Mechanism of action 
The TZDs are selective ligands of the nuclear transcription factor peroxisome 
proliferator-activated receptor (PPAR)-y. The PPARs are part of the nuclear hormone 
receptor family. This is a super-family of ligand modulated transcription factors and 
includes the steroid and thyroid hormone receptors (Escher and Wahli, 2000). They 
activate target genes by binding specific DNA sequences or response elements and have 
a cotrunon structure. 
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There are 3 known PPAR isotypes, PPAR-a, ｐｐａｒＭｾ＠ (or PPAR-o) and PPAR-y and 
they share a relatively close amino acid sequence homology (Escher and Wahli, 2000). 
In hmnans there are three transcripts of the PPAR-y gene, PPAR-y1, PPAR-y2 and 
PPAR-y3. When PPARs were discovered they were orphan receptors i.e. they had no 
known physiological ligands or activators identified. It is now known that the natural 
ligands for PP AR receptors are medium and long chain fatty acids and eicosanoids. 
(Escher and Wahli, 2000). Other synthetic ligands for PP AR include the fibrate class of 
lipid lowering drugs which show preferential activation of PP AR-a. PP ARs are 
expressed in many tissues in humans. PPAR-a is expressed predominately in the liver, 
heart and muscle as well as in the vascular wall. PP AR-8 is expressed predominately in 
skin, brain and adipose tissue and may play a role in wound healing and nerve 
myelination (Yki-Jarvinen, 2004). 
The TZDs are high affmity ligands for PPAR-y in-vitro (Camp et al, 2000). PPAR-y is 
particularly highly expressed in adipose tissue. It is also found in pancreatic beta cells, 
vascular endothelium and macrophages and has low expression in skeletal muscle, liver, 
heart and bone tnarrow stromal cells (Yki-Jarvinen, 2004). It is thought that activated 
PP AR-y modulates transcription of genes that are important in glucose and lipid 
metabolism, for example LPL, fatty acid transport protein and fatty acid translocase in 
adipose tissue (Escher and Wahli, 2000). 
Ligand binding causes a conformational change in PP AR-y. This promotes the 
recruitment of co activators such as steroid receptor co activator -1 (SRC-1) and causes 
the release of corepressors. Ligands differ in their ability to interact with co-activators 
which explains the various biological mechanisms observed (Yki-Jarvinen, 2004). 
PP ARs can then regulate gene expression by 2 different 1nechanisms. The frrst is 
transactivation which involves binding to PP AR response elements of target genes and 
heterodimerization with the retinoid X receptor. The second mechanisn1 is 
transrepression which involves interfering with other transcription factor pathways in a 
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DNA independent manner (Camp et al, 2000; Escher and Wahli, 2000; Schoonjans et al, 
1997; Stumvoll and Haring, 2002; Yki-Jarvinen, 2004). 
Mutations ofPP AR-y provide evidence that it plays a role in adipocyte differentiation. A 
1nutation that makes PP AR-y more active causes increased adipocyte differentiation and 
obesity. Conversely a loss of function mutation leads to partial lipodystrophy with 
subcutaneous fat loss frmn the litnbs and gluteal region but preservation in the 
subcutaneous and visceral abdominal depots (Gurnell et al, 2003). Severe insulin 
resistance is a consistent finding in subjects with loss of function mutations. 
The insulin sensitising action of TZDs is probably secondary to effects on adipose 
tissue. TZDs increase the number of small adipocytes and subcutaneous adipose tissue 
1nass in animal models (Yki-Jarvinen, 2004). It has been hypothesised that part of their 
insulin sensitising effect may occur through the uptake and storage of fatty acids in 
adipose tissue. This increases adipose tissue 1nass but 1neans that other insulin sensitive 
tissues such as liver and skeletalinuscle are spared from increased fat concentrations and 
this leads to an improve1nent in insulin sensitivity (Ravussin and Smith, 2002; 
Schoonjans et al, 1997; Shulman, 2000; Yki-Jarvinen, 2004). TZDs seem to 
preferentially induce differentiation of subcutaneous adipose tissue rather than visceral 
adipose tissue. Subcutaneous fat is more metabolically favourable than visceral fat 
(Stumvoll and Haring, 2002). There is evidence from rats that decreased circulating fatty 
acid levels may precede the hnprovetnents in blood glucose (Tordjman et al, 2003). 
There is also supporting evidence for this from human in-vivo studies looking at liver 
and muscle fat content before and after TZD treatment. TZDs have been shown to lower 
circulating FF As and triglyceride content in the liver but not in skeletal n1uscle (Bajaj et 
al, 2003; Bajaj et al, 2004; Mayerson et al, 2002). 
It is now recognised that adipose tissue is not just a storage depot for fat, it is also 
metabolically active. It releases various proteins or adipocytokines in response to certain 
stimuli. These proteins include leptin, TNF-a, resistin and adiponectin. They appear" to 
play important roles in insulin resistance, hyperglycaemia and dyslipidae1nia (Bajaj et al, 
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2004). TZDs tnay also improve insulin sensitivity by altering the expression and release 
of these adipocytokines (Stmnvoll and Haring, 2002). 
Adiponectin is reduced in hutnans with type 2 diabetes and it has been postulated that 
this may contribute to the development of type 2 diabetes and obesity. Treatment of 
humans with TZDs leads to an increase in adiponectin and this may 1nediate smne of 
their insulin sensitising effects possibly related to a decrease in hepatic fat (Bajaj et al, 
2004). 
The action of TZDs may not be restricted to adipose tissue, PP AR-'Y is also present in 
skeletal muscle and liver where TZDs may directly affect insulin sensitivity. There is 
evidence for this theory frmn the lipoatrophic mouse where thiazolidinediones improved 
insulin sensitivity despite the absence of adipose tissue (Stumvoll and Haring, 2002). 
To sunm1arise, the effects ofTZDs can be seen in a variety of tissues and probably result 
from a number of different mechanisms including altering expression of genes involved 
in lipid and glucose tnetabolism, effects on adipocyte differentiation and production of 
adipocytokines. 
PPAR-a 
PPAR-a. regulates expression of genes involved in lipid catabolism such as LPL. The 
fibrate class of drugs which are used as lipid lowering agents activate PPAR-a.. The 
increased expression of LPL causes increased lipolysis of triglyceride rich lipoproteins 
and the uptake of fatty acids by cells (Escher and Wahli, 2000). They increase HDL 
production by the liver, increase cholesterol removal from cholesterol laden 
macrophages to HDL by the transporter ATP cassette binding protein- I (ABCI) and the 
receptor SRBl and increase cholesterol uptake from HDL to the liver (Sacks, 2002). 
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Clinical effects of thiazolidinediones 
Blood glucose lowering 
The blood glucose lowering effect ofTZDs have been demonstrated in animal models of 
insulin resistance, for instance the db/db and ob/ob mouse (Chang et al, 1983; Stevenson 
et al, 1990; Young et al, 1995). Similar effects have been detnonstrated in the KK mouse 
and the Zucker fatty rat (Fujita et al, 1983; Fujiwara et al, 1988). Blood glucose 
improves without an increase in insulin levels and studies have shown a decrease in 
insulin levels (Chang et al, 1983; Fujiwara et al, 1988; Stevenson et al, 1990). TZDs 
have been shown to have no effect on blood glucose in insulin deficient animal 1nodels 
of diabetes including the spontaneously diabetic Chinese hamster and 1nice with 
streptozotocin induced diabetes (Chang et al, 1983). They also have been shown to have 
no blood glucose lowering effect in nonnal rats (Fujiwara et al, 1988). This led to the 
conclusion that these agents work by sensitising the body to endogenous insulin 
(Stumvoll and Haring, 2002). 
Euglycaemic hyperinsulinaetnic cla1np studies in dogs (Matsuhisa et al, 1997) and in rats 
(Lee et al, 1994; Oakes et al, 1994) have confn·med that thiazolidinediones improve 
insulin resistance. The iinprovement in insulin sensitivity has been demonstrated to be 
mediated through increased insulin stimulated glucose disposal (i.e. peripheral insulin 
sensitivity) (Lee et al, 1994) and by enhancing the suppressive effect of insulin on 
hepatic glucose production (Lee et al, 1994; Oakes et al, 1994). Interestingly 
enhancement of peripheral glucose disposal was confmed to insulin resistant rats (Oakes 
et al, 1994) and in alloxan induced diabetic dogs who are insulin deficient and insulin 
resistant there was no marked effect on glucose disposal (Matsuhisa et al, 1997). 
Evidence from human studies 
The blood glucose lowering effect of TZDs has also been de1nonstrated in clinical 
studies in humans. Troglitazone was demonstrated to be effective at lowering blood 
glucose and glycosylated haetnoglobin in 1nonotherapy and in combination with 
metformin in patients with type 2 diabetes (Inzucchi et al, 1998). In a placebo controlled 
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trial troglitazone was den1onstrated to lower HbAlc and fasting glucose when used in 
combination with insulin. This was despite insulin doses being decreased to prevent 
hypoglycaetnia in the treatment group (Schwartz et al, 1998). 
The first large scale multi-centre trial ofpioglitazone was published in 2000 (Aronoff et 
al, 2000) confirming the effects detnonstrated in smaller Japanese studies. 408 patients 
with type 2 diabetes were randomised to placebo or 7.5, 15, 30 or 45mg ofpioglitazone 
for 26 weeks. Patients had to have an HbAlc of more than 7% and if they were already 
receiving anti-diabetic medication they were required to stop this 8 weeks before 
commencing the study medication. 31% of patients were on no anti-diabetic medication 
· prior to entering the trial and 13% were on 2 or more medications. There was a high 
drop out rate in the study mainly due to poor diabetic control. Only 33% of patients in 
the placebo group cmnpleted the study and between 44 and 58% in the pioglitazone 
groups. Pioglitazone ilnproved fasting glucose and HbAlc when compared to placebo. 
There was no statistically significant effect on HbAlc with 7.5mg compared to placebo. 
Statistically significant decreases in fasting blood glucose were noticed by the second 
week of therapy and in HbAlc by the 14111 week of treatment in the 15, 30 and 45mg 
groups. HbAlc fell by 1% in the 15mg group and the 30mg group and 1.6% in the 45mg 
group when compared to placebo. 
Other studies have demonstrated sin1ilar effects on glycaetnic control with pioglitazone 
monotherapy (Rosenblatt et al, 2001). Since then pioglitazone has been studied in 
cmnbination with sulphonylureas (Kipnes et al, 2001; Miyazaki et al, 2001 i) and been 
shown to decrease HbAlc and fasting glucose when compared to placebo. HbAlc 
typically decreases by about 1% with 15mg pioglitazone and 1.3% with 30nlg 
pioglitazone. 
The effects of pioglitazone have been studied in cmnbination with metformin with 
similar results (Einhorn et al, 2000). In an open label e>..1ension of this study the effects 
on HbAl c were tnaintained for over a year. Pioglitazone has also been shown to produce 
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reductions in HbA1c in cmnbination with insulin in type 2 diabetes (Rosenstock et al, 
2002). 
Similarly rosiglitazone has been shown to have anti-hyperglycaemic effects as 
monotherapy (Lebovitz et al, 2001) reducing HbAlc by 1.2% with 4mg and 1.5% with 
8mg. It has been den10nstrated to be effective in combination with sulphonylureas 
(Wolffenbuttel et al, 2000), tnetformin (Fonseca et al, 2000) and insulin (Raskin et al, 
2001). 
There is evidence fron1 human studies that the anti-hyperglycaetnic effect of 
thiazolidinediones is mediated through unproving insulin resistance. lndu·ect evidence is 
provided by the finding that insulin levels decrease despite an improvement in blood 
glucose (Mayerson et al, 2002). Hyperinsulinaemic euglycaetnic clamp studies in 
subjects with type 2 diabetes have confirmed unproved insulin sensitivity with 
rosiglitazone (Carey et al, 2002; Mayerson et al, 2002; Miyazaki et al, 2001h). Similar 
results have been found with troglitazone (Inzucchi et al, 1998) and pioglitazone 
(Kawamori et al, 1998; Miyazaki et al, 2001i). 
Clamps using supraphysiological doses of insulin have shown this increase in insulin 
sensitivity to be mediated through unproved insulin stimulated glucose disposal (Carey 
et al, 2002; Mayerson et al, 2002). However a placebo controlled study that used a 2 step 
clamp (low and high dose insulin) with stable isotopes in patients with type 2 diabetes 
before and after ｲｯｳｩｧｬｾｴ｡ｺｯｮ･＠ treatn1ent (Miyazaki et al, 200 1g) found increased insulin 
sensitivity at both the level of the liver and the periphery. ltnprovements in peripheral 
and hepatic insulin sensitivity have also been demonstrated with a 2 dose clatnp 
following pioglitazone treatment (Miyazaki et al, 200li). 
Comparisons with other agents 
A head to head study con1pared pioglitazone (initial dose 30mg, titrated to 45mg) and 
glibenclamide (initial dose 1. 75mg, titrated to 1 0.5mg) in patients with type 2 diabetes 
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(Tan et al, 2004). In this study which was sponsored by Eli Lilly and Cotnpany, effects 
on HbAlc were similar (-0.4% glibenclatnide and -0.5% for pioglitazone) in the 
intention to treat analysis although there was a significantly greater effect on HbAlc 
with pioglitazone for completers (-1.2 vs. -0.6%). The authors point to a difference in 
the pattern of response to treatment, HbAlc declined earlier for patients on 
glibenclatnide, HbAl c was significantly lower at 12 weeks but was significantly higher 
at 52 weeks than with pioglitazone. However again this appears to be a cmnpleter 
analysis rather than intention to treat analysis. Adverse events were higher in the 
glibenclamide group but weight increased tnore with pioglitazone (mean increase 3.0 
compared to l.lkg) and peripheral oedema was more cmnmon affecting 26% of patients. 
Approxitnately 60% of patients completed the trial in both groups and the most cmnmon 
reason for discontinuing treatment was perceived lack of efficacy. The authors suggest 
that this study provides evidence of a sustained pattern of effectiveness over time of 
TZDs compared to glibenclamide. However it must be remembered this pattern was only 
seen in the completers analysis and in addition to draw firm conclusions about 
glycaetnic effectiveness over time subjects should be studied for longer than 52 weeks. 
Pioglitazone (initial dose 15mg, titrated to 45n1g) has also been compared to metformin 
(initial dose 850tng, titrated to 2550mg) as add-on therapy to sulphonylureas in a double 
blinded controlled trial in 639 patients in Europe and Canada (Hanefeld et al, 2004). 
After 5 weeks cmnpletion rate was higher in the tnetformin group (87.2 vs. 81.5%) and 
HbAlc decreased tnore in the tnetformin group (1.36% vs. 1.2%) although this was not 
statistically significant. The pattern of response to treatment and the adverse event rate 
were similar in both groups although the serious adverse event rate was higher in the 
metformin group. There was a tnean weight gain of 2.8kg in the pioglitazone group 
compared to a mean weight loss of lkg in the tnetfonnin group. Studies which compared 
pioglitazone and metfonnin as tnonotherapy for type 2 diabetes have also found similar 
effects on HbAl c but more weight gain with pioglitazone (Pavo et al, 2003; 
Schernthaner et al, 2005). 
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These studies suggest that TZDs are as effective and as well-tolerated as sulphonylureas 
and tnetfonnin. They cause tnore weight gain than both agents and there is smne 
possible support for the theory that the hypoglycaemic effect of TZDs may be more 
sustained than with sulphonylureas. 
Effect of TZDs on lipids 
TZDs consistently lower free fatty acid concentrations in clinical studies, (Bajaj et al, 
2004; Miyazaki et al, 200lf; Yki-Jarvinen, 2004). Both pioglitazone and rosiglitazone 
have been reported to increase HDL cholesterol. However it has been proposed that they 
have· different effects on LDL-cholesterol and triglyceride concentrations. This has 
important clinical itnplications. A systetnatic review of the published evidence on the 
effect ofpioglitazone and rosiglitazone on plasma lipids is included on page 62. 
Possible mechanism accounting for effect of TZDs on lipids 
The action ofTZDs intnodulating the expression of genes involved in lipid metabolism 
has been discussed. However it is still not clear how they exeti their effect on lipids and 
in particular why there is a differential effect. Pioglitazone and rosiglitazone both 
increase HDL-cholesterol whereas only pioglitazone seems to reduce triglyceride 
concentration. This suggests that these 2 effects are independent of each other. Also both 
drugs reduce glucose and HbAlc concentration so it would seem that the lipid 
modulating effects are independent of the effects on glucose tnetabolism. In addition 
both drugs decrease FF As by a sitnilar amount (Yki-Jarvinen, 2004). Troglitazone has 
been found to increase HDL-cholesterol concentration even in patients whose plastna 
glucose levels did not change again providing evidence for a direct effect of TZDs on 
lipid n1etabolistn (Nozue et al, 1999). The increase in HDL cholesterol may be because 
of enhanced reverse cholesterol transpmi secondary to the promotion of the expression 
of one of the key regulators of HDL metabolism, the ABCAl gene. This action is 
connnon to both PP AR-a and PP AR-y activation and may explain why increases in 
HDL occur with rosiglitazone, pioglitazone and fibrates (Taskinen, 2003). In vitro work 
with macrophages has shown that troglitazone increased the expression of HMG-CoA 
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synthase and reductase and led to an increase in intracellular cholesterol. It had no effect 
on expression ofLPL unlike PPAR-a. agonists (!ida et al, 2003). 
Other effects of TZDs 
Because of their effects on components of the insulin resistance syndro1ne such as 
hyperglycaemia and dyslipidaemia there has been interest in the effects of TZDs on 
other markers of cardiovascular risk. Studies have found a reduction in C reactive 
protein and tnatrix metalloproteinase 9 with TZD treatment (Haffner et al, 2002) and 
possible beneficial effects on PAI-l, vascular function, blood pressure and urinary 
albumin to creatinine ratio (Yki-Jarvinen, 2004). This is an area that continues to 
generate tnuch research interest. 
Troglitazone has been demonstrated to delay the decline in beta cell function which 
leads to the onset of type 2 diabetes (Buchanan et al, 2002). In a placebo controlled trial 
Hispanic women with a previous history of gestational diabetes were randmnised to 
placebo or troglitazone. The trial was stopped early when troglitazone was withdrawn 
fron1 the U.S . market. However during this tune the annual incidence of diabetes was 
12.1 and 5.4% in the placebo and troglitazone groups respectively. Those protected from 
diabetes showed an initial improvetnent in insulin sensitivity (1neasured by intravenous 
glucose tolerance test) and the protective effect was most prominent in those who 
responded to the increase in insulin sensitivity by increasing insulin output. Current 
studies (Gerstein et al, 2004) are ongoing to see if diabetes can be prevented in high risk 
individuals using rosiglitazone. 
Currently TZDs are only licensed for the treatment of type 2 diabetes. However because 
of their action on insulin resistance they are being tested for a variety of other conditions 
where insulin resistance is thought to play a role. These include polycystic ovary 
syndrome, lipodystrophies and non-alcoholic fatty liver. 
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Non-alcoholic fatty liver is a condition where lipid, mainly as triglyceride accmnulates 
in the liver. Extensive accumulation is regarded as a pathological condition which can 
progress to cirrhosis and unpaired liver function (Mayes, 2003). Fatty liver is now the 
most common cause of elevated liver enzytnes in the United States (Yki-Jarvinen, 2004) 
and is strongly associated with insulin resistance. It has been suggested that it results 
from increased Inobilization of fat from adipose tissue and decreased hepatic fatty acid 
oxidation (Bajaj et al, 2004). Recently TZDs have been shown to reduce fat 
accumulation in the liver in patients with type 2 diabetes, (Bajaj et al, 2003; Bajaj et al, 
2004), and 1nay also induce improvements in liver histology (Yki-Jarvinen, 2004). 
Several studies have found improvements in liver function in individuals with type 2 
diabetes treated with pioglitazone (Hanefeld et al, 2004; Tan et al, 2004), and this is an 
area that is currently generating n1uch research interest. 
Diffel'ential effects of TZDs 
There is son1e evidence from in-vitro studies that TZDs may act differently at the PP AR-
'Y receptor (Camp et al, 2000). It has also been observed that troglitazone and 
rosiglitazone have different effects on gene transcription. The authors speculate that this 
could represent differential recruitment of coactivators or be associated with differential 
expression of the PPAR-yl, and PPAR-y2 isofonns. There has been speculation that the 
differential effect on lipids Inay be explained because pioglitazone tnay act like a partial 
PP AR-a. agonist in vitro whereas rosiglitazone seems to be a pure PP AR-y agonist (Yki-
Jarvinen, 2004). The liver toxicity that resulted in the removal ·of troglitazone from the 
tnarket has not been demonstrated to be a problen1 with pioglitazone and rosiglitazone. 
This may be because of different metabolic degradation by the cytochrome P450 
enzyme cmnplex and the different structure oftroglitazone (Stumvoll and Haring, 2002). 
Problem witlt TZDs 
As previously discussed weight gain is a problem with TZDs. This may be due to 
expansion of the subcutaneous fat depot and in some cases to oedema. Oedema develops 
ii1 between 3 and 5% of patients when a TZD is used as Inonotherapy and is slightly 
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tnore fi·equent when these agents are used as combination therapy (Nesta et al, 2004). 
This percentage increases up to about 15% in cmnbination with insulin. Up to 1% of 
patients develop congestive cardiac failure and this is pat1icularly in patients already on 
insu_lin therapy, on higher doses ofTZDs or with pre-existing cardiac disease. The initial 
trials of TZDs excluded patients with New York Heart Association grade 3 or 4 cardiac 
functional status so these figures may under-estimate the risk in a non-selected 
population. 
Another problem with TZDs is that to date there is no long term outcome data. The 
UKPDS has demonstrated the safety of sulphonylureas, metfonnin and insulin for the 
chronic treatment of type 2 diabetes. However the longest studies using TZDs are a 
maximum of 4 years and most are a year or less. Most of the excess morbidity and 
mortality in type 2 diabetes is related to macrovascular disease but studies assess 
efficacy using surrogate markers such as HbA 1 c. Ideally studies would demonstrate not 
only that these agents are safe for chronic use, that they improve glycaetnic control but 
also that they decrease morbidity and n1ortality associated with type 2 diabetes. This 
may well be addressed when the results of ongoing studies such as 'The prospective 
Pioglitazone Clinical Trial in Macrovascular Events (PROactive)' are published 
(Charbonnel et al, 2004). 
As discussed earlier, troglitazone was withdrawn because of liver toxicity. Because of 
this when rosiglitazone and pioglitazone were launched it was recon1111ended that liver 
function tests were checked prior to initiation of therapy and then bi-tnonthly. However 
it seems that the hepatoxicity associated with troglitazone was an idiosyncratic reaction 
related to the generation of a toxic tnetabolite and not a class effect (Yki-Jarvinen, 
2004). Recently the European Medicines Evaluation Agency has retnoved the 
requirement for bi-n1onthly monitoring of liver function and now recmnmends that liver 
function is checked before initiation of therapy and thereafter on clinical grounds. 
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The effect of the thiazolidinediones pioglitazone and rosiglitazone 
on lipids in patients with type 2 diabetes mellitus: a syste1natic 
revrew 
Abstract 
Background: The thiazolidinediones have recently been introduced for the treatment of 
type 2 diabetes. As well as effects on glucose lowering there is evidence they may affect 
blood lipids. 
Method: Double blind, randmnised, placebo controlled trials of rosiglitazone or 
pioglitazone which included data on lipids cmnpared to baseline or placebo were 
identified using Medline, E1nbase and the Cochrane controlled trials database. 
Results: 10 studies using pioglitazone and 12 studies using rosiglitazone were identified. 
Rosiglitazone increased LDL and total cholesterol compared to baseline whereas 
pioglitazone had no effect. Both drugs increased HDL cholesterol and pioglitazone 
decreased triglycerides. 
Discussion: · The two commercially available thiazolidinediones have different effects on 
blood lipids in patients with type 2 diabetes. This difference remains to be explained and 
1nay have therapeutic hnplications. 
Introduction 
There is evidence that the 2 cmrunercially available thiazolidinediones (TZDs), 
pioglitazone and rosiglitazone have different effects on blood lipids. This has 
implications for prescribing. The objective ofthis chapter is to systematically review the 
evidence for the effect of pioglitazone and rosiglitazone on lipids (total cholesterol, 
LDL-cholesterol, HDL-cholesterol and triglyceride). 
Method 
Search Strategy 
A search was made ofMedline, Embase and the Cochrane controlled trials database. In 
addition the citation lists of related papers were searched. 
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Search Methods 
The key words pioglitazone and rosiglitazone were used. Inclusion criteria were double 
blind, randomised, placebo controlled trials that include measurement of total 
cholesterol, LDL-cholesterol, HDL-cholesterol or triglyceride before and after treattnent 
with pioglitazone or rosiglitazone in monotherapy, combination therapy or with insulin. 
Selected studies were written in English and participants were adults with type 2 
diabetes. The outcome measures were change in total cholesterol, LDL-cholesterol, 
HDL-cholesterol and triglyceride compared to placebo or baseline following therapy 
with TZDs. 
Results 
The initial search was carried out in Septetnber 2003. With Medline, using rosiglitazone 
as a keyword 842 references were identified. The search was restricted to 'English 
language' and 'hmnan' leaving 476 references. With Medline, using pioglitazone as a 
keyword 590 references were identified, this was reduced to 290 ｲ･ｦ･ｲｾｮ｣･ｳ＠ when 
restricted to 'human' and 'English language' papers. Abstracts for all 476 rosiglitazone 
references and all 290 pioglitazone references were screened and if the paper was 
deemed suitable the whole paper was read. The search was repeated in March 2004 
when 2 reviews of thiazolidinediones were identified (Buse et al, 2004; van Wijk et al, 
2003). From the citation list of these 2 review papers 2 additional papers were identified 
(Carey et al, 2002; Kawamori et al, 1998). No extra papers were identified by doing 
searches ofEmbase and the Cochrane randomised controlled trial database. 
A total of 10 suitable papers using pioglitazone and 12 suitable papers using 
rosiglitazone were identified. There were no direct head to head comparisons of 
rosiglitazone and pioglitazone. One study (Khan et al, 2002) randomised patients to 
pioglitazone or rosiglitazone after troglitazone was withdrawn but was rejected as it was 
an open study. Studies that were not placebo controlled (Miyazaki et al, 2002a), not 
randomised (Ballary and Desai, 1999; Ko et al, 2003; Yamasaki et al, 1997) or open (St 
John et al, 2002; Vongthavaravat et al, 2002) were also rejected. In addition double 
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blinded placebo controlled studies that had no outcome data· on lipids were rejected 
(Scherbautn et al, 2002). Studies that compared pioglitazone to tnetformin rather than 
placebo were also rejected (Bajaj et al, 2004; Pavo et al, 2003). 
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Table 5 and Table 6 contain the characteristics of suitable studies that were identified. In 
total 4170 subjects were treated with rosiglitazone and 2487 subjects with pioglitazone. 
Table 7 and Table 8 contain the clinical characteristics of the selected studies. Some of 
the studies were dose fmding studies and used much smaller doses of TZDs than would 
be used clinically. Therefore for effect on HbAlc and lipids only clinically relevant 
doses have been given (for pioglitazone 15n1g, 30mg and 45mg and for rosiglitazone 
4mg and 8mg). 
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Table 5 Characteristics of selected rosiglitazone studies 
First Author y= Copatry .or. % ｾ･＠ Dose$ Duratioa ' %''·· 1i< JP1e a.sea. of study. 
'X pu. ｾｾ ｾ ｰｬｹ＠ --'' 11::o au ｾｾｾＭＺＫ＠ _.. " '"', 'f; isecl'; Ｑ ｾＺ＠ Jill[' ｾ＠ weeb 
Barnett 2003 UK 177 77 28-78 4BD 26 
(54) 
Carey 2002 Australia 33 82 (56) 4BD 16 
Fonseca 2000 USA 348 68 (58) 4,8 26 
(Gomez- 2002 Mexico 116 26 40-76 2BD, 26 
Perez et al) (53) 4BD 
Lebovitz 2001 USA 533 66 (60) 2BD 26 
4BD 
Miyazaki 2001 USA 29 55 (55) 8 12 
2001a 
Nolan 2000 Europe 380 62 39-83 4, 8, 8 
(63) 12 
Patel 1999 USA 380 68 30-83 0.05 12 
(58) BD 
0.25 
BD 1 
BD,2 
BD 
(Phillips et 2001 USA 959 63 (57) 4, 2 26 
al) BD, 
8, 4 
BD 
Raskin 2001 2001 USA 319 56 26-80 4,8 26 
(57) 
Raskin 2000 2000 USA 303 61 (59) 2BD 8 
4BD, 
6BD 
Wolfenbuttel 2000 Europe 593 59 (61) 1 BD, 26 
2BD 
Total 4170 
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Table 6 Characteristics of selected pioglitazone studies 
First Author Yearef , Cowlfry ｎＭ｢･ｲｾ ｩ＠ Age DoSes Daratloa § 
... ｾ＠ Sit, Jatiject$ ", ,Jiale ｾ＠ used, ofqdy Ｇｾ＠ i,vll! '· nu.Cloalised ﾷＭｾ＠ ｾ･ｯＩ＠ llll I" 
!!< Ｇｾ＠ ﾷｾ＠ ·"' ' '''· Ｊｾｾ＠ '¥! 
"" ""''"' ' Aronoff 2000 USA 408 58 29-75 7.5, 26 
(54) 15, weeks 
30,45 
Einhorn 2000 USA 328 57 30 16 
(56) weeks 
Herz 2003 Canada 297 53 24-85 30, 45 16 
and Spain (58) weeks 
Kawamori 1998 Japan 30 63 (59) 30 12 
weeks 
Kipnes 2001 USA 560 59 30-75 15, 30 16 
(57) weeks 
Miyazaki 2001 USA 23 74 (55) 45 16 
2001b weeks 
Miyazaki 2002 USA 58 59 (54) 7.5 26 
2002b 15, weeks 
30, 45 
Nakamura 2001 Japan 20 60 (54) 30 3 
months 
Rosenblatt 2001 USA 197 53 (54) 30 16 
weeks 
Rosenstock 2002 USA 566 47 (57) 15, 30 16 
weeks 
Total 2487 
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Table 7 Clinical characteristics of selected rosiglitazone studies 
Study ｃｯ•｣ﾷｲｲ･ＺＺ ｾ ｲ＠ ｾｾｾｾ ｅｴｦ･､＠ OD ••• ｊｦｾｐｾﾷ＠$ dia ies · · Ale • HbAlc .. ｾａＮＩ＠ te Ｎ ｾﾷﾷﾷＬ＠ ¥< m " do ･ｯｭｰ｡ｾ＠ to ' 
ﾷ［ＧＱＨＧｾ［Ｂ＠ \ll ｾｾ＠ il!l'!§ ｾ＠ !ll baseline f; 
Barnett Added to SU PL 9.06 (1.3) +0.26 93% 
8mg 9.21 (1.27) -1.16 
Carey Diet alone, PL 7.1 (1.4) +0.4 100% 
metformin 4mg BD 7.8 (1.3) -0.7 
withdrawn 
Fonseca Added to PL 8.6 (1.3) +0.45 83% 
metformin 4mg 8.9 (1.3) -0.56 
8mg 8.9 (1.5) -0.78 
Gomez-Perez Added to PL +0.3 78% 
metformin, 2mg BD not given -0.7 
SUs 4mgBD -1.2 
withdrawn 
Lebovitz Monotherapy, PL 9.0 (1.7) +0.9 68.4% 
others 2mg BD 9.0 (1.5) -0.3 
withdrawn 4mg BD 8.8 (1.6) -0.6 
Miyazaki Monotherapy PL 8.3 (0.4) +0.4 100% 
2001a 8mg 8. 7 (0.4) -1.3 
Nolan Monotherapy, Not given Not given 89.7% 
others 
withdrawn 
Patel Monotherapy, PL 9.1 +0.3 82% 
others 2mgBD9.0 -0.1 
withdrawn 
Phillips Monotherapy PL 8.9 (1.5) +0.35 PL 62.6% 
others 4mg 8.9 (1.6) -0.85 ROSI 79.3% 
withdrawn 2mg BD 8.9 (1.5) -0.89 
8mg 8.9 (1.5) -0.80 
4mg BD 9.0 (1.5) -1.11 
Raskin Monotherapy, PL 8.7 (1.6) +1.0 ROSI 87% 
2000 others 2mg BD 8.7 (1.4) +0.4 PL76% 
withdrawn 4mg BD 8.9 (1.4) not given 
6mg BD 8.7 (1.5) not given 
Raskin With insulin PL 8.9 (1.1) +0.1 PL79% 
2001 2mg BD 9.1 (1.3) -0.6 2mgBD 81% 
4mg BD 9.0 (1.3) -1.2 4mg BD 77o/o 
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Wolffenbuttel With SU 
Completi011 
rate 
';; 
PL 9.21 (1.3) +0.2 70% 
ｾＭＭＭＭｾｾＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭｾ＠ 2mg BD 9.23 (1.18) -0.8 
PL = placebo, ROSI = rosiglitazone PIO = pioglitazone and SU = sulphonylurea 
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Table 8 Clinical Characteristics of selected pioglitazone studies 
Study 
1
, A, ConCurRat Meaa iRidal ｾ ｾ ｩｦｬＧ･･ｴ＠ oa Completioa ､ｩ｡｢･ｾ＠ ｾ Ｑ ｾﾷ ｾ＠ bAle{%) rate , 
ｾ Ｇｪ＠ aneclieaftia ｾ＠ mPJ!IMlo ｾﾷ＠
I< '!i ｾ＠ ' ＬｾＬ＠ base1in ' i" ;,; "' !!! , ., e 
Aronoff Monotherapy, PL 10.4 (0.22) +0.7 PL33% 
others 15mg 10.2 (0.22) -0.3 PIO 44-58o/o 
withdrawn 30mg 10.2 (0.21) -0.3 
45mg 10.3 (0.22) -0.9 
Einhorn With PL 9.75 (1.3) +0.2 76% 
metformin, 30mg 9.86 (1.4) -0.6 
others 
withdrawn 
Herz Monotherapy, PL 7.5 -0.2 91.6% 
treatment 30mg 7.5 -0.8 
naive 45mg 7.6 -0.9 
Kawamori Diet or SU PL 8.7 (1.3) -0.9 100% 
30mg 8.4 (1.4) -0.8 
Kipnes With SU, PL9.9 +0.1 85% 
others 15mg10.0 -0.8 
withdrawn 30mg 9.9 -1.2 
Miyazaki With SU PL 7.9(0.3) 0 100% 
2001b 45mg 8.9 (0.3) -1.7 
Miyazaki Monotherapy, PL 8.6 (0.5) +1.2 Not given 
2002b others 15mg 8.0 (0.3) -0.1 
withdrawn 30mg 8.5 (0.5) -0.8 
45mg 9.1 (0.3) -1.8 
Nakamura Mono therapy PL Not given Not given 
or with SU 30mg 7.21 -0.6 
Rosenblatt Monotherapy, PL 10.42 (1.7) +0.76 73% 
others 30mg 10.65 (1.77) -0.6 
withdrawn 
Rosenstock With insulin, PL 9.75 (0.1) -0.26 88% 
others 15mg 9. 75 (0.1) -0.99 
withdrawn 30mg 9.84 (0.1) -1.26 
PL = placebo ROSI = rosiglitazone, PIO = pioglitazone and SU = sulphonylurea 
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Effect on lipids 
In the papers identified effect on lipids was described as change :fi:mn baseline, change 
compared to placebo or both. The most conunonly used method was change fi·om 
baseline. In some papers actual values were given whereas others gave percentage 
changes. Some papers commented on whether the changes seen were significant or not 
without giving absolute values. In addition different papers have used different statistical 
methods. Smne give mean and standard deviation whereas others give geometric mean 
or least squared means and confidence intervals. The significance of change from 
baseline and change cmnpared to placebo was also calculated using a variety of methods 
including t-test and ANOV A. 
The effect of rosiglitazone and pioglitazone on total cholesterol concentration are 
smmnarised in Table 9 and Table 10 respectively. 10 of the 12 rosiglitazone studies 
report on changes in cholesterol concentration. Of these 2 report no significant changes. 
5 find increased cholesterol compared to baseline and placebo, 1 reports increased 
cholesterol compared to placebo and 2 report increased cholesterol cmnpared to 
baseline. In contrast 7 of the 10 pioglitazone studies find no significant change in 
cholesterol concentration following treatment and 3 report an increase compared to 
baseline. 
The effect ofrosiglitazone and pioglitazone on LDL-cholesterol is summarised in Table 
11 and Table 12 respectively. Again rosiglitazone increases LDL-cholesterol in more of 
the studies than pioglitazone. Out of 11 studies that report results for rosiglitazone, 2 
report no significant increase in LDL-cholesterol, 5 report an increase in LDL-
cholesterol compared to baseline and placebo, 3 report an increase cmnpared to baseline 
and 1 reports an increase compared to placebo. 2 pioglitazone studies give no results and 
3 report no significant effect. 1 study finds an increase in LDL-cholesterol compared to 
baseline and placebo but only with 15tng and not with 30mg (Rosenstock et al, 2002). 4 
studies note an increase in LDL-cholesterol compared to baseline however in 2 of these 
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studies the effect is not consistent at different doses (Aronoff et al, 2000; Herz et al, 
2003). 
The effect ofrosiglitazone and pioglitazone on HDL cholesterol is summarised in tables 
Table 13 and Table 14 respectively. Most studies show that these drugs increase HDL-
cholesterol. Only 1 study for each agent finds a non-significant effect. 
The effect of rosiglitazone and pioglitazone on triglyceride concentration is summarised 
in Table 15 and Table 16 respectively. In 9 out of 12 of the rosiglitazone studies there 
was no significant effect on triglyceride concentration. In contrast in 2 of the 
pioglitazone studies there was no effect on triglyceride concentrations, 5 studies found a 
reduction compared to baseline and placebo, 2 studies found a reduction compared to 
baseline and 1 study found a reduction cmnpared to placebo. 
For tables 9-16: 
H represents no statistically significant change 
I represents a statistically significant increase 
-1 represents a statistically significant decrease 
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Table 9 Effect ofRosiglitazone on Total Cholesterol 
Study 
Barnett PL 5.13 Not given 
8mg 5.05 H 
Care Not iven 
Fonseca PL 5.32 5.5 i 
4mg 5.25 5.97 i i 
8mg 5.19 6.01 i i 
Gomez-Perez PL 5.34 5.39 
2mgBD 5.04 5.42 Not given Not given 
4mgBD 5.15 5.71 
Lebovitz PL 5.53 5.68 i Not given 
2mgBD 5.61 6.27 i 
4mgBD 5.64 6.37 i 
Miyazaki PL 4.45 4.38 H 
200la 8mg 4.66 5.05 H 
Nolan Placebo 6.1 6.08 H 
4mg 6.0 6.6 i i 
8mg 6.0 6.78 i i 
Patel PL 5.59 5.74 Not given 
2mgBD 5.42 6.12 i 
Phillips PL 5.5 5.48 
4mg 5.33 5.95 i i 
2mgBD 5.47 6.08 i i 
8mg 5.43 6.28 i i 
4mgBD 5.37 6.12 i i 
Raskin PL 5.7 5.8 H 
2000 2mgBD 5.4 6.2 i i 
4mgBD 5.6 6.4 i i 
Raskin PL 5.36 5.54 i Not given 
2001 2mgBD 5.48 5.99 i 
4mgBD 5.43 6.18 i 
Wolffenbuttel PL 5.6 5.7 H 
2mgBD 5.6 6.0 i i 
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Table 10 Effect ofPioglitazone on Total Cholesterol 
Olaoge 
compand 
ｴｯｾ｢ｯ＠
Aronoff PL 5.82 5.99 
15mg 5.7 5.86 ｾ＠
30mg 5.77 5.89 ｾ＠ ｾ＠
45mg 5.53 5.86 1' ｾ＠
Einhorn PL 5.49 5.55 Not given ｾ＠
30mg 5.51 5.74 1' 
Herz PL 
30mg Not given Not given 1' ｾ＠
45mg ｾ＠ ｾ＠
Kawamori PL 5.2 5.2 
30mg 5.0 5.5 ｾ＠ ｾ＠
Kipnes PL 5.49 5.72 1' 
15mg 5.49 5.54 ｾ＠ ｾ＠
30mg 5.54 5.59 H H 
Miyazaki PL 4.45 4.43 H 
2001b 45mg 4.38 4.20 ｾ＠ Not given 
Miyazaki PL 5.96 5.98 H 
2002b 15mg 5.31 5.36 H H 
30mg 5.78 5.57 H H 
45mg 5.41 5.54 H H 
Nakamura Not given H 
Rosenblatt PL 5.72 Not given H 
30mg 5.75 ｾ＠ ｾ＠
Rosenstock PL 5.54 5.51 H 
15mg 5.52 5.6 H ｾ＠
30mg 5.37 5.39 H H 
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Table 11 Effect ofRosiglitazone on LDL-cholesterol 
Study ＼ｩｾ＠
ｾ＠ Dose ｾｯ･＠ , LDLafter Cltauge Change 
'' treatnleat ｾｰｌ ﾷ＠ Ｎｾ＠ ｾｰ｡ｲ･､Ｎ＠ to compared 
ｾ＠
"'· ·.-
ﾷＬ［［ｾｾ＠ ＼ｭｭｯｬｬｦｩｲ ｾｾｾｾ＠ (mmoJ1L) ﾷＧ ｾｕｮ･＠ to placebo 
Barnett PL 2.98 Not given 
8mg 2.95 H 
Carey 8mg Not given 
Fonseca PL 3.03 3.12 i 
4mg 2.99 3.45 i i 
8mg 2.91 3.45 i i 
Gomez-Perez PL 3.0 2.98 
2mgBD 2.8 2.96 H Not given 
4mgBD 2.77 3.2 i 
Lebovitz PL 3.15 3.3 i 
2mgBD 3.13 3.56 i Not given 
4mgBD 3.21 3.82 i 
Miyazaki PL 2.8 2.82 
2001a 8mg 2.8 3.0 H H 
Nolan PL 4.51 4.63 H 
4mg 4.55 5.04 i i 
8mg 4.39 5.19 i i 
Patel PL 3.37 3.41 Not given 
2mgBD 3.25 3.69 i 
Phillips PL 3.28 3.21 i 
4mg 3.23 3.60 i i 
2mgBD 3.36 3.72 i i 
8mg 3.34 3.88 i i 
4mgBD 3.23 3.62 i i 
Raskin PL 3.4 3.4 H 
2000 2mgBD 3.2 3.7 i i 
4mgBD 3.3 3.7 i i 
Raskin PL 3.1 3.1 H 
2001 2mgBD 3.19 3.43 i Not given 
4mgBD 3.23 3.73 i 
Wo lffenbuttel PL 3.6 3.6 H 
2mgBD 3.6 3.8 i i 
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Table 12 Effect ofPioglitazone on LDL-cholesterol 
Study Dlt.· BaseQn,e ｾｾ＠ aDLafter Change Change ﾷｾ＠ ' ｾ＠ ,, "' ＬｾＮｓ＠ LDL ｾｾｾ＠ ｾ ｴｲ･｡ｴｭ･ｮｴ＠ ,, f• eomj)aJR to compared '*! '?&-' ｾＧＭ il' :(mmol/L)<* , ;r(mmoi!Ll ｾＭ ｬ ｬＧｬ ｢ｾ ｾ＠ to olaeebo 
Aronoff PL 3.59 3.68 H 
15mg 3.42 3.58 i H 
30mg 3.51 3.61 H H 
45mg 3.28 3.51 i H 
Einhorn PL 3.06 3.42 Not given H 
30mg 3.09 3.33 i 
Herz PL 
30mg Not given i H 
45mg H H 
Kawamori Not given 
Kipnes PL 3.21 3.39 i 
15mg 3.21 3.32 i H 
30mg 3.29 3.37 i H 
Miyazaki PL 2.87 2.87 Not given 
2001b 45mg 2.77 2.72 H 
Miyazaki PL 3.7 3.39 H 
2002b 15mg 3.19 3.11 H H 
30mg 3.6 3.42 H H 
45mg 3.34 3.44 H H 
Nakamura Not given 
Rosenblatt PL 3.46 H 
30mg 3.33 H H 
Rosenstock PL 3.39 3.34 H 
15mg 3.3 3.46 i i 
30mg 3.15 3.24 H H 
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Table 13 Effect ofRosiglitazone on HDL cholesterol 
Study Dose BaseHne HDLafter Change Chaage 
HDL treatmeat compared to compared 
(mmoiiL) XmmoiiL) baseline to placebo 
Barnett PL 1.24 Not given Not given 
8mg 1.23 H 
Carey PL 1.0 1.11 i Not given 
8mg 1.0 1.17 i 
Fonseca PL 1.14 1.2 i 
4mg 1.18 1.32 i i 
8mg 1.2 1.32 i i 
Gomez-Perez PL 1.28 1.27 Not given 
2mgBD 1.25 1.38 i 
4mgBD 1.33 1.5 i 
Lebovitz PL 1.11 1.17 i Not given 
2mgBD 1.09 1.2 i 
4mgBD 1.09 1.2 i 
Miyazaki PL 1.01 0.96 i i 
2001a 8mg 0.9 0.98 
Nolan PL 1.17 1.26 i 
4mg 1.21 1.32 i H 
8mg 1.18 1.30 i H 
Patel PL 1.23 1.29 Not given 
2mgBD 1.24 1.39 i 
Phillips PL 1.09 1.22 i 
4mg 1.14 1.24 i i 
2mgBD 1.19 1.29 i i 
8mg 1.11 1.22 i i 
4mgBD 1.09 1.24 i i 
Raskin PL 1.19 1.24 i 
2000 2mgBD 1.13 1.2 i H 
4mgBD 1.17 1.25 H H 
Raskin PL 1.2 1.26 i 
2001 2mgBD 1.21 1.28 H Not given 
4mgBD 1.18 1.34 i 
Wo lffenbuttel PL 1.2 1.2 H 
2mgBD 1.1 1.2 i i 
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Table 14 Effect ofPioglitazone on HDL-cholesterol 
Study nos\( ·"' Basetine '%"' 
1 
*HDI;-•fter Change ｾ＠ Change 
BbL ｾ＠ treatment compand to compared 
'": ·'*" ,;)ifl, ., ﾷｾ＠ 11; ｾ＠ ,.'01/L) ｾｾ＠ ｾ Ｇｬ•ｮｭｬｬｴｬ＠ ., ti'&seline to placebo 
Aronoff PL 1.08 1.15 i 
15mg 1.05 1.18 i H 
30mg 1.06 1.17 i H 
45mg 1.05 1.24 i i 
Einhorn PL 1.09 1.11 Not given 
30mg 1.11 1.22 i i 
Herz PL 1.2 Not given Not given 
30mg 1.14 1.32 i i 
45mg 1.13 1.36 i i 
Kawamori PL 1.5 1.5 Not given 
30mg 1.2 1.3 i H 
Kipnes PL 1.11 1.06 H 
15mg 1.06 1.14 i i 
30mg 1.09 1.19 i i 
Miyazaki PL 0.96 0.93 
2001b 45mg 0.91 0.91 H H 
Miyazaki PL 1.11 1.19 H 
2002b 15mg 1.04 1.17 H H 
30mg 0.96 1.09 i H 
45mg 1.06 1.19 i H 
Nakamura PL Not given Not given H Not given 
30mg i 
Rosenblatt PL 1.02 Not given H 
30mg 1.03 1.19 i i 
Rosenstock PL 1.1 1.1 H 
15mg 1.12 1.2 i i 
30mg 1.11 1.21 i i 
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Table 15 Effect ofRosiglitazone on Triglyceride (TG) 
Study Dose Bilseline TG ｾ＠ TG after Change ,Change 
,. {mmoi/L) I. treatmeJlt 'Compared tO eompared 
ｾ＠ ,. ｾ＠
"' 
ｾ［ＢＢ＠
. ＧＧ､ＧＧｾ＠ .'\ I ｾ ＨｭｭｯｩＯｌＩ ＬＬ＠ baseline to placebo Barnett PL 2.02 Not given Not given 
8mg 1.98 H 
Carey PL 1.6 1.71 H Not given 
8mg 2.6 2.52 H 
Fonseca PL 2.77 2.78 H 
4mg 2.54 2.62 H H 
8mg 2.56 2.57 H H 
Gomez-Perez PL 2.57 2.64 
2mgBD 2.25 2.19 J, Not given 
4mgBD 2.31 2.26 J, 
Lebovitz PL 2.55 H 
2mgBD 2.85 Not given H Not given 
4mgBD 2.66 H 
Miyazaki PL 1.75 2.29 Not given 
2001a 8mg 2.07 2.05 H H 
Nolan PL 2.64 2.5 H 
4mg 2.58 2.85 H H 
8mg 2.45 2.7 H H 
Patel PL 2.35 2.53 H 
2mgBD 2.14 2.34 H H 
Phillips PL 1.97 1.93 J, 
4mg 1.82 2.12 i H 
2mgBD 1.89 2.12 i H 
8mg 2.09 2.38 i H 
4mgBD 2.18 2.18 H H 
Raskin PL 2.9 2.9 H 
2000 2mgBD 2.6 2.7 H H 
4mgBD 3.0 3.2 H H 
Raskin PL 2.57 3.1 Sig 
2001 2mgBD 2.66 2.91 H Not given 
4mgBD 2.45 2.5 H 
Wolffenbuttel PL 1.8 1.9 H 
2mgBD 2.0 2.2 Sig H 
79 
Table 16 Effect ofPioglitazone on Triglyceride 
Study ｾ＠ ｂ｡ｳ･ｬｩｮ･Ｍｾ ｜ ｲ＠ after Change Change (mmoiiL) ｾ＠ ｴｲ･｡ｴｭ･ｾｴ＠ . ｩ ﾷ ｳｲｾｴｯ＠ compared 111 ., " Ｑ ［Ｑ［ｾﾷＮ＠ :• [11 !Ilk '"''' ' lQln011t.) ＺＮ［Ｌｾ＠ line ·, . ." to plaeeho 
Aronoff PL 2.97 2.86 H 
15mg 3.21 2.55 J_ H 
30mg 2.95 2.54 J_ H 
45mg 2.93 2.47 l H 
Einhorn PL 3.39 3.68 Not given 
30mg 3.38 3.05 l l 
Herz PL 1.72 Not given Not given 
30mg 1.91 1.81 H H 
45mg 1.99 1.67 l j, 
Kawamori PL 1.1 1.1 H 
30mg 1.5 1.2 H H 
Kipnes PL 2.93 3.02 j, 
15mg 3.07 2.6 H J_ 
30mg 2.94 2.24 l l 
Miyazaki PL 1.39 1.39 H 
2001 45mg 1.56 1.19 J_ J_ 
Miyazaki PL 2.8 3.4 H 
2002 15mg 2.53 2.31 H H 
30mg 2.89 2.31 H H 
45mg 2.24 1.97 H H 
Nakamura PL 
Not given Not given 
Not given 
30mg J_ Not given 
Rosenblatt PL 3.16 3.22 H 
30mg 4.02 3.42 l j, 
Rosenstock PL 2.74 3.1 i 
15mg 2.61 2.75 H H 
30mg 2.96 2.66 H j, 
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Discussion 
The main findings of this systetnatic review are that in clinically used doses 
rosiglitazone increases total cholesterol fi·otn baseline by between 7 and 15.8% whereas 
pioglitazone has no significant effect. Rosiglitazone increases LDL cholesterol between 
5 and 19% whereas pioglitazone tnay increase it by a few percent. Both drugs increase 
HDL-cholesterol by between 9 and 15%. Rosiglitazone generally does not have a 
significant effect on triglyceride concentration. Pioglitazone generally decreases 
triglyceride concentration by between 5 and 20%. Overall these results suggest that 
although they have a similar ability to lower HbAl c pioglitazone has a more beneficial 
effect on blood lipids. 
This review has a number of limitations. It has combined the results frmn many different 
studies with varying methodologies and statistical analysis. Most data in the studies that 
have been selected is presented as change cmnpared to baseline rather than placebo. 
Change compared to placebo is probably more impmtant and often if this data is given 
the actual change is not significant for example in the Aronoff paper (Aronoff et al, 
2000) triglyceride levels are significantly lower compared to baseline but this effect is. 
not significant cmnpared to placebo. 
Most of the studies were not specifically designed to look at lipid variables. Some of the 
stnaller studies were looking pat1icularly at physiologicalmeasuretnents such as insulin 
sensitivity measured by the euglycaetnic hyperinsulinaemic clamp (Carey et al, 2002; 
Miyazaki et al, 2001e; Miyazaki et al, 200li). As lipid effects were often only a 
secondary outcome measure not all the relevant data are given. In addition if a 
significant effect is noted it is more likely to be reported than a non-significant effect. 
Studies such as the Barnett study which did not fmd any effect on lipid variables do not 
give all the raw data (Barnett et al, 2003). 
Some of the suitable studies were very stnall, one rosiglitazone paper had 29 subjects 
(Miyazaki et al, 2001d) and another had 33 (Carey et al, 2002). 4 of the pioglitazone 
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papers had between 10 and 15 subjects per group, (Kawmnori et al, 1998; Miyazaki et 
al, 200li; Miyazaki et al, 2002b; Naka1nura et al, 2001). The small sample size means 
that in smne studies although lipid changes were of a similar magnitude to those in the 
larger studies they were not statistically significant. Also itnpoxtantly there are more 
studies using rosiglitazone than pioglitazone, in total the review includes 4170 patients 
treated with rosiglitazone and 2487 patients treated with pioglitazone. 
There is a marked difference between baseline lipids. One study is from Japan and 
subjects in this study had a low starting triglyceride, tnean 1.1 in the placebo group and 
1.5 in the treatment group (Kawamori et al, 1998). Subjects in Miyazaki's rosiglitazone 
study and one of his pioglitazone studies had lower total and LDL cholesterol than other 
ｳｵ｢ｪｾ｣ｴｳ＠ (Miyazaki et al, 2001c; Miyazaki et al, 2001i). Subjects in Nolan's group had 
higher starting total cholesterol (6-6.hmnoVL) and LDL cholesterol (4.39-4.55InmoVL) 
than seen in other groups (Nolan et al, 2000b). 
Most studies do not give any information about the percentage of participants taking 
lipid lowering drugs although some do, for instance the Herz study in which 29-31% of 
patients are on lipid lowering drugs (Herz et al, 2003). Where this information is given 
the percentage may seem surprisingly low but recruitment for these studies was often 
carried out before publication of the landmark statin trials. Some, but not all studies 
comment that lipid lowering therapy was kept stable throughout the trial. The difference 
in baseline lipids implies that even though the percentage on treatment is not given for 
Inany studies it must be quite different. 
Some of the studies were designed as safety studies rather than to look at the clinical 
effects of these drugs. Consequently they were possibly shorter than the time needed to 
see an effect on lipids (and HbA1c). For example in 2 studies (Nolan et al, 2000a; 
Raskin et al, 2000) the treatment period was 8 weeks. 
Some studies had very high drop-out rates. In one study (Aronoff et al, 2000) only 33% 
of subjects in the placebo group and between 44 and 58o/o of subjects in the treatment 
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groups completed the study. This was a reflection of the study tnethodology, in order to 
take pmt subjects were withdrawn :fi:om their existing treatment which led to a 
worsening of their glycaetnic control. If they were then randomised to placebo this 
continued to get worse resulting in their withdrawal fi·om the study. 
Changes in HbA1c have been given compared to baseline. Son1e studies do not show a 
great change in HbA1c. This may reflect an initial worsening of subjects' control when 
their oral hypoglycaemic agents were withdrawn in order to enter the study. Interestingly 
some studies draw attention to the itnprovement in HbA1c cmnpared to placebo group. 
If the placebo group's HbA1c increases then comparing the treatment group to the 
placebo group gives a 1nisleading result, it appears that HbA1 c has improved 1nore than 
it actually has with TZD treattnent, the actual itnprovement it1 HbAlc attributable to the 
TZD can be very small. 
Despite these methodological problems the review undoubtedly reveals a difference in 
the effect on lipids of the two drugs. The reason for this is not clear but has important 
therapeutic implications. 
The question arises of how applicable to the general population the results of this review 
are. Most patients with type 2 diabetes are now on statit1s, particularly since the CARDs 
study (Colhoun et al, 2002). Baseline lipids and HbA1cs seen it1 these studies would not 
be tolerated in tnost diabetes clinics. However effects seen on lipids were seen in 
patients with good starting lipids too, for instance significant increases were seen in 
HDL with starting values of 1.1 and 1.2mmo1/L (Kipnes et al, 2001; Patel et al, 1999) 
and pioglitazone reduced triglyceride cotnpared to placebo with starting triglycerides of 
1.5tmno1/L in the Japanese population (Kawamori et al, 1998) and 1.56mtnol/L in a 
North American and Mexican Atnerican population (Miyazaki et al, 2001i). 
TZDs are generally used as add on therapy to sulphonylureas or metformin rather than 
first line treatment. In the majority of the studies in this review TZDs were used as 
monotherapy and other oral hypoglycaemic tnedication were withdrawn before TZDs 
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were cmmnenced. However recent studies where TZDs have been used as add-on 
therapy and compared to sulphonylureas or 1netfonnin and have found similar effects on 
HbAlc and lipid variables (Hanefeld et al, 2004; Tan et al, 2004). 
To date there have been no head to head double blinded controlled trials of pioglitazone 
and rosiglitazone and it is unlikely that there ever will be any large studies of this type. 
Therefore the best evidence that we have of the differential effects of the TZDs on lipids 
cmnes from systematic reviews such as this. Frmn this work it can be concluded that 
there is a difference in the effect of the 2 clinically available TZDs. Despite similar 
ability to lower HbAic rosiglitazone causes increases in total and LDL-cholesterol 
whereas pioglitazone does not. Both drugs increase HDL-cholesterol but pioglitazone 
lowers triglyceride as well. These differences have implications for their clinical use. 
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Sumn1ary and state1nent of hypothesis 
Type 2 diabetes is a cmrunon and impmiant condition. It is associated with morbidity 
and mortality, particularly vascular disease. There is a wotTying increase in the 
prevalence of type 2 diabetes so 1nuch so that it has been described as a world wide 
epidetnic. This can be attributed to lifestyle change, natnely the increase in obesity and 
sedentary lifestyles. Type 2 diabetes develops as a result of a cotnbination of insulin 
resistance and inadequate insulin secretion and insulin resistance precedes type 2 
diabetes for many years. 
The metabo lie syndro1ne or insulin resistance syndrome is a constellation of risk factors 
for vascular disease including hyperglycaetnia, hypertension, obesity and dyslipidae1nia. 
There is increasing evidence that dysregulation of fatty acid metabolis1n is fundamental 
in the development of insulin resistance and associated macro vascular disease. 
The development of the thiazolidinediones for the treatment oftype 2 diabetes was met 
with great excitetnent since it was the first new drug group for diabetes for several 
decades. Of particular interest is their action reversing insulin resistance. There has been 
1nuch interest in whether they have additional effects on other aspects of the insulin 
resistance syndrome and this would have enormous therapeutic potential. There is 
evidence :fi·om double blinded placebo controlled trials that TZDs affect plasma lipids 
and that pioglitazone has a tnore beneficial effect than rosiglitazone. In particular studies 
show that pioglitazone seen1s to reduce triglyceride concentration whereas rosiglitazone 
does not. Stable isotope studies provide a way of studying lipoprotein metabolism in 
more detail. It was hypothesised that pioglitazone would reduce VLDL apo B absolute 
secretion rate thus reducing plasma triglycerides whereas rosiglitazone would have no 
effect on VLDL apo B absolute secretion rate. 
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Methods 
Subjects and ethical consent 
A total of 24 subjects with type 2 diabetes were studied. They were recruited from the 
diabetes clinic of the Royal Surrey County Hospital, Guild ford and fron1 6 local pritnary 
care diabetes clinics. All subjects gave written infonned consent and the study was 
approved by the South West Surrey Ethics Conunittee. All subjects had been diagnosed 
with type 2 diabetes for at least 6 months and the diagnosis was tnade by oral glucose 
tolerance test or fasting glucose concentration of greater than or equal to 7mmol/l. 
Subjects were required to have normal liver function, be on diet alone or metformin 
treatment at stable dose and not to be on any lipid lowering tnedication (statins or 
fibrates). Patients were asked. to maintain their diet, exercise level and general routine 
unchanged throughout the study. 
Study protocol 
Body composition 
Body weight was measured on an electronic balance with subjects wearing light clothes 
and without shoes. Height was assessed by a stadiotneter. Bioelectrical itnpedance 
analysis was perfonned in the erect position after voiding using a TBF-305 body fat 
analyser, (Tanita Corp, Illinois, USA). This method depends on the principle that lean 
body mass contains virtually all the body water and conducting electrolytes and is 
therefore a good conductor. In contrast fat tissue contains little water and is a poor 
conductor of electricity. The bioitnpedance analyser applies a low frequency alternate 
current to a subject and measures body itnpedance. Based on equations which take into 
account body weight, height and gender the measured itnpedance can be converted into 
an estitnate of total body water. The hydration of lean tissue is assmned to be constant 
and therefore lean body mass can be calculated. Fat mass is then obtained as the 
difference between total body weight and lean body mass and is expressed as a 
percentage of total body weight. 
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Trial medication 
The study was a double-blinded randomised and placebo controlled trial. After 
informed, written consent was obtailied frmn each subject they were stratified into one 
of two groups depending on whether they were taking tnetformin or were on diet 
treatment alone. Randomisation was performed by the phannacy department of the 
Royal Surrey County Hospital, Guildford using random numbers in blocks of three. 
Subjects were randomised into one of three groups, 8 subjects received placebo, 8 
subjects received pioglitazone 30tng and 8 subjects received rosiglitazone 8mg tablets. 
These doses were chosen as they were the maximum allowable dose in the UK at the 
beginnil1g ofthe study. Pioglitazone tablets were supplied by Takeda UK Lhnited (High 
Wycombe, UK). Rosiglitazone tablets were manufactw·ed by GlaxoSmith.Kline 
(Uxbridge, UK) and were supplied by Unichem (Chessh1gton, UK). Placebo tablets were 
obtained :fi·om Martindale Pharmaceuticals (Romford, UK) and consisted of 180mg of 
lactose. The tablets were dispensed in identical bottles frmn pharmacy. Subjects were 
instructed to take one tablet per day in the tnorning, starting the 1norning after they were 
admitted to the i11vestigation unit for their first lipoprotein turnover study and fmishing 
the morning before their second lipoprotein turnover study. Cotnpliance was assessed by 
pill counting and the return of the bottles at the end of the study. 
Identical metabo lie investigations were performed before and after three months of 
treatlnent. All subjects were admitted to the clinical investigation unit at 08.00 after an 
overnight fast. They were studied in a setni-recumbent position and were allowed to 
drink water only throughout the study. An indwelling catheter was inserted into a 
superficial vein in the antecubital fossa for the administration of 1-13C leucine. Another 
indwelling catheter was inserted into a superficial vein of the contralateral arm for blood 
sampling. The blood sampling schedule is given in Figure 6. At the beginning of the 
study 4tnl blood was taken for the measurement of insulin and C-peptide. 6ml of blood 
was taken for the measuretnent of glucose, electrolytes, urea, creatinine, and liver 
function tests. 7ml of blood was taken for measurement of full blood count, HbAlc, total 
cholesterol, LDL cholesterol, triglycerides, apo B, HDL-cholesterol and FFAs. A bolus 
of l-13C leucine (lmg/kg) was administered followed by a constant infusion of 
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1 mg/kg/hour for 10 hours. This dose of leucine has been shown previously to give 
measurable enrichment of VLDL, IDL and LDL apo B (Christ et al, 1999; Christ et al, 
2004). At baseline and at 30, 60, 90, 120, 150, 180, 240, 300, 360, 420, 480, 540 and 
600 minutes samples were taken for the determination of VLDL, IDL and LDL apo B 
enrichment. At baseline, 180, 300, 420, 540 and 600 minutes samples were taken to 
determine 13C enrichment of a-ketoisocaproate (a-KIC). At baseline and at 180, 360, 
540 and 600 minutes samples were taken to measure the concentration of VLDL-
cholesterol, VLDL-triglyceride, VLDL-apo B, IDL-cholesterol, IDL-triglyceride, IDL-
apo B, LDL-cholesterol, LDL-triglyceride and LDL-apo B. 
Figure 6 Clinical protocol (blood sampling schedule) of lipoprotein turnover study 
Bolus Be_ 
leucine Constant 13C-leucine infusion 
t 
0 0 
* * * ++ + + ++ + + + + 
0 2 3 4 5 
Time in hours 
+ 
* 0
VLDL, IDL and LDL enrichment 
a-KIC 
VLDL, IDL and LDL concentration 
0 
* + + 
6 7 
0 0 
* * + + + 
8 9 10 
I 
t Baseline bloods (full blood count, urea and electrolytes, glucose, liver function tests, insulin C-peptide, HbA1 c) 
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Sample Collection 
Blood samples were taken with sterile syringes and added to vacutainers containing 
various anticoagulants. Blood for full blood count, HbAI c, VLDL, IDL and LDL apo B 
enrichment and lipid concentrations (VLDL, IDL and LDL cholesterol, triglyceride, and 
apo B; total cholesterol, HDL-cholesterol, triglyceride and FFAs) were collected into 
EDTA tubes and blood satnples for a-KIC in lithium heparin tubes. Plain tubes were 
used to measure hormones (insulin, C-peptide) and glucose was measured in fluoride 
oxalate tubes. Blood for renal function and liver function was collected in tubes 
containing gel for sermn separation. 
Preparation of tracer solution 
L-(1-13C) leucine (99%) was purchased fi:mn CK Gas Products Ltd (Hampshire, U.K.). 
The pharmacy departlnent of St. Thomas' Hospital prepared sterile solutions of tracers. 
Accurately weighed amounts of leucine were dissolved in sterile pyrogen free 
physiological saline (NaCl 0.9%) to give a 15mg/ml solution. These solutions were 
filtered (filter ＰＮＲＲｾｴｭＩ＠ into sterile vials which were then aseptically sealed; a random 
sample of vials underwent sterility and pyrogen testing. The leucine vials were stored at 
room temperature. On the day of the study the tracer was filled into sterile syringes. A 
bolus of leucine (lmg/kg body weight) was administered followed by an infusion at a 
rate of lmg/kg/hour. 
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Analytical Methods 
Background 
Diagnosis and appropriate managetnent of dyslipidaetnia requires measurement of 
plasma lipid and lipoprotein concentrations. However this allows only a static view of 
lipid levels and provides no insight into the dynamic processes regulating plasma lipid 
and lipoprotein metabo listn. Abnormal plasma lipid concentrations can result from 
alterations in their rates of production and/or catabolism. In order to gain a greater 
understanding of lipoprotein tnetabolism tracer technologies can be employed. Studies 
using this 1nethodology have provided novel insights and helped to further the 
understanding of metabolic disorders (Chan et al, 2004). 
In the past tracer tnethodologies relied on radioactive isotope labels. More recently 
advances in the manufacture of stable isotopes and in computer supported tnass 
spectrometry have allowed this methodology to be used to further our understanding of 
lipoprotein kinetics. 
Stable isotopes 
The majority of ele1nents exist in a stable fonn, the tenn stable isotope is used to 
describe those that occur at low natural abundance, for example 13C 1.11 %, 2H 0.015% 
and 15N 0.37%. The most commonly used stable isotopes for metabolic studies are 2H, 
13C, 15N and 180. 
Stable isotopes offer many advantages over radioactive isotopes. Studies with 
radioactive isotopes cmnmonly used exogenous labelling (for example exogenous 
labelling of LDL with 125Iodine (Demant et al, 1996)) to avoid the substantial dose of 
radiation associated with endogenous labelling. However exogenous labelling can result 
in modification of lipoprotein particles ex vivo, non unifonn labelling of lipoprotein 
particles and n10dification of lipoprotein behaviour ex vivo. Label tnay also be 
introduced into protein and possibly carbohydrate. Radioactive isotopes estimate 
lipoprotein production rate from rates of catabolism whereas stable isotopes can measure 
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production rates of lipoproteins directly frotn the incorporation of amino acid into the 
apolipoprotein (Cummings and Watts, 1996). 
The use of stable isotopes confers several advantages: they have no adverse effects, 
specifically there is no radiation dose associated with their use. Therefore they allow the 
study of subjects such as children, pregnant and lactating women which was previously 
not possible. The nature of the amino acid stable isotope is known and it exhibits 
tnetabolic behaviour identical to the tracee. Therefore the appearance of the tracer in the 
apolipoprotein can be followed by repeated blood sampling and isolation of the 
apolipoprotein of interest. In addition stable isotopes allow several lipoproteins to be 
studied at once and their use tninimises interference from the isotope itself on 
physiological processes (Cmrunings and Watts, 1996). In general there has been good 
agreement between studies using stable isotopes and those using radio-iodinated tracers 
to measure lipoprotein metabolisn1 (Packard et al, 2000). 
Disadvantages of stable isotope studies are the large dose given which can complicate 
the calculation of kinetic data from kinetic variables. The other problem is recycling 
(Packard et al, 2000). After 20-40 hours the initial dose of tracer has passed through the 
VLDL, IDL and LDL apo B cascade and tracer returns fi:mn large body pools at a slow 
rate. This has little itnpact on short (<10 hours) studies but is tnore important for the 
slowly turning over lipoproteins, such as LDL. Another problem is that there is a low 
level of tracer incorporation into lipoproteins with a slow turnover rate such as LDL 
(Packard et al, 2000). 
The principles of stable isotope methodology 
In order to be used in kinetic studies a stable isotope tracer tnust be physically, 
chetnically and biologically identical to the tracee yet be readily distinguishable. It must 
be a major constituent of the compound which one wishes to study and must not disturb 
the dynatnics of the system under investigation (Chan et al, 2004). 
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In this particular study stable isotopes can be used to measure directly the hepatic 
secretion of apo B. The tracee is unlabelled leucine and the tracer employed is 1-13C 
labelled leucine, Figure 7. Atnino acids labelled with stable isotopes have been used as 
the tracers for lipoprotein studies for more than 10 years. Comparative studies of 
different amino acid tracers have found no difference in measured lipoprotein kinetics so 
it can be concluded that turnover rate is independent ofthe tracer used (Cutmnings and 
Watts, 1996). 
Figure 7 Structure of leucine 
I-13C leucine is useful as a tracer for a nun1ber of reasons, leucine is an essential amino 
acid, therefore it is not synthesised endogenously. This means that there is only a small 
amount of endogenous leucine frmn protein breakdown. It is metabolised primarily by 
peripheral tissues which minimises hepatic recycling. It is metabolised by deamination 
to a-ketoisocaproate (a-KIC), its keto acid and not to other amino acids, Figure 8. 
Therefore infusion of labelled leucine does not significantly influence the pool of other 
amino acids in the liver. In addition leucine is one of the most abundant amino acids in 
apo B so it is ideal for studying apo B tnetabolisnl (Cmmnings and Watts, 1996). Plastna 
a-KIC enrichment is used as an estimate of intracellular leucine enrichment. This is 
because plasma leucine enriclnnent is higher than intracellular leucine enrichment, 
firstly due to the intravenous infusion of leucine tracer and secondly due to unlabelled 
leucine from protein breakdown diluting intracellular leucine enrichtnent. 
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Figure 8 Metabolism of leucine to a-ketoisocaproate 
leucine 
a-ketoisocaproate 
The principles underlying this tnethodology are that the stable isotope tracer (I -13C 
leucine) is incorporated into apo B in the liver. Then the tracer: tracee ratio can be 
tneasured in VLDL apo B secreted from the liver by tnass spectrometry. This can be 
used to calculate the kinetics of the system. There is one molecule of apo B within a 
VLDL particle. Based on the assumption that the same an1otmt of 1-13C-leucine is 
incorporated into every apo B molecule the tracer can be seen to be a label for the whole 
VLDL particle. VLDL apo B has a rapid turnover. This allows kinetic information to be 
obtained after only 9-10 hours of study avoiding recycling of the tracer. The apo B 
molecule stays within the VLDL particle as it is tnetabolised to IDL and LDL and this 
allows further study of the kinetics ofiDL and LDL. 
The principles of Gas-Chromatography Mass-Spectrometry (GCMS) Analysis 
The analysis of stable isotope enrichtnent for metabolic tracer studies is performed by 
GCMS which involves several stages. To be separated by gas chromatography (GC) the 
samples must first be converted to molecules (derivatives) that are thermally stable, 
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chemically inert and volatile at te1nperatures below approximately 300°C. Derivatisation 
can also allow chromatographic behaviour or detectability to be hnproved. 
The derivatised satnples are injected into the GC and then vaporised by heating the 
injection chamber of the GCMS. They are swept through the GC column by an inert 
carrier gas, (helium in this study). GC separates the components of the sample by their 
differential migration through a two phase system consisting of a mobile phase (inert 
gas) and a stationary phase (a fixed porous sorbent). The temperature can be adjusted to 
optimise separation of components of a given satnple. 
Next sample tnolecules enter an ionisation chatnber where they pass tln·ough a beam of 
electrons. If the sample is struck by an electron sufficient energy may be imparted to 
remove an electron from the satnple molecule resulting in a molecular ion. The energy in 
excess ofthat required to ionise the satnple molecule is dissipated by fragmentation of 
the molecular ion and the pattern of the tnass spectrum is characteristic for that analyte. 
The principle of a mass-analyser is that the path of an ionised molecule can be 
influenced by a magnetic field in a mass dependent fashion. The quadrupole mass filter 
used in this study separates ions according to their mass to charge ratio (m/z). By 
changing the magnitude of the electrodynmnic field it is possible to select pat1icular ions 
for analysis. 
The ions that exit :fi:om the mass analyser botnbard the surface of an electron multiplier 
causing electrons to be ejected frmn its surface. The ejected electrons in turn cascade 
through the multiplier causing the ejection of more electrons and this leads to a massive 
amplification of the signal of each ion. The ion beam current is converted into an 
electrical signal which is processed by a computer to provide ion chromatograms. 
This study also used the GC-cmnbustion-isotope ratio mass spectrometer (C-IRMS). 
This measures the isotopic enrichment of gases such as carbon dioxide (C02), nitrogen 
and hydrogen. It is used for samples which have very low levels of enrichment as it is a 
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very sensitive methodology. Atnino acids are derivatised, separated by GC and then 
analysed after combustion to gases. Following electron impact ionisation ions can are 
separated by a fixed tnagnetic field. Deflection of ions is dependent upon their mass with 
heavier ions being deflected less. 
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Experimental protocol for examining VLDL, IDL and LDL apo B Metabolism 
A smruuary of steps involved in preparing san1ples for GCMS is summarised in Figure 
9. All reagents used were obtained fi·om Sigma Aldrich (Dorset, UK) or VWR 
Intetnational (Dorset, UK) and were analytical grade unless otherwise stated. Sodimn 
chloride density was verified by measuring the density of saline using a glass 25ml 
volumetric flask with a hole in the stopper. This adaptation is to ensure that no air is 
trapped in the flask when weighing the flask with a solution and is therefore used for the 
accurate determination of densities of liquids 
Separation of VLDL 
Firstly VLDL was separated by ultracentrifugation. Whole blood samples collected into 
EDTA tubes were iintnediately centrifuged at 2000rpm for 10 minutes at 4°C in a 
Clinispin 240R centrifuge (Woodley Equiptnent Cmnpany, Bolton, UK) to separate 
plasma. A 3tnl aliquot of plastna was overlaid with 1.5tnl sodium chloride density 
solution (d = 1.006g/ml) and ultracentrifuged for 16 hours at 37,000rpm, 147 000 x g 
with a Beckman Coulter Optima LE80-K ultracentrifuge, (High Wycon1be, UK) using a 
type 50.4 Ti fixed angle rotor. The supen1atant containing VLDL was obtained by tube 
slicing off hnl of the sample which was collected into glass vials usii1g a Pasteur pipette. 
Separation of ｉｄｾ＠
The remaining satnple was then prepared in order to separate IDL. The plasma was 
made up to 4mls by the addition of sodimn chloride density solution (d = 1.006g/ml). 
O.Sml of sodium chloride density solution was added (1.123g/ml) giving a density of 
1.019g/ml. The sample was then ultracentrifuged for 18 hours. The supernatant 
containing IDL was again obtained by tube slicing off 1ml of the satnple which was 
collected into glass vials using a Pasteur pipette. 
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Separation of LDL 
The remaining infra-natant was then made up to 4mls with sodium chloride density 
solution (d = 1.019g!tnl) and then 0.5Inl of sodium chloride density solution 1.415g/ml 
was added giving a density of 1.063. This sample was ultracentrifuged for a further 20 
hours. Again the supernatant containing LDL was obtained by tube slicing of lml of the 
smnple. 
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Figure 9 Smrunary of experimental protocol for measuring isotopic enrichment 
Samples for tneasuring VLDL, IDL and LDL apo B em·ichment 
u 
Separation ofVLDL, IDL and LDL by sequential density 
ultracentrifugation 
Precipitation of apoB using isopropanol 
+ 
Delipidation ofapo Busing ether-ethanol 
Hydro lysis of apo B using hydrochloric acid 
Derivatisation 
..... 
Samples for a.-KIC 
ｾ＠
,, 
GCMS analysis to determine isotopic enrichtnent 
98 
Separation of LDL subfractions 
To tneasure LDL subfractions 2 and 3 a satnple of whole blood was taken into an EDTA 
bottle. This sample was imtnediately centrifuged for 10 n1inutes at 4°C. Then 1ml of 
soditnn chloride density solution (1.006g/ml) was added to 3mls of plasma. A further 
O.Stnls of sodium chloride density solution (1.123g/ml) was added resulting in a density 
of 1.019g1Inl. This sample was then ultracentrifuged for 18 hours. After this linl of the 
sample containing the VLDL and IDL was tube sliced off leaving the LDL behind. The 
remaining satnple was tnade up to 4mls with sodium chloride density solution 1.019g/ml 
and O.Smls of sodimn chloride density solution 1.244g!tnl was added resulting in a 
density of 1.044g/ml. This sample was ultracentrifuged for 20 hours. After this lml was 
tube sliced off for LDL2 tneasuretnent. The retnaining satnple was made up to 4mls with 
sodium chloride density solution (1.044g/ml) and O.Smls of sodium chloride density 
solution was added (1.196gltnl) resulting in a density of 1.063gltnl. This sample was 
ultracentrifuged for a further 20 hours. After this ltnl was tube sliced off for 
measuren1ent ofLDL3. 
Isolation of apo B 
Apo B was precipitated by isopropanol. This has been shown to be a convenient way of 
precipitating apo B and is equivalent to methods using tetramethlyurea (TMU). In 
addition isopropanol is cheaper than TMU and tnore easily maintained in a pure forn1 
(Egusa et al, 1983). lml of isopropanol was added to and tnixed with each VLDL, IDL 
and LDL fraction for the selective precipitation of apo B. Samples were incubated for 60 
minutes at 20°C and then centrifuged (3000rpm, 2000x g, 30 minutes, S°C) (Heraeus 
Sepatech centrifuge, Germany). The apo B precipitate was visible as a white precipitate 
adhering to the glass vial. The isopropanol was removed using a drawn out glass Pasteur 
pipette leaving the precipitated apo B within the vial. The precipitate was delipidated by 
washing with 3tnl ether-ethanol solution (1:3 v/v) at -20°C for 48 hours. After 
recentrifugation for 30 minutes at soc the supernatant was removed by aspiration. Then 
a 3tnl ether wash was performed at -20°C for 48 hours. After this the sample was 
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recentrifuged. The supernatant was removed and the remaining sample was left to air 
dry for 30 minutes at ro01n temperature. 
Hydrolysis of apo B 
Apo B was hydrolysed in 3tnl of 6 M hydrochloric acid (BDH, Poole, UK). The samples 
were heated in uncapped vials for 16 hours at 115°C (Techne Droblock, DB 3H, 
Germany) to ensure c01nplete hydrolysis and then frozen at .. gooc until needed. 
Derivatisation of VLDL and IDL samples 
The prepared samples were thawed to room temperature. 300fll of dichlormnethane was 
added to each vial and tnixed well. The sample was then dried under oxygen free 
nitrogen (OFN) to remove any moisture. Then lOOj..tl of a solvent, acetonitrile and 1 OOJ.!l 
of N .. tnethyl-N-(tertbutyldilnethylsilyl)-trifluoroacetamide (MTBSTFA) was added to 
each vial. The vials were mixed well and derivatised at 70°C for 60 minutes. MTBSTF A 
is a silylation reagent. It derivatises the an1ino and carboxyl groups of leucine resulting 
in an increased mass, volatility and stability for gas chromatography separation. 
Derivatised leucine is shown in Figure 10 and fragmentation of derivatised leucine is 
shown in Figure 11. 
Figure 10 Derivitisation of leucine with MTBSTFA 
C(CH3)3 
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tertiary-butyldimethylsilyl (t-BDMS) derivative is formed, tnolecular weight 359 
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Figure 11 Fragmentation oft-BDMS leucine 
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Electron impact ionization causes the loss of a C4H9 fragtnent (tnolecular weight 57) 
which can occur fi·om either of the places shown by the dotted lines. This leaves ions 
with m/z of302 (359-57) and for 13C-leucine m/z 303. 
When the satnple vials had cooled smne of the extra reagent was retnoved by drying 
with OFN. Samples were not cotnpletely dried. After this the samples were reconstituted 
in decane. 100!-ll of decane was added to the VLDL samples and 50!-ll was added to the 
IDL samples. The satnples were mixed well and were then ready for GCMS analysis. 
Derivatisation of LDL samples 
LDL samples were derivatised with N-acetyl n-propyl ester, Figure 12. This is because it 
has a lower mass than MTBTSF A and contains less carbon atoms. Hence there is less 
dilution of the LDL san1ples (which have much lower 13C-leucine em·ichtnent). 
Propanol/HCl was prepared by the addition of acetyl chloride to propanol. Then 0.5 tnl 
of propanol!HCL was added to the sample which was heated at 1 00°C for 20 minutes, 
following this excess reagent was removed under OFN. After this 0.5ml pyridine/acetic 
anhydride was added and the satnple was left to stand at room tetnperature for 5 to 10 
tninutes. Excess reagent was removed under OFN and then the residue was dissolved in 
ethyl acetate. 
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Figure 12 Derivatisation of leucine with N-acetyl n-propyl ester 
0 
II 
CH3-C 
I 
NH 
I 
/H-CH2-CH- COO-C3H7 
H3C 
Determination of apo B isotopic enrichment 
VLDL and IDL apo B enrichment was measured using GCMS, specifically Agilent 5973 
N mass selective detector (Agilent Technologies, Bracknell, U.K.) in the electron impact 
ionisation tnode. Chromatographic separations were catTied out using a HP-1MS column 
fused silica dimethylpolysiloxane column (dhnensions: 30m, 0.25tnm i.d., 0.25J.Ltn film 
thickness); (Agilent Technologies)) and helium carrier gas at 1 Okpa, flow rate 
1tnllminute. The transfer line to the mass spectrometer was held at 280°C and the 
column was directly coupled to the ion source ofthe mass spectrometer. Samples were 
analysed every 10 minutes. Isotopic abundance of 12C and 13C was detennined by 
selected ion tnonitoring of leucine fragments with a mass to charge ratio (m/z) of 302 
(M) and 303 (M + 1) respectively. Chrmnatographic peaks were integrated and the 
13C/12C area of leucine calculated. 
Standard enrichment c1:1rves (0-1 0 APE) were run before and after each set of satnples to 
tnonitor instrumental drift. Stock solutions of leucine and 13C-leucine were used to make 
solutions of known enrichments which were derivatised and analysed by GCMS as 
described above. The measured 13C/12C-area ratio was plotted against expected to obtain 
the standard curve. 
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Isotopic enrichment ofLDL apo B was determined using a GC-C-IRMS. This is because 
the enrichment of apo B in LDL was very low and this instrument is much 1nore 
sensitive than the GCMS. Specifically a Sira Series 2 IRMS (VG Instrwnents, Hellingly, 
UK) was used coupled to an Orchid Gas Chromatograph Interface Module (Europa 
Scientific, Crewe, UK). The GC was equipped with an AT-1 Capillary Column (60m, 
0.25trun internal diameter, lfJ.m film thickness, Alltech, UK). The carrier gas was helium 
and the injector temperature was set to 250°C. For sample analysis the column was held 
isothermal at 70°C for 1 minute, then programmed to increase at 20°C per minute up to 
200°C, 3 oc per minute from 200-250°C, 30°C per minute from 250-300°C and was held 
at 300°C for 5 minutes. Isotopic abundance was expressed relative to pulse peaks of 
reference C02 gas. Data were analysed using the manufacturer's software (Orchid Post 
Processor, Version 2.3c. Europa Scientific). 
A standard enrichment curve (fron1 0-1 APE) was run once a week to check for 
instrumental drift. It was not done 1nore :fi:equently than this because of the long run time 
for each sample (40 1ninutes) on the IRMS. Enrichment quality controls were prepared 
by 1nixing leucine and 1-13C leucine to give baseline, medium (0.05 APE) and high (0.5) 
enriched samples. These were derivatised and nm with each set of samples. 
Measurement of a-KIC enrichment 
Plas1na a-KIC enrichment was used as a measure of intracellular leucine enrichment. 
Samples for the detennination of a-KIC enrichment were taken into lithium heparin 
vacutainers. They were then centrifuged for 10 minutes at 4°C at 2000rpin. Then plasma 
was separated and frozen at -70°c until needed. 
Extraction 
The samples were thawed, mixed and recentrifuged for 10 minutes. Then ＵＰｾｴｬ＠ of plasma 
was pipetted into a small glass test tube. 0.5ml of ethyl alcohol was added in order to 
precipitate proteins. The samples were recentrifuged and the supernatant was transferred 
to a Y2 dram vial and blown dry under OFN. lOOfJ.l ofwater and 50J..ll offi·eshly tnade 0-
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phenylenediamine (2% in 4M HCl) were added to the residue. The samples were heated 
at 90°C for I hour. Then 0.5ml ethyl acetate was added and the satnple was mixed. The 
layers were then allowed to separate before the top organic layer containing keto-acids 
was transfened to a clean vial containing a spatula endful of sodium sulphate. The 
extraction was repeated and the washings combined and mixed. The dried extracts were 
transferred to a clean vial and allowed to evaporate to dryness under OFN at room 
temperature. 
Derivatisation 
50J.Ll of acetonitrile and ＵＰｾｴｬ＠ of MTBSTF A was added and the sample was welltnixed. 
Then it was derivatised by heating at 120°C for 45 minutes. After cooling the satnples 
were dried under OFN and reconstituted in 50J.Ll decane with 5% MTBSTFA. The 
samples were now ready for GCMS. 
Stock solutions (hng tnr1) of KIC and 1_13C KIC were prepared and aliquots were 
stored at -20°C. On the day of the assay an enrichtnertt calibration curve was prepared 
(range 0-10 APE). The standards were prepared in the san1e manner as the samples of 
interest fi·mn the point ofthe addition of water and ｯＭｰｨ･ｮｹｬ･ｮｾ､ｩ｡ｭｩｮ･Ｎ＠ The enrichtnent 
curve was run at the beginning and the end of each sample run to check for instrmnental 
drift across the samples run. Enrichtnent quality controls were prepared by spiking 
plasma with I-13C KIC to give baseline, tnedium (-3 APE) and high ＨｾＶ Ｎ ＵＩ＠ enriched 
samples. The satnples for quality control were treated in the satne manner as the plastna 
satnples. 
Isotopic enrichment of a.-KIC was performed on an Agilent 5973N Mass Selective 
Detector, as before. Isotopic abundance of 12C and 13C was determined by selected ion 
tnonitoring of :fragments at m/z 259 (M) and 260 (M + 1). The isotopic em·ichment was 
calculated as for leucine: chrmnatographic peaks were integrated and the 13C/12C- area 
ratio of a.-KIC calculated. 
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Analysis of isotopic enrichment data 
Figure 13 shows an example of an enrichment curve (APE) ofVLDL apo B IDL apo B 
and a-KIC in one subject during a constant primed infusion of 1-13C-leucine. Figure 14 
shows an example of an enrichment curve for LDL apo B for the same subject. VLDL 
enrichment follows a curve is rather than a straight line. VLDL apo B enrichment 
approaches a plateau level towards the end of the 10 hour infusion. The plateau 
enrichment should equal the precursor enrichment a measure ofwhich is provided by a-
KI C enrichment. 
Figure 13 Isotopic enrichment of VLDL and IDL apo B (apo B APE) and a-
ketoisocaproic acid (KIC-APE) 
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Figure 14 Isotopic enriclunent ofLDL apo B (apo B APE) 
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Previous studies have shown that the precursor pool enrichment (a-KIC) is obtained 
after less than an hour and remains stable during the study suggesting a constant hepatic 
1-13C leucine pool and therefore a constant input of tracer into VLDL apo B can be 
assumed. If the em·iclunent of precursor pool (a-KIC) and the rate of increase in 
em·iclunent in apo Bare known this allows the calculation of the secretion rate of apo B. 
Linear regression analysis can be used to calculate the fractional secretion rate (FSR) in 
pools/day: 
FSR = change of em·iclunent of apo B/ enrichn1ent of precursor pool 
At steady state, shown by constant concentrations of VLDL, IDL and LDL apo B, 
fi·actional catabolic rate (FCR) (pools/day), the proportion of apo B being removed from 
the circulation per unit tin1e is equal to FSR. Absolute secretion rate (ASR) (mg/kg/day) 
is the product of the FSR and the apo B pool size divided by subject's body weight 
which gives the amount of apo B secreted per unit time. Apo B pool size (mg) is the 
product of apo B concentration and plasma volume. 
Metabolic clearance rate (MCR) can be calculated as the FCR tnultiplied by plastna 
volume. 
Plasma volume (PV) was calculated using the method of Pearson et al (Pearson et al, 
1995) as follows: 
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for males, PV (tnl) = 1578 x S 
and for females, PV (tnl) = 1395 x S 
Where S = surface area (m2), = w 0.425 x h 0·725 x 0.007184 
Where w = weight (kg) and h = height (em) 
This method overcon1es the problems of others which use body weight alone for plastna 
volume prediction and lead to falsely elevated levels in obese subjects. 
Isotopic em·ichment of LDL data was analysed using linear regression analysis as the 
LDL enrichinent curve has not reached a plateau by 10 hours and follows a straight line, 
Figure 14. Enrichinent ofLDL apo B is plotted against tin1e and a curve is fitted. LDL 
enrichtnent between 4 and 10 hours is used for the calculations as this is when the line 
becomes linear. The fi·actional secretion rate can be calculated as the slope of the curve 
divided by precursor enriclunent or a-KIC enrichment. The other parameters can be 
calculated from FSR as above. 
Because the curves followed by the enrichment ofVLDL and IDL apo Bare not straight 
lines the data for each patient was analysed using Sitnulation Analysis and Modelling 
(SAAM) II software (SAAM, Seattle, WA, USA). This uses a tnulti-compartmental 
tnodel, Figure 15. A forcing function corresponding to precursor enrichment (a-I<IC) is 
used. In addition a delay function accounting for the titne required for the synthesis and 
secretion ofVLDL apo BlOO into the plastna is incorporated into the model. 
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Figure 15 Multi-compartmental model for analysis ofapo B metabolism 
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Compartment 1 represents precursor (a-KIC) enrichment 
Delay function represents the time taken for VLDL to be secreted into the circulation 
Compartment 2 represents VLDL 
Compartment 3 represents IDL 
K (0, 2) represents FSR ofVLDL apo B 
K (0, 3) represents FSR of IDL apo B 
VLDL is modelled first, then IDL. K (0, 2) from the VLDL model becomes K (3 2) for 
the IDL modelling 
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Measurement of other metabolites 
Apo B Concentration 
VLDL and IDL apo B 100 concentration was determined using a sandwich enzyme-
linked immunoassay (ELISA) tnethod cotnbining a polyclonal antibody against apo B 
(the Binding Site Ltd, Birn1ingham, UK) as capturing antibody and a monoclonal 
antibody raised specifically against apo B 100 ( 4G3) as second antibody (Ottawa Heart 
Institute, Ottawa, Canada). This is because the itnmunochen1ical tnethod used for the 
tneasurement ofLDL apo B is not sufficiently sensitive to measure VLDL and IDL apo 
B, the concentrations of which are approximately 10 to 20 times lower. The 
tneasurement of satnples using the 2 assays shows a good correlation (for 65 LDL 
satnples analysed using both assays, r = 0.93). The quality control (QC) for both 
tnethods is a washed LDL fraction. The interassay coefficient variant (CV) for the 
ilntnunochemical assay was 4% and for the ELISA was 11%. 
Microtiter wells were coated with the polyconal antibody and then washed with wash 
buffer (phosphate buffer, pH 7.4, containing 0.2% bovine serutn albutnin [BSA], 0.1% 
Tween 20 and 0.01% thiotnersol). Then apo B standard (Dade Behring Marburg GmbH, 
Marburg, Germany) and the lipid fraction were diluted with assay buffer (phosphate 
buffer containing 0.5% BSA and 0.01% thiomersol). Lipid fractions had been prepared 
by sequential density ultracentrifugation as for enrichment samples. However after tube 
slicing and pipetting into glass vials the samples were accurately made up to 2tnls with 
the appropriate density solution. The dilutions were added to each well in triplicate and 
then incubated at 37°C for 2 hours. Then the wells were washed again with wash buffer. 
Following this the wells were incubated for 2 hours at 37°C with the biotinylated 
tnonoclonal antibody. The wells were washed again with buffer and next strepavidin 
alkaline phosphatase (Alnersham, UK) was added and incubated at 37°C for 1 hour. 
After further washing with wash buffer, phenolphthalein tnonophosphate 
di(cyclohexatnmonium) salt 0.8% in 1M diethanolamine buffer was added and incubated 
for a fmther hour at 3 7°C. The reaction was stopped with stop buffer and then the 
absorbance at 540nm was detennined using a Microplate reader (Anthos Labtec HT2). 
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LDL apo B and LDL sub:fraction (LDL2 and LDL3) apo B was determined using a 
cmmnercially available kit :fi·om Dade Behring (Marburg, Germany). This kit uses an 
immunochemical tnethodology whereby specific antibodies form immune complexes 
with apo B in the sample. These complexes scatter a bean1 of light passed through the 
satnple. The intensity of scattered light is proportional to the concentration of apo B in 
the sample and can be determined by comparison with a standard of known 
concentration. 
Lipid concentrations 
Plasma, VLDL, IDL, LDL and LDL subfractions (LDL2 and LDL3) triglyceride, 
cholesterol, HDL-cholesterol and FFA concentrations were all determined enzymatically 
and absorbancy was measured on a Cobas Para analyser (Roche, Welwyn Garden City, 
UK). The CV was less than 5% for all lipid assays and the QCs supplied with the assay 
kits were used. Triglyceride and total cholesterol concentrations were tneasured using 
conunercially available kits from ABX Diagnostics (Montpellier, France). 
Triglyceride was detennined according to the following principle: 
Triglycerides lipase --7 glycerol + fatty acids 
glycerol+ ATP glycerokinase --7 glycerol3 phosphate+ ADP 
glycero 1 3 phosphate 
H202 
glycerol 3 phosphate oxidase -0 dihydroxyacetone phosphate + 
2 H202 + parachloropheno 1 + 4-amino antipyrine 
H20 
ｰ･ｲｯｸｩ､｡ｳ･ｾ＠ quinoneitnine + 4 
lOJ..Ll of sample is mixed with hnl of reagent which contains the enzytnes lipase, 
glycerokinase, glycerol-3-phosphate oxidase and peroxidase as well as ATP, 4-mnino 
antipyrine and parachlorophenol causing the reactions above and the generation of a 
blue colour. After incubation at 37°C for 5 minutes absorbancy was measured at 505 
nm. 
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Cholesterol concentration was determined according to the following principle: 
Cholesterol ester cholesterol esterase -7 cholesterol+ fatty acids 
Cho }estero 1 cholesterol oxidase -7 4-cholesten-3-one + H202 
peroxidase 2 H202 +phenol+ 4-amino antipyrine -7 quinoneimine + 4 H20 
lOJ.!l of sample is tnixed with lml of reagent that contains cholesterol esterase, 
cholesterol oxidase, peroxidase, 4-atnino antipyrine and phenol. After incubation at 
37°C for 5 tninutes absorbancy is tneasured at 500nm. 
HDL-cholesterol and FF As were measured using cmnmercially available kits from 
Wako Chemicals GmbH (Neuss, Gennany). The HDL reagent contains anti hun1an P-
lipoprotein antibody that binds lipoproteins other than HDL. The immune complexes 
which are formed prevent these lipoproteins reacting on the addition of cholesterol 
esterase and cholesterol oxidase. Therefore these enzymes react only with HDL and the 
chemicals produced yield a blue colour that can be measured at the optimum wavelength 
of593mn. 
The FFA kit depends on the principle that FF As treated with acyl-CoA synthetase in the 
presence of ATP, magnesimn cations and CoA fonn acyl-CoA, AMP and 
pyrophosphate. Acyl-CoA is oxidised by the addition of acyl-CoA oxidase to produce 
hydrogen peroxidase which in the presence of added peroxidase allows the oxidative 
condensation of3-methyl-N-ethyl-N-(p-hydroxyethyl)-aniline with 4-aminoantipyrine to 
fonn a purple colour that can be tneasured at an optimum wavelength of 550nm. 
Insulin 
Insulin concentrations were detennined using a commercially available kit from 
Mercodia (Uppsala, Sweden). This kit uses a solid phase two site enzyme immunoassay. 
Two monoclonal antibodies are directed against separate antigenic determinants on the 
insulin molecule. 25J.ll of satnple or calibrator is pipetted into the appropriate well of the 
tnicroplate and then 50f..Ll of enzytne conjugate is added to each well. The samples are 
incubated, during incubation insulin in the satnple reacts with peroxidase conjugated anti 
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insulin antibodies and anti insulin antibodies bound to the microtitration well. Then 
washing retnoves unbound enzyn1e labelled antibody and the bound conjugate is 
detected by reaction with 3,3',5,5'-tetramethlybenzidine (TMB). The reaction is stopped 
by adding acid to give a colormetric endpoint that is read spectrophoton1etrically. 
C-peptide 
C- peptide concentrations were detennined using a commercially available kit from 
Mercodia (Uppsala, Sweden). This kit uses a solid phase two site enzyme immunoassay. 
Two n10noclonal antibodies are directed against separate antigenic determinants on the 
C-peptide tnolecule. During incubation c-peptide in the sample reacts with antic-peptide 
antibodies bound to the tnicrotitration well. After washing peroxidase conjugated antic-
peptide antibodies are added and it is incubated again. Then washing removes unbound 
enzyme labelled antibody and the bound conjugate is detected by reaction with 3,3>,5,5'-
tetratnethlybenzidine. The reaction is stopped by adding acid to give a colormetric 
endpoint that is read spectrophotometrically. 
Glucose, HbAJ c, urea, electrolytes and liver function 
Glucose, HbAlc, urea, electrolytes and liver function were measured for all subjects by 
the Clinical Chemistry Department of the Royal Surrey County Hospital using an 
ADVIA 1650 Chetnistry System, (Bayer Healthcare, Leverkusen, Germany). 
Measurement of glucose uses the hexokinase principle. Hexokinase catalyses the 
phosphorylation of glucose to glucose-6-phosphate which in the presence of glucose-6-
phosphate dehydrogenase is oxidised leading to the generation of NADH which can be 
measured spectrophotometrically at 340nm. 
To measure HbAlc initially whole blood is tnixed with a reagent which lyses red blood 
cells and hydrolyses the haemoglobin chain. Then total haetnoglobin is 1neasured. 
HbAlc is measured using a latex agglutination inhibition assay. HbAlc competes with 
the agglutinator (synthetic latex containing multiple copies of the imtnuno-reactive 
portion of HbAlc) for the anti-HbAlc antibody thereby reducing the rate of 
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agglutination. The change in scattered light is monitored as a change of absorbance 
which is inversely proportional to HbA1c concentration. The ratio of HbAlc to total 
haetnoglobin is reported as percent HbAlc. 
Adiponectin 
Adiponectin concentrations were determined using a cmmnercially available 
imtnunoassay kit frmn Lince Research Inc (St. Louis, Mo, USA). This assay is a 
Sandwich ELISA based on concurrent capture of human adiponectin molecules fi·otn 
samples to the wells of a microtiter plate coated with a tnonoclonal anti-human 
adiponectin antibodies, and binding of a second biotinylated monoclonal anti-human 
antibody to the captured molecules, washing of unbound materials from samples, 
binding ofstreptavidin-horseradish peroxidase conjugate to the immobilized biotinylated 
antibodies, washing of excess of free enzyme conjugates, and fmally quantification of 
itnmo bilized antibody-enzyme conjugates by monitoring horseradish peroxidase 
activities in the presence of the substrate 3,3 ',5,5 '-tetramethylbenzidine. The enzyme 
activity is measured spectrophotometrically by the increased absorbance at 450 run -
590mn after acidification of fanned products. The intra-assay precision is 1.0-7.4% and 
the inter-assay precision is 2.4-8.4%. 
Insulin sensitivity 
Homeostatic model assessn1ent (HOMA) of ｾＭ｣･ｬｬ＠ function and insulin resistance was 
calculated using the HOMA cmnputer model (HOMA2, version 2.2) (Wallace et al, 
2004). HOMA analysis uses a structural mathematical model to estimate insulin 
sensitivity and beta cell function from fasting plasma glucose and insulin concentrations. 
The predictions used in the tnodel arise from experimental data in humans and animals. 
The 1985 HOMA model calculates insulin resistance (HOMA-IR) whereas the current 
model calculates insulin sensitivity (o/oS) as a percentage of a reference value (100%). 
The reference value was derived from a population of 40 young, lean non-diabetic 
controls (Adler et al, 2005). Insulin resistance index (IR) is calculated as 1/%S * 100. 
The n1odel can also be used to estimate beta cell function (%B). HOMA IR has been 
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found to correlate well with estimates of insulin resistance fi:om the euglycaemic clatnp 
in subjects with diet controlled diabetes (Matthews et al, 1985) and in subjects with 
sulphonylurea treated diabetes (Emoto et al, 1999). It has also been used to estimate 
insulin sensitivity in subjects treated with tnetfonnin (Inchiostro, 2005). 
Full blood count 
Full blood count was measured by the Haematology Labaratory at the Royal Surrey 
County Hospital using an automated ADVIA 120 (Bayer Diagnostics). 
Power calculation 
To detenuine the sample size a power calculation was performed. The work of 
Cummings et al (Cummings et al, 1995a) was used to predict expected VLDL apo BlOO 
ASR and response to treatment. In this work at baseline mean VLDL apoB100 ASR was 
24.5mg/kg/day in 6 subjects with type 2 diabetes. Following intervention (insulin 
infusion) tuean VLDL apo B100 ASR fell to 12.2 mg/kg/day (Cun1mings et al, 1995a). 
Based on a prediction that active intervention would decrease VLDL apo BlOO ASR 
:fi:mn 24mg/kg/day to 12mg/kg/day in order to have 80% power to detect a difference at 
the 0.05 significance level it was calculated that the study required 8 subjects per group. 
Within groups the study.had 80% power to detect a difference of this magnitude with a 
significance level of< 0.01. 
Statistical Analysis 
Data is presented as mean ± SEM or median and interquartile range for non-
parametrically distributed variables (triglyceride, ASR and FCR). Comparison between 
groups at baseline was made using one-way ANOV A or Kruskal-Wallis for non-
parametrically distributed variables. Post-hoc analysis was performed using a Bonferroni 
correction. Within each group cmnparison of variables before and after treatment was 
perfonued using Student's t-test or Wilcoxon rank test for non-parametrically distributed 
variables. Change in variables after treatment was compared across groups using one-
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way ANOV A or Kruskal-Wallis as above. All statistical analysis was performed using 
SPSS. P-values of less than 0.05 were regarded as significant. 
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Results 
Subjects 
In total 32 subjects were screened. 4 failed screening, 1 because of abnormal liver 
function tests, 1 because of inadequately controlled diabetes necessitating addition of 
another oral agent, 1 because of needle phobia, and 1 because of weight loss. 2 subjects 
were withdrawn after screening but before taking part in the study, 1 due to admission to 
hospital with renal failure and 1 due to admission to hospital with an acute coronary 
syndrome and subsequent insulin therapy. In addition 2 subjects changed their tnind 
about taking part after screening. 
Baseline characteristics 
Table 17, Table 18 and Table 19 contain demographic information about the subjects in 
the study. 13 subjects were on treatment for hypertension. Table 20 summarises baseline 
characteristics for subjects. Subjects were tniddle-aged/ elderly with a tnean age 62.75 
years± 1.93. They were overweight/obese, mean weight 97.42 kg± 3.14 and mean BMI 
30.92 kg!In2 ± 0.82. There were 6 female subjects and 18 male subjects. 2 out ofthe 24 
subjects were current smokers. Subjects had had diabetes for a n1ean of 3. 75 years ± 
0.46. 16 subjects were on tnetformin and 8 subjects were on diet alone. Subjects in the 3 
groups were well-tnatched. There was no significant difference in sex distribution, age, 
weight, BMI, fat percentage or thne since diagnosis between the 3 groups. 
Glycaemic variables 
In general subjects had well controlled diabetes, mean HbAlc 7.02% ± 0.15 and mean 
fasting glucose 8.16tnmoVL ± 0.28. There was no significant difference in fasting 
glucose, insulin, C-peptide or insulin resistance as measured by HOMA2 between the 
three groups. However there was a significant difference in baseline HbA1c between the 
3 groups. Post-hoc analysis showed that there was no significant difference in HbA1c 
between the placebo and rosiglitazone group (p = 0.925), and the rosiglitazone and 
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pioglitazone group (p = 0.25). There was a significant difference in baseline HbAlc 
between the placebo and pioglitazone group (p = 0.028), Table 21. 
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Table 20 Baseline characteristics 
Sex (M/F) 7/1 7/1 4/4 
Age (years) 60.75 ± 3.45 61.00 ± 3.93 66.50 ± 2.51 
Time since diagnosis 2.88 ± 0.40 4.00 ± 0.80 4.38 ± 1.03 (years) 
Number on metformin 5 5 6 
Weight (kg) 103.91 ± 5.61 96.39 ± 3.62 91.95 ± 6.52 
BMI (kg/m2) 31.96 ± 1.56 30.81 ± 1.26 29.99 ± 1.50 
Fat Percentage 32.81 ± 2.92 30.44 ± 3.96 32.75 ± 4.67 
Table 21 Diabetes variables at baseline 
Fasting glucose 8.21 ± 0.36 8.15 ± 0.30 8.11 ±0.75 (mmol/L) 
HbA1c (%) 6.60 ± 0.14 7.53 ± 0.21a 6.94 ± 0.30 
Fasting Insulin 71.63 ± 14.22 84.13 ± 13.99 52.13 ± 8.61 (pmol/L) 
Fasting C-peptide 849.13 ± 108.99 1057± 146.91 840.88 ± 79.88 (pmol/L) 
HOMA2%B 44 ± 6.32 49.5 ± 4.63 41.65 ± 7.58 
HOMA2IR 1.5 ± 0.30 1.75 ± 0.30 1.10 ± 0.18 
a p = 0.028 compared to placebo 
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Changes in baseline characteristics after treatment 
Changes in baseline characteristics following treatment are smmnarised in Table 22. 
There was a significant increase of 1.94 kg ± 0. 76 in weight in the pioglitazone group 
compared to baseline, (p = 0.04). There was no significant change in weight in the 
placebo or rosiglitazone group compared to baseline. There was no significant difference 
in weight change frotn baseline to after treatn1ent between the 3 groups. There was a 
significant increase in fat percentage in the placebo group but there was no significant 
change in the other 2 groups and there was no difference in the change between groups. 
Change in glycaemic variables following treatment 
There was an ahnost significant change in fasting glucose compared to baseline in the 
rosiglitazone group (p = 0.06) but there was no significant change in the placebo (p = 
0.34) or the pioglitazone group (p = 1) cotnpared to baseline, Table 23. The change in 
fasting blood glucose concentration was significantly different between groups (p = 
0.024). Post hoc analysis showed that there was no difference in the change in fasting 
blood glucose between the placebo and pioglitazone group (p = 1.0), and the 
rosiglitazone and pioglitazone group (p = 0.11), there was a significant difference in the 
change between the placebo and rosiglitazone group (p = 0.03). 
Fasting insulin decreased in the rosiglitazone group although this did not reach statistical 
significance (p = 0.06). There was no change in fasting insulin in the placebo or 
pioglitazone group and there was no difference between groups in change in fasting 
insulin (p = 0.076). There was a significant in1provement in HbA1c in the rosiglitazone 
(p = 0.04) and pioglitazone (p = 0.01) group after treatment but there was no change in 
the placebo group (p = 0.28). The change between groups was statistically significantly 
different (p = 0.007), post-hoc analysis showed that in the pioglitazone group this 
change was significantly different fi·om placebo (p = 0.008) and the difference in the 
rosiglitazone group frmn placebo ahnost reached statistical significance (p = 0.06). 
There was no statistical difference between the change in the pioglitazone and the 
rosiglitazone groups (p = 1.0). 
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C-peptide increased significantly in the placebo group (p = 0.02). There was no change 
in the rosiglitazone or pioglitazone group. Across the group the change in C-peptide was 
significantly different (p = 0.015), post-hoc analysis showed there was no difference in 
the change between the rosiglitazone and pioglitazone groups (p=1) but the change in 
the placebo group was significantly different from the pioglitazone (p = 0.028) and the 
rosiglitazone group (p = 0.041). 
At baseline insulin resistance (IR) as measured by HOMA2 varied between groups from 
1. 75 in the pioglitazone group and 1.5 in the placebo group to 1.1 in the rosiglitazone 
group although these values were not significantly different, Table 24. Despite their 
weight, fat% and BMI the rosiglitazone group in particular were not insulin resistant as 
1neasured by HOMA2. This may reflect that the majority of subjects were metformin 
treated, hence increasing their insulin sensitivity. It may also be partly related to the fact 
that all groups had decreased beta cell function (%B) 1neasured by HOMA2 and they 
1nay have had predominately beta cell failure rather than insulin resistance causing their 
diabetes. There was no significant change in the %B measuretnent in any group after 
treatment and no difference in the change between groups. TheIR component ofHOMA 
decreased in subjects on rosiglitazone and this change almost reached statistical 
significance (p = 0.06). There was no difference across the groups in change in HOMA 
IR, (p = 0.09). 
Adverse events 
In general treatment was well tolerated and no subjects dropped out of the study once 
they had been stmied on treatment. Subject 17 who was on pioglitazone developed ankle 
swelling. This improved after a few weeks of treatment but did not completely resolve 
until the end of the study when the drug was stopped. Subject 5 who was on pioglitazone 
developed joint pains which again resolved when the drug was stopped at the end of the 
study. Subject 18 who was on rosiglitazone and had a previous history of breast cancer 
developed a swelling in her left axilla which was fotmd at the time of the 2nd lipoprotein 
tun1over study. She was urgently referred back to the breast clinic where the lump was 
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excised and found to be a lipoma with no evidence of malignancy. Interestingly the 
development of multiple lipomas during treatment with rosiglitazone in a patient with 
HIV associated lipoatrophy has recently been described (Mafong et al, 2004). There 
were no other adverse effects and no serious adverse events. 
Table 22 Change in baseline characteristics following treatment 
>< ｾＢｦｵＬＢ＠ "''.'" ¥fi.' ''" k 
-''\"\ ｐｾ･･｢ｯ＠
'"t "' 
PiOgtitazooe 'Resiglitazoae 
,, '' 
Weight (kg) 
Baseline 103.91 ± 5.61 96.39 ± 3.62 91.95 ± 6.52 
After treatment 104.38 ± 5.76 98.33 ± 3.963 92.63 ± 6.44 
Change 0.46 ± 0.47 1.94 ± 0.76 0.68 ± 0.81 
Fat Percentage 
Baseline 32.81 ± 2.92 30.44 ± 3.96 32.75 ± 4.67 
After treatment 34.03 ± 2.96 32.28 ± 3.97 32.89 ± 4.23 
Change 1.21 ± 0.21 1.84 ± 0.99 0.14 ± 0.78 
a p = 0.04 compared to baseline 
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Table 23 Change in baseline characteristics fo Bowing treatment diabetes variables 
Fasting glucose (mmoi/L) 
Baseline 8.21 ± 036 
After treatment 8.55 ± 0.47 
Change 0.34 ± 0.33 
Fasting insulin (pmoi/L) 
Baseline 71.63 ± 14.22 
After treatment 87.88 ± 17.37 
Change 16.25 ± 12.15 
HbAlc (0/o) 
Baseline 6.60 ± 0.14 
After treatment 6.79 ± 0.24 
Change 0.19 ± 0.16 
Fasting C-peptide (pmoi/L) 
Baseline 849.13 ± 108.99 
After treatment 
Change 
1062.5 ± 143.76h 
213.38 ± 74.73i 
8.15 ± 0.30 
8.15 ± 0.31 
0.00 ± 0.25 
84.13 ± 13.99 
83.13±21.21 
-1.00 ± 8.09 
7.53 ± 0.21 
6.81±0.18d 
-0.71 ± 0.20[ 
1057 ± 146.91 
950.75 ± 188.40 
-106.25 ± 82.18 
",,Rosiglitazone 
8.11 ± 0.75 
6.83 ± 0.50a 
-1.29 ± 0.57b 
52.13 ± 8.61 
36.25 ± 6.60c 
-15.88 ± 7.25 
6.94 ± 0.30 
6.46 ± 0.19e 
-0.48 ± 0.19g 
840.88 ± 79.88 
754.13 ± 91.79 
-86.75 ± 79.51 
a p = 0.06 compared to baseline b p = 0.03 compared to placebo, c p = 0.06 compared to 
baseline, d p = 0.0 I compared to baseline, e p = 0.04 compared to baseline f p = 0.08 
compared to placebo, g p = 0.06 compared to placebo, h p = 0.02 compared to baseline i 
p = 0.028 compared to pioglitazone, p = 0.041 compared to rosiglitazone 
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Table 24 Change in baseline characteristics following treatment HOMA 
HOMA2 °/oB 
Baseline 44 ± 6.32 
After treatment 46.24 ± 5.88 
Change 2.24 ± 2.26 
HOMA2IR 
Baseline 1.5 ± 0.3 
After treatment 1.84 ± 0.37 
Change 0.34 ± 0.27 
a p = 0.06 compared to baseline 
Lipid concentrations 
49.5 ± 4.63 
45.34 ± 6.59 
-4.16 ± 3.68 
1.75 ± 0.30 
1.71 ± 0.45 
-0.04±0.17 
RosigUtazoae 
41.65 ± 7.58 
42.08 ± 5.44 
0.43 ± 5.55 
1.1 ± 0.18 
0.76 ± 0.13a 
-0.34 ± 0.15 
In general subjects had well controlled lipids, Table 25. They were well-matched at 
baseline with no significant difference between the three groups for any lipid variable. 
There was no change in total cholesterol following treatment in any group and there was 
no difference between the change in any group (p = 0.94). Following treatment there 
was no significant difference in triglyceride concentrations in any of the groups and 
there was no difference in the change seen in the three groups. 
The increase in HDL-cholesterol in the rosiglitazone group almost reached statistical 
significance (p = 0.07). There was no change in HDL-cholesterol following treatment in 
the placebo or the pioglitazone group and the change in HDL-cholesterol across groups 
was not statistically significant (p = 0.36). 
Following treatment FFA concentration decreased significantly in both the pioglitazone 
and the rosiglitazone group (p = 0.02 and p = 0.003 respectively). This change was 
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significantly different across the group, p = 0.02. Post-hoc analysis revealed that there 
was a significant difference between the placebo and the pioglitazone group (p = 0.006) 
and the placebo and the rosiglitazone group (p = 0.004). There was no significant 
difference between the pioglitazone and the rosiglitazone group (p = 1.00). 
Table 25 Lipid concentrations at baseline and after treatment 
Total cholesterol (mmoi/L) 
Baseline 4.52 ± 0.19 5.14 ± 0.35 5.08 ± 0.29 
After treatment 4.77 ± 0.27 5.49 ± 0.41 5.32 ± 0.25 
Change 0.25 ± 0.18 0.35 ± 0.34 0.24 ± 0.13 
Triglyceride (mmoi/L) medians and interquartile ranges 
Baseline 2.15 (1.26 2.44) 1.61 (1.42, 1.93) 1.38 (1.21 , 1.68) 
After treatment 2.22 (1.76 2.37) 2.12 (1.34, 2.55) 1.41 (1.17, 1.59) 
Change 0.15 ± 0.18 0.23 ± 0.34 -0.09 ± 0.16 
HDL cholesterol (mmoi/L) 
Baseline 1.09 ± 0.06 1.23 ± 0.16 1.30 ± 0.08 
After treatment 1.15 ± 0.10 1.28 ± 0.17 1.45±0.128 
Change 0.05 ± 0.05 0.05 ± 0.04 0.15 ± 0.07 
FFA (mmoi/L) 
Baseline 0.64 ± 0.06 0.66 ± 0.08 0.68 ± 0.09 
After treatment 0.72 ± 0.08 0.48 ± 0.04b 0.49 ± 0.10c 
Change 0.08 ± 0.15 -0.18 ± 0.06d -0.19 ± 0.04e 
a p = 0.07 compared to baseline, b p = 0.02 compared to baseline, c p = 0.003 compared 
to baseline, d p = 0.006 compared to placebo e p = 0.004 compared to placebo 
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VLDL data 
VLDL lipid data is summarised in Table 26. At baseline there was no significant 
difference in apo B concentration, VLDL cholesterol or VLDL triglyceride 
concentration between groups. There was no significant difference in the ratio of VLDL 
cholesterol or VLDL triglyceride to apo B at baseline in the three groups. Following 
treatment there was no significant change in apo B, VLDL cholesterol, VLDL 
triglyceride or VLDL cholesterol/apo B in any of the groups. However in the 
pioglitazone and the rosiglitazone group there was a significant decrease in VLDL 
triglyceride/apo B, (p = 0.04, p = 0.01 respectively). There was no significant difference 
in the change across the groups (p = 0.08). 
VLDL turnover data 
VLDL turnover data is summarised in Table 27. At baseline there was no significant 
difference in FCR between the three groups (p = 0.14). Following treatment there was 
no significant change in any groups in FCR. At baseline median ASR was significantly 
different between the three groups (p = 0.04). Following treatment there was a 
significant decrease in ASR in the rosiglitazone group (p = 0.017) but no change in the 
placebo or pioglitazone groups. The change in ASR between groups was compared 
using Kruskal-Wallis nonparametric test of independent samples. There was no 
significant difference in the change in ASR between the three groups (p = 0.08). 
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Table 26 VLDL variables before and after treatment 
Apo B (mg/L) 
Baseline 46.26 ± 10.84 38.15 ± 5.84 31.88 ± 4.26 
After treatment 49.36 ± 10.86 44.20 ± 8.40 34.55 ± 5.67 
VLDL cholesterol (mmoi!L) 
Baseline 0.47±0.10 0.51±0.12 0.28 ± 0.04 
After treatment 0.53 ± 0.10 0.54 ± 0.12 0.27 ± 0.04 
VLDL triglyceride (mmoi/L) medians and interquartile ranges 
Baseline 1.44 (0.85, 1.87) 1.41 (0.92, I. 72) 0.85 (0. 78, 0.98) 
After treatment 1.55(1.17 1.78) 1.17 (1.05 1.58) 0.83 (0.69 0.86) 
VLDL cbolesterollapo B 
Baseline 4.35 ± 0.76 4.87 ± 0.79 3.40 ± 0.32 
After treatment 4.86 ± 1.05 4.50 ± 0.72 3.14 ± 0.27 
VLDL triglyceride/apo B 
Baseline 30.64 ± 6.19 31.04 ± 3.91 25.51 ± 2.70 
After treatment 34.56 ± 9.07 25.29 ± 3.71 a 20.64 ± ＲＮＴＷ ｾ＠
Change 3.91 ± 4.83 -5.75 ± 2.22 -4.87 ± 1.32 
a p = 0.04 compared to baseline b p = 0.01 compared to baseline 
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Table 27 VLDL turnover variables (median+ interquartile ranges) 
FCR (pools/day) 
Baseline 5.78 (4.13-9.43) 4.09 (2. 76-5.31) 9.12 (6.87-11.04) 
After treatment 5.63 (3.56-9.26) 4.29 (3.71-5.98) 7.13 (4.68-10.19) 
ASR (mg/kg/day) 
Baseline a 8.56 (7.02-10.16) 5.19 (4.41-6.08) 10.04 (8.38-10.59) 
After treatment 8.21 (6.82-8.84) 6.64 (5.96-8.1 0) 7.86 (6.02-8.81)b 
Chan gee 
-1.22 ( -2.53- 1.28) 1.27 (0.0 1-2.09) -2.19 ( -3.12- -1.87) 
a p = 0.04 between groups, b p = 0.017 compared to baseline, c p = 0.08 between groups 
IDL data 
IDL data is summarised in Table 28. At baseline there was no significant difference in 
IDL apo B concentration, IDL cholesterol IDL triglyceride IDL cholesteroVapo B or 
IDL triglyceride/apo B between groups. Following treatment there was no significant 
change in any IDL lipid variable in any group. 
IDL turnover data 
IDL turnover data is summarised in Table 29. Because of problems with curve fitting the 
data for study 2 for subject 2 (male subject in placebo group) and subject 5 (male subject 
in pioglitazone group) could not be modelled. Therefore these 2 subjects have been 
discounted. There was no significant difference in IDL apo B FCR or ASR at baseline 
between groups. Following treatment there was no significant change in IDL apo B FCR 
or ASR in any group. 
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Table 28 IDL lipid variables before and after treatment 
Apo B (mg/L) 
Baseline 27.27 ± 4.04 35.05 ± 7.74 28.64 ± 4.45 
After treatment 24.63 ± 2.69 31.89 ± 7.24 35.04 ± 5.35 
IDL cholesterol (mmoi/L) 
Baseline 0.089 ± 0.011 0.150 ± 0.034 0.096 ± 0.015 
After treatment 0.095 ± 0.011 0.145 ± 0.036 0.109 ± 0.014 
IDL triglyceride (mmoi/L) 
Baseline 0.07 ± 0.009 0.10 ± 0.019 0.08 ± 0.011 
After treatment 0.08 ± 0.009 0.10±0.025 0.08 ± 0.011 
IDL cholesterol/apo B 
Baseline 1.31 ± 0.10 1.61 ±0.16 1.30 ± 0.09 
After treatment 1.49 ± 0.10 1.72 ± 0.22 1.26 ± 0.14 
IDL triglyceride/apo B 
Baseline 2.42 ± 0.33 2.71 ± 0.22 2.64 ± 0.24 
After treatment 2.86 ± 0.30 2.81 ± 0.16 2.68 ± 0.34 
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Table 29 IDL turnover variables before and after treatment 
,,. 
" 
Placebo(n=7) Pioglitazone (n=7) ｾ＠ ｒｯｾｈｴ｡ｺｯｮ･＠
.. ,,, ｾＭ ｾ＠ !1!fb<e " " 
FCR (pools/day) 
Baseline 3.66 (3.31-5.43) 2.89 (0.90-7.33) 4.77 (4.07-6.61) 
After treatment 4.93 (1.38-7.25) 4. 78 (3.46-6.85) 4.86 (2.59-1 0.20) 
ASR (mg/kg/day) 
Baseline 3.61 (2.61-4.16) 3.53 (0.88-9.44) 4.93 (3.54-6.88) 
After treatment 4.10 (0.93-5.11) 9.06 (2.42-1 0.17) 5.33 (3.30-6.17) 
LDL data 
LDL data at baseline is summarised in Table 30. At baseline there was no difference in 
LDL apo B, LDL cholesterol, LDL triglyceride, LDL cholesteroVapo B or LDL 
triglyceride/apo B between groups. Fo Bowing treatment there was no significant change 
in LDL apo B, LDL triglyceride or LDL triglyceride/apo B in any group. There was a 
significant increase in LDL cholesterol in the placebo group. The change in LDL 
cholesterol was significantly different between groups and post-hoc analysis showed that 
the change in the placebo group was significantly different to the pioglitazone group (p 
= 0.025) but there was no statistical difference between the placebo and the rosiglitazone 
group (p = 1) or the rosiglitazone and the pioglitazone group (p = 0.19). There was a 
significant increase in LDL cholesteroVapo B in the placebo and the rosiglitazone group. 
The change between groups was also significant. Post-hoc analysis revealed that the 
change in both the placebo and the rosiglitazone group was significant compared to 
pioglitazone (p = 0.003 p = 0.04 respectively) but there was no difference between the 
rosiglitazone and placebo group (p = 0. 765). 
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LDL turnover data 
At baseline there was no significant difference between groups in LDL ASR or FCR. 
There was a significant reduction in FCR in the placebo group but there was no change 
in the pioglitazone or rosiglitaione groups. There was no significant difference in LDL 
ASR in any group following treatment, Table 31. Individual subjects' LDL ASR and 
FCR before and after treatment are given in Table 32. 
Table 30 LDL variables before and after treatment 
Apo B (mg/L) 
Baseline 586.67 ± 28.01 715.42 ± 84.49 651.39 ± 73.73 
After treatment 618.61 ± 50.96 667.08 ± 54.78 640.00 ± 56.41 
LDL cholesterol (mmoi/L) 
Baseline 2.06 ± 0.10 2.82 ± 0.33 2.42 ± 0.22 
After treatment 2.50 ± 0.19a 2.42 ± 0.27 2.58 ± 0.21 
Change 0.43 ± 0.16b -0.40 ± 0.30 0.16±0.08 
LDL triglyceride (mmoi/L) 
Baseline 0.33 ± 0.05 0.44 ± 0.07 0.37 ± 0.06 
After treatment 0.31 ± 0.07 0.38 ± 0.05 0.36 ± 0.06 
LDL cholesterollapo B 
Baseline 1.37 ± 0.06 1.54 ± 0.08 1.46 ± 0.06 
After treatment 1.57 ± 0.07c 1.40 ± 0.08d 1.56 ± 0.05e 
Change 0.20 ± o.o8r -0.13 ± 0.06 0.10 ± 0.03g 
LDL triglyceride/apo B 
Baseline 0.48 ± 0.06 0.56 ± 0.09 0.51 ± 0.08 
After treatment 0.42 ± 0.08 0.51 ± 0.07 0.50 ± 0.08 
133 
a p = 0.03 compared to baseline, b p = 0.025 compared to pioglitazone, c p = 0.04 
compared to baseline, d p = 0.07 cmnpared to baseline, e p = 0.008 compared to baseline, 
r p = 0.003 compared to pioglitazone, g p = 0.04 compared to pioglitazone 
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Table 31 LDL turnover variables before and after treatment 
ＬＭｾＭＭ "'" """·., '''*' !j)j Placebo Pioglitazooe Ｎ ｾ＠ . " Rosigtitazoae . ,,, "' ｾＧ＠
FCR (pools/day) 
Baseline 0.26 (0.21-0.29) 0.18 (0.09-0.25) 0.31 (0.25-0.37) 
After treatment 0.24 (0.17-0.27)a 0.21 (0.16-0.26) 0.30 (0.22-0.34) 
ASR (mg/kg/day) 
Baseline 5. 11 ( 4. 0 1-5.5 7) 3.79 (2.13-5.16) 5.86 (5.50-8.60) 
After treatment 4.50 (3.88-5.05) 4.48 (3.70-5.56) 6.13 ( 4. 73-8. 00) 
a p = 0.02 compared to baseline 
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Table 32lndividual subjects' LDL apoB100 ASR and FCR before and after treatment 
ＭＧ｜ｾＢｩＭｾＢＺＧＬｾＬｾｾｾﾷｾｾＧ｜ｔＬｾ［ｾＭｾｴｲＦｾｾｊｾｾｾＬＧＺＱＧｔＺＧｩＢＧＢｩｾＧＱｾＱＧ｜Ｙ｡Ｇ｜•ＢＤｦＧｾＢＧ Ｔ ｾｾｾｾＢＧｾＧｩｾＧＱｾＺＧＧＭＭｦＢｾｾｶＧｬＧＢ［ｾｾｾＺｾＢ＠ ｾＺＬ＠ "';': 1: :· .. ; ' ＭＧ［ＡﾷＧｾＢｴＧｾＮＺＺｾ＠ .· . . . .. .. ,., ::' "'i>' ｾ＠ ｾＺＧＺ＠ ﾷｾＺ＠ .. - .. . . , .• : ' 
ｦＮｾＭＭｾ＠ . , ··" Ｎｾﾷ［ｹＺ･ｾｾＺﾷＺｾｾＭＺ＠ Ｂ［ｾｾＺｾＬ＠ .: ＧＬｾＬ＠ ＺＮｾＮＺＢＮＢｾＧ＠ tt· ﾷＧＧＺＧ［ＺＺﾷＺＺﾷｾｾ［ｾﾷｾＬＢＧＺ｜Ｂ＼ＺＭ］＠ .. ｾｶＮＬﾷ＠ ＢＦＮﾥｴＮＺＬｾｾＬ＠ ::: 
Placebo 
Subject 2 3.83 3.42 0.16 0.11 
Subject 7 5.56 4.63 0.27 0.26 
Subject 8 4.88 5.13 0.30 0.31 
Subject 13 4.07 4.03 0.26 0.25 
Subject 15 3.00 2.57 0.15 0.13 
Subject 16 5.63 4.38 0.29 0.24 
Subject 20 5.34 5.03 0.23 0.19 
Subject 22 7.12 7.39 0.40 0.38 
Pioglitazone 
Subject I 2.16 4.21 0.07 0.21 
Subject 5 4.34 5.36 0.28 0.25 
Subject 9 2.04 1.50 0.09 0.06 
Subject 10 1.51 6.18 0.04 0.27 
Subject 12 5.63 3.67 0.24 0.17 
Subject 17 9.16 8.77 0.54 0.51 
Subject 19 3.24 3.71 0.12 0.13 
Subject 24 5.01 4.74 0.24 0.21 
Rosiglitazone 
Subject 3 8.46 8.29 0.28 0.30 
Subject 4 11.66 13.47 0.74 0.71 
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Subject 6 5.53 4.98 0.38 0.34 
Subject 11 5.85 6.38 0.24 0.30 
Subject 14 5.88 3.67 0.25 0.18 
Subject 18 3.61 7.90 0.15 0.35 
Subject 21 5.41 3.98 0.34 0.23 
Subject 23 9.01 5.88 0.36 0.21 
LDL subfractions 
LDL subfraction concentrations before and after treatment are summarised in Table 33. 
There was a significant increase in LDL2 cholesterol and a significant decrease in LDL3 
cholesterol with rosiglitazone treatment. The decrease in LDL3 cholesterol was 
significant compared to placebo (p = 0.03) and pioglitazone (p = 0.004). There was no 
change in LDL2 and LDL3 triglyceride in any group. In the rosiglitazone group there 
was a significant increase in LDL2 apo B and a decrease in LDL3 apo B which almost 
reached statistical significance (p = 0.06). The change in LDL3 apo B was different 
across the group and this was because of a significant difference in the rosiglitazone and 
pioglitazone groups (p = 0.03). There was no change in LDL2 cholesterol/ape B, LDL3 
cholesterol/ape B LDL2 triglyceride/ape B or LDL3 triglyceride/ape B in any group 
following treatment. 
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Table 33 LDL subfraction variables before and after treatment 
Placebo "'" Piog6tazone Rosiglitazone 
II! ""' ｾＧＦ＠ II! ' ｾ＠ @' "" ｾＧ＠
LDL2 cholesterol (mmol/L) 
Baseline 0.78 ± 0.08 1.08 ± 0.15 1.02±0.14 
After treatment 0.80 ± 0.10 1.21 ± 0.07 1.39 ± 0.20a 
Change 0.02 ± 0.06 0.14 ± 0.12 0.37 ± 0.12 
LDL3 cholesterol (mmol/L) 
Baseline 1.28 ± 0.16 1.25 ± 0.15 1.33 ± 0.12 
After treatment 1.41±0.18 1.53 ± 0.23b 0.96 ± 0.14c 
Change 0.13±0.12 0.28 ± 0.12 -0.37 ± 0.13d 
LDL2 triglyceride (mmol/L) 
Baseline 0.15 ± 0.01 0.16 ± 0.02 0.14 ± 0.02 
After treatment 0.14 ± 0.01 0.17 ± 0.02 0.16±0.03 
LDL3 triglyceride (mmol/L) 
Baseline 0.12 ± 0.02 0.09 ± 0.01 0.11 ± 0.02 
After treatment 0.10 ± 0.01 0.11 ± 0.02 0.09 ± 0.01 
LDL2 apo B (mmol/L) 
Baseline 0.21 ± 0.02 0.26 ± 0.03 0.25 ± 0.03 
After treatment 0.21 ± 0.02 0.29 ± 0.03 0.34 ± 0.05e 
Change 0.00 ± 0.02 0.02 ± 0.03 0.09 ± 0.03 
LDL3 apo B (mmol/L) 
Baseline 0.37 ± 0.05 0.37 ± 0.04 0.38 ± 0.05 
After treatment 0.41 ± 0.05 0.46 ± 0.07 0.30 ± 0.05[ 
Change 0.04 ± 0.05 0.09 ± 0.05 -0.09 ± 0.048 
a p = 0.02 compared to baseline b p = 0.05 compared to baseline, c = p 0.02 compared to 
baseline, d p = 0.03 compared to placebo, p = 0.004 compared to pioglitazone e p = 0.02 
138 
compared to baseline, f p 
pioglitazone 
0.06 compared to baseline, g p 0.03 compared to 
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Adiponectin 
Adiponectin concentrations are summarised in Table 34. There was no significant 
difference in adiponectin concentrations between the groups at baseline. In both 
rosiglitazone and pioglitazone groups there was a significant increase in adiponectin 
concentrations. The difference across the groups was significant. Post hoc analysis 
showed that the change in rosiglitazone group was significant compared to placebo (p = 
0.002), the change in the pioglitazone group was not significant compared to placebo (p 
= 0.08) and there was no difference in the change between the rosiglitazone and 
pioglitazone groups (p = 0.29). 
Table 34 Adiponectin concentration before and after treatment 
Adiponectin concentration (mcg/ml) 
Baseline 6.43 ± 0.57 5.46 ± 1.07 7.33 ± 1.16 
After treatment 6.39 ± 0.67 10.34±1.71a 15.93 ± 3.40b 
Change -0.04 ± 0.3 4.90 ± 0.93 8.60 ± 2.58c 
%Change -0.6 +89.7 + 117.3 
a p = 0.001 compared to baseline, b p = 0.016 compared to baseline, c p = 0.002 
compared to placebo 
Relationship between adiponectin, lipid and insulin resistance variables 
Table 35 summarises Pearson correlation coefficients and significance values for 
adiponectin lipid and diabetes variables for subjects in the current study. There was a 
significant inverse association between adiponectin concentration and the insulin 
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resistance index of HOMA. However there was no significant relationship between 
serum adiponectin concentration and any lipid parameter or VLDL apo B ASR or FCR. 
There was a significant relationship between HOMA IR score and VLDL apo B ASR 
triglyceride concentration and VLDL apo B and an inverse correlation with HDL 
cho !estero I. 
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Discussion 
This study is the first to directly compare rosiglitazone and pioglitazone using a double-
blinded placebo .controlled 1nethodology. In addition it is the first tilne that the effect on 
lipids and lipoprotein turnover of the 2 cmmnercially available TZDs has been 
compared. The results of this study are important as differences between these 2 drugs 
have implications for clinical usage. 
Summary of main findings 
The main fmdings of this work were that despite good diabetes control at baseline 
subjects in both the rosiglitazone and pioglitazone groups had a significant reduction in 
HbA1c. Subjects in the rosiglitazone group had a decrease in fasting glucose, fasting 
insulin and the insulin resistance (IR) index ofHOMA2 which ahnost reached statistical 
significance (p = 0.06). There was a marked (and significant) increase in adiponectin 
concentration in both of the active treatn1ent groups. It increased by 90% in the 
pioglitazone group and by 117% in the rosiglitazone group. Weight increased in all three 
treatment groups, in the pioglitazone group this increase reached statistical significance. 
The effect of pioglitazone and rosiglitazone on lipid concentrations was not as marked as 
expected. FFAs decreased significantly in the pioglitazone and the rosiglitazone group. 
Subjects in the rosiglitazone and pioglitazone group had a non-significant increase in 
total cholesterol and HDL-cholesterol. There was no significant change in triglyceride in 
any group. LDL-cholesterol increased in the rosiglitazone group and decreased in the 
pioglitazone group but these changes did not reach significance compared to baseline. 
The change in LDL-cholesterol in the pioglitazone group was significant compared to 
placebo. 
With respect to lipoprotein turnover the dominant fmding was that ASR ofVLDL apo B 
decreased significantly in the rosiglitazone group. There was no change in ASR in the 
pioglitazone or placebo group and there was no change in FCR in any group. There was 
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a significant decrease in FCR of LDL apo B in the placebo group but apart from this 
there was no difference in ASR or FCR for LDL or IDL apo B after treatment. 
The other interesting findings were a significant decrease in VLDL triglyceride/apo Bin 
the pioglitazone and the rosiglitazone group. In the rosiglitazone group a significant 
increase in LDL2 cholesterol and apo B and a significant decrease in LDL3 cholesterol 
were seen. LDL cholesterol/apo B increased significantly in the placebo group and the 
rosiglitazone group. 
Therefore it can be seen that the effects on glycaemic variables in this study were tnuch 
as expected whereas less of an effect was seen on lipid concentrations and lipoprotein 
kinetics. How can this be explained? Also why was an effect on VLDL apo B ASR seen 
only in the rosiglitazone group? 
Factors influencing results 
The fact that there was an improvetnent in both the pioglitazone and rosiglitazone group 
in HbAlc suggests that compliance was not an issue. The subject nutnbers were small 
compared to the large tnulti-centre studies of rosiglitazone and pioglitazone. However 
the tnethodology used is a very sensitive way of picking up small differences in 
lipoprotein metabolism as each subject acts as their own control. The studies are 
expensive and time-consuming to do because of the labour intensive methodology: the 
length of the lipoprotein turnover study, the use of stable isotopes, the separation of lipid 
fractions and the preparation for and subsequent use of GCMS. Therefore the sample 
size used in this study is standard for this type of work. 
Glycaemic control 
The group of subjects selected may have been an atypical group. They had excellent 
glycaemic control (n1ean HbAlc 7.02%). This particular group ofpatients would not be 
expected to see the tnore dramatic effects of TZDs seen in some other studies. In the 
studies included in the systematic review the mean HbAl c at baseline for most of the 
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rosiglitazone studies is between 8 and 10% and for the pioglitazone studies between 8.5 
and 11%. For both drugs the biggest changes in HbAlc following treatment tend to be 
when the mean HbAlc at baseline is greater than 9%. However in a placebo controlled 
trial it is not ethical to recruit patients who need an additional agent to control their 
diabetes adequately if one of the recruittnent options is placebo. Therefore patients with 
poorly controlled diabetes were not recruited. In fact poorly controlled diabetes 
necessitating addition of another oral agent led to screening failure in one potential 
subject who was referred back to his pritnary care physician. Similarly many suitable 
subjects were identified through prin1ary care databases. If individuals with poor 
diabetes control were identified, since the general practitioner screened the list before 
subjects were approached for the study those with poor diabetes control were removed 
or identified for intensified treatment. 
Some of the large trials of TZDs had very high drop-out rates. This was partly because 
they recruited subjects with poor diabetes control into trials where one of the potential 
treatments was placebo. For example in the Aronoff study (Aronoff et al, 2000) subjects 
were required to have an HbAlc of greater then 7% to be enrolled in the study. There 
then followed a 6 to 8 week washout period where all their current anti-diabetic 
treattnent was stopped. This meant that the mean HbAlc in all groups at baseline was 
greater than 10%. They were then rand01nised to placebo, 7.5mg, 15mg, 30mg or 45mg 
of pioglitazone. Unsurprisingly only 33% of subjects in the placebo group cmnpleted 26 
weeks of treattnent and even in the active treatment groups the nmnber completing the 
study ranged fi·om only 44 to 58%. The tnost common reason for withdrawal frotn the 
study was lack of glycaemic control. The percentages withdrawn from each group 
because of this were 49%, 35%, 33% and 29% for the placebo, 7.5mg, 15mg, 30mg and 
45mg of pioglitazone group respectively. Interestingly even in the 45mg group the 
reduction in HbAlc compared to baseline was only 0.9% but this is presented as a 1.6% 
reduction compared to placebo. 
In the current study it was essential to try and ensure that all patients completed their 
treatment because subject nutnbers were comparatively small. Therefore it is important 
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to have paired data for each subject. The overall cost of a lipoprotein turnover study is 
very high so ideally all subjects who had a baseline study should come back at 3 months 
for the second study. More hnportantly it is crucial that taking part in a clinical study 
does not have an adverse effect on patients' care. By recruiting subjects known to have 
poor diabetes control and randmnising then1 to placebo it can be argued that smne of the 
large clinical studies ofTZDs did just that. 
Baseline lipid concentrations 
In this study subjects had nonnal lipids at baseline (mean total cholesterol 4.9ltrunolll, 
tnean LDL-cholesterol 2.43nm1olfl, median triglyceride I.61nm10lfl and mean HDL-
cholesterol 1.21mmol!l) with no evidence of the typical pattern of diabetic 
dyslipidaetnia. These lipid concentrations are all less than the ATP Ill and the ADA 
guidelines for the treatment of dyslipidaemia in diabetes (Executive Sutnmary of the 
third report of the National Cholesterol Education Progratmne, 2001; Haffner, 2003). 
This was despite the fact that one of the exclusion criteria for the study was lipid 
lowering therapy, therefore none of the subjects were on statin or fibrate drugs. This was 
because these drugs affect lipoprotein turnover they may have affected the study results. 
Again screening through databases allowed those with very poor lipids to be identified 
by their own primary care physician and started on treatment so then they were not 
suitable for the study. 
The baseline lipids of subjects in this study were lower than the lipids of subjects in the 
studies h1cluded in the systetnatic review. Mean cholesterol was greater than 5.2trunol/l 
in 9 of the rosiglitazone studies and 7 of the pioglitazone studies, LDL-cholesterol was 
greater than 3tnmo1/l in 7 of the rosiglitazone studies and 6 of 7 pioglitazone studies 
where it is given. Similarly HDL cholesterol is less than 1.2nunol!l in 9 of the 
rosiglitazone studies and 8 of the pioglitazone studies and triglyceride is greater than 
2mtnolll in 7 ofthe rosiglitazone studies and 6 ofthe pioglitazone studies. 
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The current study was designed before the publication of some of the lipid-lowering 
trials. For instance the Heart Protection Study (Heart Protection Study Collaborative 
Group, 2003) showed that people with diabetes but without known coronary artery 
disease had a 25% reduction in major vascular events when treated with 40mg 
shnvastatin compared to placebo. This has increash1gly led to the routine prescription of 
stath1s to people with type 2 diabetes, even those with so-called 'normal' cholesterol. 
The recruitment period of this study coincided with a time of increasing awareness of 
the benefits of statins in people with diabetes and consequently it was relatively difficult 
to identify patients who were not on lipid-lowering therapy. Additionally it is not ethical 
to with-hold a treatment such as a statin from a patient who may benefit frmn it because 
they wish to take part in a clinical study. A group who are currently doing sitnilar work 
in the US have managed to gain ethical approval for withdrawing patients from statins in 
order to take part in their research. However before subjects are withdrawn frotn their 
statin they have to know that they have a low risk of having a vascular event in the 3 
months in which they will be in the study. Consequently they are performing stress 
echocardiography in subjects who are not known to have normal coronary atteries 
(Nagashima et al, 2004). 
There is evidence fi:om studies of statins and fibrates that their effects on lipid 
parameters are more marked in subjects with worse dyslipidaemia at baseline. Indeed it 
has been suggested that one of the reasons that pioglitazone is thought to have a tnore 
marked effect on dyslipidaetnia is that subjects in the original pioglitazone studies had a 
more pronounced dyslipidaemia at baseline (van Wijk et al, 2003). There is also 
evidence frmn stable isotope studies of lipoprotein turnover that more profound changes 
are seen in subjects with dyslipidaetnia at baselh1e. For instance in a study of patients 
with type 2 diabetes during acute hyperinsulinaemia a more profound fall in VLDL apo 
B secretion was observed in individuals who had hypettriglyceridaetnia at baseline 
(Cummings et al, 1995a). In this work mean triglyceride concentration during the 
control study was 3.8nunoVI. 
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Rosenblatt and co-workers (Rosenblatt et al, 2001) divided subjects in their 23 week 
placebo controlled double-blinded tnulti-centre trial of pioglitazone depending on their 
lipids at baseline. They found that following treat1nent with pioglitazone 30mg 
triglyceride concentration significantly decreased by 14.8% from a mean starting 
concentration of 4.52mmolll. However when they looked at subjects Who had 
triglyceride levels less than 2.26trunol/l at baseline they only had a 4.9% decrease in 
triglyceride fo Bowing treatment. This was statistically significant cmnpared to the 
placebo group where triglyceride actually increased but it was not significant compared 
to baseline. The group with low starting triglyceride concentration did have a significant 
increase in HDL cholesterol (mean at baseline 1.15 mmol/l) cotnpared to baseline and 
placebo. They also looked at results based on starting HDL-cholesterol concentration. 
They found that in patients with baseline HDL-cholesterol concentration of greater than 
1.16mnml/l there was a non-significant increase of 0.03 mmol/1 with pioglitazone. 
However the pioglitazone group as a whole had a 15.8% increase in HDL-cholesterol 
levels. 
Looking at the studies in the systetnatic review with respect to pioglitazone's effect on 
triglyceride concentrations 3 ofthe studies had non-significant effects. Of the 7 that state 
there was a significant decrease in triglyceride, one does not give baseline values. In 4 of 
the studies baseline triglycerides were nearly 3tnmol/1 or over. The 2 studies with lower 
starting triglyceride levels which found a significant effect (Herz et al, 2003; Miyazaki 
et al, 2001i), both used 45mg ofpioglitazone. The Herz study did not find an effect with 
30tng pioglitazone. There were 2 studies with similar starting triglyceride concentration 
to the current study. The first was a Japanese study (mean triglyceride at baseline 
1.51lllnol/l) (Kawamori et al, 1998) and this study also did not find a significant decrease 
following treatment but found an increase in HDL- cholesterol from 1.2 to 1.31lllnol/l. 
The second study (Miyazaki et al, 2001 i) (tnean starting triglyceride 1.56nunol/l) used 
45mg pioglitazone and found a significant reduction but they also found a very large 
reduction in HbA1c from 8.9 to 7.2%. 
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Therefore the evidence :fi:01n the systen1atic review papers also suggests that large 
changes in lipid concentrations tended to be in subjects with more tnarked dyslipidaetnia 
at baseline. Subjects with relatively well controlled lipids had some changes but 
generally these were of stnaller absolute and relative magnitude. In addition there is 
some possible evidence that 45tng of pioglitazone may have a n10re 1narked effect on 
lipids than 30mg. 
Another possible explanation for the lack of change in triglyceride concentration in the 
current study compared to studies in the systematic review is that some of the 
improvement in these studies may stein fr01n an improve1nent in glycaemic control 
particularly if it was poor at baseline. One study (Rosenstock et al, 2002) only found a 
significant iinprove1nent in triglycerides compared to placebo and not to baseline and 
this reflected the fact that triglyceride concentration in the placebo group actually 
increased (possibly linked to worsening of glycaemic control). 
Looking more closely at the studies included in the systematic review reveals that the 
changes in lipid concentrations are relatively small. For instance the increase in HDL-
cholesterollevels seen with both pioglitazone and rosiglitazone is between 10 and 15% 
in most studies. The ii1crease in LDL and total cholesterol seen with rosiglitazone is of a 
similar magnitude. The reduction in triglyceride seen in pioglitazone studies varies from 
5 to 24% but the tnost fi·equent reduction seen is of about 10%. Obviously if the starting 
lipid concentrations are higher then the absolute change is larger than in a study such as 
the current one where subjects had normal lipids at baseline. With changes at this level 
in order for results to gain statistical significance studies require a large number of 
participants. 
Insulin resistance 
HOMA2 was used to provide an estiinate of insulin sensitivity. As a whole the subjects 
were not particularly insulin resistant as measured by HOMA2, in particular the 
rosiglitazone group had a mean insulin resistance index of 1.1 at baseline. This was 
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despite their weight and BMI (mean 30.92kg/m2). This was unexpected as insulin 
resistance is a characteristic feature oftnost patients with type 2 diabetes and is ahnost a 
universal fmding in patients with type 2 diabetes who are overweight (Olefsky, 2000). 
HOMA provides an estimate of insulin resistance based on fasting insulin and glucose 
measurement, the gold standard tnethodology for measuring insulin sensitivity is the 
euglycaemic hyperinsulinaetnic clatnp. Insulin resistance assessed by HOMA has been 
found to correlate well with insulin resistance measured by the euglycaemic clamp in 
subjects with diet (Matthews et al, 1985) and sulphonylurea (Emoto et al, 1999) treated 
diabetes. HOMA has also been used as an estimate of insulin sensitivity in subjects 
treated with metformin (Inchiostro, 2005) but this was not validated against the 
euglycaetnic clamp. There is no data on the use of HOMA in subjects treated with 
TZDs. In addition the tnean of three insulin samples taken at 5 tninute intervals to 
compute HOMA is better than a single smnple, however in practice single samples are 
usually used. The coefficient ofvariation for individuals is 10.3% for HOMA-%S and 
7.7% for HOMA-%B. Despite these issues HOMA is a widely used tnethod of assessing 
insulin resjstance patiicularly in population based studies. Therefore it seems that the 
subjects in the study, in pmiicular in the rosiglitazone group were more insulin sensitive 
than would be expected based on their BMI. It has been demonstrated that efficacy of 
troglitazone depends on the pre-treatment insulin resistance index estimated by HOMA, 
those who are more insulin resistant respond better (Nagasaka et al, 1997). Similarly 
subjects with greater insulin resistance and preserved beta cell function as tneasured by 
HOMA were found to respond better to pioglitazone (Nagasaka et al, 2004). 
The subjects' relative insulin sensitivity and poor beta cell function tnay be a reflection 
of the length of time subjects had been diagnosed with diabetes. However one of the 
inclusion criteria was that diabetes had been diagnosed for more than 6 tnonths. This 
was to ensure that subjects were stable and changes that were seen reflected the effect of 
TZDs rather than dietary changes or acute changes due to the recent diagnosis. In 
practice by recruiting stable patients with type 2 diabetes the patients who were recruited 
had had diabetes for some years (tnean time since diagnosis 3.75 years) yet were only on 
150 
diet or metformin. These patients may well have made dietary changes initially, lost 
weight and improved their insulin sensitivity. The fact that they still had diabetes 
reflected their failing beta cell function rather than insulin resistance. 
Other factors 
The trial participants were a cmnparatively well group, although more than half were on 
treatment for hypertension only 2 subjects had had a tnacrovascular event (a myocardial 
infarction in subject 19 and a transient ischaemic attack in subject 9). This partly reflects 
the fact that people who volunteer to be in clinical studies are usually well and also even 
if people who have 1nore medical problems volunteer they are likely to be excluded 
based on the inclusion and exclusion criteria. 
Subjects had to have liver function within the reference range of the laboratory of the 
Royal Surrey County Hospital to take part in the study. It is increasingly recognized that 
abnormal liver function tests secondary to liver steatosis are relatively common in type 2 
diabetes and form another part of the insulin resistance spectrum. Interestingly there is 
evidence of a positive con-elation between fasting triglyceride levels and liver fat 
measured by proton spectroscopy in humans (Taskinen, 2003). Therefore excluding 
individuals with abnormal liver function tnay have led to the exclusion of particularly 
insulin resistant individuals and have also contributed to the relatively low triglyceride 
concentrations seen in the group as a whole. Of course because of the problems of 
hepatotoxicity with troglitazone and the consequent restriction of TZD prescribing this 
was entirely necessary. However liver toxicity has not been a probletn with pioglitazone 
and rosiglitazone and recent studies show they actually may reduce liver fat, lead to an 
improvement in liver function tests and therefore be a possible treatn1ent for non-
alcoholic liver steatosis (Bajaj et al, 2003; Bajaj et al, 2004). 
Subjects in the study were allowed to be on 1netformin. Ideally subjects would have had 
diet controlled diabetes only but this would have made recruitinent of an adequate 
number of subjects very difficult if not impossible. However metformin is known to 
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have effects on lipids. It inhibits adipose tissue lipolysis, reduces circulating FF As and 
decreases VLDL production and triglyceride concentration (Tiikkainen et al, 2004; 
Witters, 2001). This is probably due to its effect activating AMP-activated protein 
kinase which is a major regulator of lipid and glucose metabolis1n (Zhou et al, 2001). 
However the randomisation process was stratified to ensure an equal distribution of 
metfonnin treated subjects in each group. In addition despite subjects being on 
metformin a consistent decrease in FF As was seen in both active treatment groups 
suggesting that TZDs can have an effect on lipids over and above the effect of 
metformin. 
Other drugs such as angiotensin converting enzyme (ACE) inhibitors and bendrofluazide 
can also affect lipid metabolistn. In the placebo group 4 subjects were on an ACE 
inhibitor, in the pioglitazone group 2 subjects were on an ACE inhibitor, 2 were on an 
angiotensin II receptor antagonist and 1 subject was on bendrofluazide and in the 
rosiglitazone group 1 subject was on an ACE inhibitor and 1 was on bendrofluazide. The 
difference in the distribution of the use of these drugs between groups may be an 
additional confounding factor. 
So to summarise there are a nmnber of reasons why the results of the current study, 
particularly the effect on baseline lipids, were not as expected. Tight exclusion and 
inclusion criteria led to the selection of a group of subjects with few confounding 
variables. They had much better diabetic and lipid control than subjects in previous 
studies of TZDs. Another important consideration is that the actual effect of TZDs on 
lipid paratneters is small and not consistent between studies. In order for such small 
changes to reach statistical significance a large number of subjects are necessary. The 
sensitivity of isotopic techniques allows few subjects to be studied. However it could be 
argued that since the publication of the landtnark lipid lowering trials dyslipidaemia is 
actively treated and we rarely see people with type 2 diabetes who have such marked 
dyslipidaetnia as in the earlier TZD studies. This 1neans that the results of this study are 
now 1nore relevant to this population. 
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Discussion of results 
Despite the lack of significant changes in total cholesterol, HDL cholesterol, LDL-
cholesterol and triglyceride, significant decreases in FFAs were found in both active 
treabnent groups. VLDL triglyceride/apo B decreased significantly in the pioglitazone 
and rosiglitazone groups and LDL/apo B increased significantly in the rosiglitazone 
group. LDL2 cholesterol and apo B increased significantly in the rosiglitazone group 
and there was a significant decrease in LDL3 cholesterol. In addition there was a 
significant decrease in VLDL apo B ASR in the rosiglitazone group. There was also an 
increase in LDL cholesterol in the placebo group which probably arose as a result of the 
decrease in the FCR ofLDL in this group. What are the implications of these results? 
Many other studies have also found a significant reduction in FF As with TZDs 
(Miyazaki et al, 2001 b; Patel et al, 1999). This may result from a number of 
mechanisms. There may be an improvetnent in adipose tissue sensitivity to the anti-
lipolytic effect of insulin and therefore an inhibition of lipolysis (Tiikkainen et al, 2004). 
Also changes in fat mass and the distribution of fat with an increase in subcutaneous fat 
and a decrease in visceral fat could play a role (Miyazaki et al, 2001a). TZDs increase 
the ability of adipose tissue to take up and store FFAs (Oakes et ｡ｾ＠ 2001) which can 
prevent their storage in other tissues such as the liver and hence ilnprove insulin 
sensitivity. 
Because previous work has shown that pioglitazone reduces triglyceride more than 
rosiglitazone it may have been expected that pioglitazone would lead to a greater 
reduction in VLDL apo B ASR. A theory that explains the tnore n1at·ked effect on lipids 
of pioglitazone is that at equivalent doses pioglitazone activates PP AR-a. more than 
rosiglitazone (van Wijk et al, 2003). As previously discussed there was no reduction in 
triglyceride in pioglitazone treated patients. Triglyceride concentration was surprisingly 
low in all three groups but was actually lower in the rosiglitazone group at baseline than 
the other two (median triglyceride at baseline 2.15, 1.61 and 1.38trunol/l for placebo, 
pioglitazone and rosiglitazone respectively). Despite this VLDL apo B ASR was higher 
in the rosiglitazone group at baseline than the other 2 groups, (median VLDL apo B 
153 
ASR at baseline 8.56, 5.19 and 10.04 mg/kg/day for placebo, pioglitazone and 
rosiglitazone respectively). There was a significant difference between these values at 
baseline (p = 0.04). Therefore this may partly explain why a significant change was seen 
in the rosiglitazone group but not the pioglitazone group. The values for VLDL apo B 
ASR obtained in this study were tnuch lower than those seen in previous studies of 
patients with type 2 diabetes. In a study that compared patients with type 2 diabetes with 
controls the mean VLDL apo B ASR in the patients with diabetes was 27.5 mg/kg/day 
and that ofthe controls was 10.7mg/kg/day (much more similar to values in tny study) 
(Cmmnings et al, 1995b). This suggests that in general subjects in my study did not have 
the lipid abnonnalities characterised by an over-secretion of VLDL typically seen in 
patients with type 2 diabetes. Therefore it was hardly surprising that there was not the 
change expected fo Bowing TZD treatment. 
Looking at individual subjects some did have VLDL apo B ASR more in keeping with 
other patients with type 2 diabetes. For example there was one subject in the 
pioglitazone group who had a baseline ASR greater than 10 mg/kg/day, and their ASR 
reduced fi:om 15.1 to 10.7 mg/kg/day following treatment. All subjects in the 
rosiglitazone group had a reduction in ASR following treatment except for one who had 
the lowest starting ASR at 5.2 mg/kg/day. The biggest reduction was seen in the subject 
with the highest initial ASR (from 14.4 to 8.9 mg/kg/day). The other striking thing is 
that there is a large variation in ASR between subjects and even if ASR changes 
following treatment it stays within a relatively narrow range. This is a standard finding 
in studies of this type and is an illustration of why it is itnportant to have paired data. 
Despite a significant reduction in FFAs in both the rosiglitazone and pioglitazone groups 
only the rosiglitazone group had a significant reduction in VLDL apo B 100 ASR. This 
suggests that FF A concentration and FF A flux to the liver is not the main factor 
regulating VLDL apo B 100 secretion :fi·onl the liver. This finding is in agreement with 
those of other studies where acute fluctuations in FFAs were not followed by changes in 
VLDL apo B100 secretion (Maln1strom et al, 1998). These authors suppressed FFAs 
using an anti-lipolytic agent, acipitnox and compared the effect of this ·to the effect of 
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using insulin. Insulin led to a greater reduction in VLDL apo B 100 ASR despite a 
similar reduction in FFAs leading to the conclusion that insulin may have a direct effect 
on VLDL apo B ASR. However this study could be criticised for using acipimox which 
is not an ideal way of lowering FF As with other potential effects on lipids. In our study 
although TZDs obviously also have other wide-ranging effects on metabolism these 
were relatively snnilar between the two groups as was the reduction in FF As. Therefore 
this study adds to the evidence of a lack of regulation of VLDL apo B ASR by FF As 
using an alternative methodology. 
Subjects in both the rosiglitazone and pioglitazone group had a significant reduction in 
HbA1c. Neither active treatment group had a significant change in fasting glucose or 
insulin concentrations. However the decrease in fasting glucose and fasting insulin seen 
in the rosiglitazone group ahnost reached statistical significance (p = 0.06). In addition 
the reduction in the insulin resistance index of the HOMA2 almost reached statistical 
significance. Perhaps if the study had been slightly larger then these figures would have 
reached statistical significance. Therefore it can be postulated that the reduction in 
VLDL apo B ASR in the rosiglitazone group may be related to an hnprovement in 
insulin sensitivity. 
This would fit with the theory that some of the increase in VLDL apo B100 secretion 
seen in type 2 diabetes is because of chronic insulin resistance causing resistance to the 
normal effects of insulin to suppress VLDL apo B100 secretion. The improvement n1 
insulin sensitivity seen with rosiglitazone treatment therefore led to hnproved 
responsiveness to the normal suppressive effects on insulin on VLDL apo B 100 
secretion. Taskinen (Taskinen, 2003) reviews possible mechanisms whereby insulin 1nay 
affect VLDL apo BlOO secretion. She believes that the assembly ofVLDL particles in 
the liver takes place in 2 distinct stages. The ftrst stage involves the lipidation of apo B 
catalysed by MTP. In the second stage the majority of lipid is h1corporated into the 
particles to form VLDL. This is driven by ADP ribosylation factor-1 (ARF-1) which 
activates phospholipase D (PLD). This activation is linked to intracellular insulin 
signalling. PI-3 kinase, (pa11 of the intracellular insulin signalling cascade) indirectly 
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prevents the activation of PLD which is necessary for the formation of VLDL. Hence 
insulin has an inhibitory effect on VLDL production and secretion. In contrast in insulin 
resistant states there is defective PI -3, hence activation of PLD and increased VLDL 
production. 
Why was there an apparent more marked improvement in insulin sensitivity in the 
rosiglitazone group? The group itself had a better starting HbA1 c than the pioglitazone 
group (1nean 6.94 compared to 7.52% in the pioglitazone group) and was a tnore 
sensitive group. Therefore if anything we would have expected this group to respond 
less than the pioglitazone group. 
One possibility is that the sex distribution between the groups may have played a role. 
There were 4 wmnen in the rosiglitazone group but only 1 in the placebo and 
pioglitazone group. Wmnen have been found to respond better to TZDs than men and it 
is hypothesised that this· tnay be because they have more subcutaneous fat. Interestingly 
in a recent Japanese study wmnen were given 15mg of pioglitazone and men 30mg 
following advice frmn Takeda Chemical Industries, Osaka, Japan as 15mg per day has 
been found to give the satne reduction in HbAlc in Japanese wmnen as 30mg per day in 
tnen (Nagasaka et al, 2004). Therefore the chance randomisation of 4 women in the 
rosiglitazone group may have led to a greater effect on insulin resistance and ASR of 
VLDL apo B in this group. 
Is rosiglitazone more potent drug at this dose i.e. is 8mg rosiglitazone tnore potent than 
30mg pioglitazone? When this study was statted the maximum dose of pioglitazone in 
the UK was 30mg, since then it has been increased to 45mg, could it be that this is more 
equipotent with rosiglitazone 8mg? There is sotne evidence for this, rosiglitazone has 
been found to have a greater PP AR-y binding activity than troglitazone and pioglitazone 
(Adatns et al, 1997; van Wijk et al, 2003). This translates to a clinical dose that is one 
sixth of the pioglitazone dose, hence 8tng of rosiglitazone is equivalent to 45mg 
pioglitazone. However other authors believe that the effect ofpioglitazone on lipids is as 
tnarked at 30mg as at 45mg (Nagashitna et al, 2004). 
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Another possible explanation for the lack of changes in lipid variables is that there is 
evidence that differential responses to TZDs tnay be individually determined. In a study 
designed to see iftroglitazone could prevent high risk women with a previous history of 
gestational diabetes tnellitus fi·otn the development of type 2 diabetes (Buchanan et al, 
2002) one third of wotnen failed to increase insulin sensitivity in response to 
troglitazone. The non-responders had no baseline characteristics by which they could be 
distit1guished from the responders such as weight, BMI or fasting glucose, and there was 
no evidence to suggest non-compliance was an issue. The authors speculate that 
differences in drug metabolism, PPAR-y or the aetiology of insulin resistance may 
account for these fmdings. 
Interestingly a consistent finding in both ofthe active treatment groups was a significant 
reduction in VLDL triglyceride/ape B. This suggests that there was a reduction in the 
VLDL particle size (i.e. the amount of VLDL triglyceride per apo B I 00 particle). As 
discussed in the introduction the increased triglyceride concentration seen in diabetic 
dyslipidaemia is secondary to an increase in large VLDL. Although the change in apo B 
and VLDL triglyceride concentration with rosiglitazone and pioglitazone was not 
significant, the change in the ratio of the 2 was. There is evidence of sitnilar changes in 
animals treated with TZDs. In primary .rat hepatocytes a PPAR-a agonist decreased the 
synthesis and secretion of triglycerides and increased apo B 100 synthesis resulting in the 
formation of more apo B 100 particles containing less triglyceride, i.e. a shift frmn large 
VLDL to smaller VLDL particles (Linden et al, 2002). Further work by this group has 
found that the PP AR-a agonist increased MTP expression and activity in rats and this 
was paralleled by a change in apo B 100 secretion (Ameen et ｡ｾ＠ 2005). This is in 
contrast to studies in hamsters which found a decrease in MTP expression following 
treatment with rosiglitazone (Carpentier et al, 2002). 
In addition there was a significant it1crease in LDL cholesteroV apo B ratio in the 
rosiglitazone group suggesting an increase in LDL cholesterol particle size. This was 
confirmed by the LDL subfi·action results. These showed a significant increase in LDL2 
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cholesterol and apo B concentration following treatment in the rosiglitazone group. This 
was accompanied by a significant reduction in small dense LDL3 cholesterol 
concentration. The reduction in LDL3 apo B concentration did not reach statistical 
significance (p = 0.06). The change in LDL3 apo B was significantly different across the 
groups (p = 0.02) and this was because of a significant difference in the rosiglitazone 
and pioglitazone group. Interestingly in the pioglitazone group there was a (non-
significant) rise in LDL3 apo B concentration. As discussed earlier small dense LDL is 
more atherogenic and associated with diabetic dyslipidaemia. According to the 
hypothesis of Packard, (Packard et al, 2000) small dense LDL is fanned if LDL has a 
residence time of greater than 3 days and is exposed to high levels of VLDL triglyceride. 
The mean residence time ofLDL (the inverse of the FCR) at baseline for subjects in this 
study was 3.85, 5.56 and 3.26 days for the placebo, pioglitazone and rosiglitazone 
groups respectively. These residence times suggest the fonnation of s1nall dense LDL in 
all subject groups. 
One study has compared the effect of pioglitazone, 1netformin and gliclazide on LDL 
subfractions in patients with type 2 diabetes (Lawrence et al, 2004). This open trial 
found a significant reduction in the LDL3 mass in both the tnetfonnin and the 
pioglitazone treated groups. Previous work has shown sitnilar results with troglitazone 
(van Wijk et al, 2003). Data on the effect of rosiglitazone on LDL subfractions in 
humans has not been published. 
The reduction in small LDL seen with rosiglitazone in this work has been seen in animal 
tnodels of insulin resistance (Lewis et al, 2004). Following 5 weeks of rosiglitazone 
treatment, insulin resistant, fi·uctose fed Syrian Golden Hatnsters had a significant 
reduction in stnall LDL. This was postulated to be due to partial normalisation of the 
elevated hepatic lipase activity seen in insulin resistant animals. The fmding in the 
cw-rent study of an increase in LDL2 and a decrease in LDL3 with rosiglitazone but not 
with pio_glitazone is interesting. It may reflect the fact, as seen in the ｳｹｳｾ･ｭ｡ｴｩ｣＠ review, 
that rosiglitazone has a tendency to increase LDL cholesterol whereas pioglitazone does 
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not. This increase in LDL cholesterol may be due to an increase in large buoyant LDL2 
and a decrease in small dense LDL3. 
The increase in LDL cholesterol, presumed secondary to the decrease in FCR in the 
placebo group is interesting. This tnay reflect seasonal change in cholesterol 
concentrations, or the (non-significant) deterioration in glycaemic control seen in this 
group manifest as increasing insulin, glucose and HbAl c concentration as well as the 
significant increase inC-peptide over the 3 tnonth study period. 
To conclude, despite a sitnilar reduction in FF As in both active treattnent groups only 
the rosiglitazone group had a reduction in VLDL apo B ASR. This may be a reflection 
of the higher baseline ASR in the rosiglitazone group or the 1nore marked improvement 
in insulin sensitivity. Possible explanations for the improvetnent in insulin sensitivity 
with rosiglitazone but not pioglitazone are that the dose of rosiglitazone given was tnore 
effective than the dose of pioglitazone or that characteristics of the rosiglitazone group 
led them to respond better to treatment. The current study provides evidence that 
circulating FF A concentration is not the main regulator of VLDL apo B ASR secretion 
and that insulin concentration or insulin sensitivity has an essential role. In addition both 
TZDs seem to reduce the size of VLDL particles that are secreted which may be 
important in reducing atherogenic risk. 
Both active treatment groups had a tnarked increase in adiponectin concentration. This is 
consistent with the work of other authors (Bajaj et al, 2004; Nagashin1a et al, 2005). 
Adiponectin secretion by adipocytes is increased by TZDs and this is thought to be 
tnediated by activation of the adiponectin promoter by PPAR-y (Bajaj et al, 2004). 
Recently published work (Ng et al, 2005) has exatnined the relationship between 
adiponectin, VLDL apo B kinetics and insulin resistance. Adiponectin concentration was 
negatively correlated with insulin concentration and HOMA score. Conversely there was 
a positive correlation between adiponectin and VLDL apo B FCR. In addition 
adiponectin concentration was found to be a predictor ofVLDL apo B concentration and 
HOMA to be a predictor of hepatic VLDL apo B ASR. In the current study (as in the 
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work of Ng, (Ng et al, 2005)) baseline adiponectin concentration was inversely 
con·elated with HOMA-IR index and HOMA-IR index was positively correlated with 
VLDL apo B ASR. However in the current work no relationship between adiponectin 
and VLDL apo B FeR was demonstrated. 
Comparison with other similar work 
There are 2 similar studies investigating the effect of TZDs on lipoprotein turnover in 
humans with type 2 diabetes. The first (Nagashima et al, 2004; Nagashima et al, 2005) 
treated 8 subjects with 30-45Ing of pioglitazone for 12-14 weeks and used stable 
isotopes of leucine and phenylalanine to estiinate VLDL and LDL apo B production and 
catabolic rate and glycerol to measure VLDL triglyceride production and clearance rate. 
A significant decrease in FFAs and increase in adiponectin following pioglitazone 
treatment was found. In addition a reduction in VLDL triglyceride but no change in 
VLDL apo B was seen. This was due to an increase in the FeR ofVLDL triglyceride, 
there was no change in VLDL triglyceride ASR or VLDL apo B ASR. There was no 
effect on LDL ASR or FeR. This study did not have a control group, was single blinded 
and additionally subjects' dose of sulphonylurea was reduced during the pioglitazone 
treatment period to try and mamtain HbAI c. Obviously reducing the dose of 
sulphonylurea may have affected the results and as there was no placebo group it is 
impossible to be sure that the effects seen were due to TZD treatment. The authors 
suggest that the increase in VLDL triglyceride FeR seen may represent increased LPL 
activity, and provide smne evidence for this, LPL mass increased significantly followii1g 
TZD treatment. There was also a significant reduction in apo ern levels in plas1na 
following pioglitazone therapy. Apo ern inhibits LPL-mediated lipolysis of VLDL 
triglyceride. Further stable isotope studies revealed that this was due to a decrease in 
production of this protein. 
In the second study (Robinson et al, 2004) 24 subjects were randomised to receive 8 
weeks oftreatment with placebo, troglitazone 200mg per day or troglitazone 600mg per 
day. They measured VLDL secretion using 1-13e leucine infusion and also assessed 
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glycerol turnover on a separate occasion using 1,2,3-21-l glycerol infusion before and 
after treatment. They found a significant reduction in FFAs with troglitazone but no 
other effect on lipid parameters. With respect to VLDL apo B ASR they found a 
decrease from 22.56mg/kg/day to 9.6mg/kg/day with 600mg troglitazone which just 
failed to reach statistical significance (note the baseline value of VLDL apo B ASR is 
much higher than subjects in the current study). Interestingly subjects in the troglitazone 
600mg group had an increase in the VLDL triglyceride/apo B ratio, the opposite of what 
was found in the present study, and this was mainly due to a reduction in apo B. There 
are a number of proble1ns with this study, frrstly 8 weeks of treatment is probably not 
enough to see the full effect of TZDs on lipids, secondly 200mg of troglitazone is a low 
dose and effects on lipids 1nay not be expected at this dose and lastly by chance subjects 
in the 600mg of troglitazone group had a n1uch lower median triglyceride concentration 
at baseline than the other 2 groups (median triglyceride concentrations 2.1, 2.6 and 
1.3mmoVl in the placebo, 200mg troglitazone and 600mg troglitazone groups 
respectively). The authors do not state whether this difference achieved statistical 
significance. 
Comparing the results of the current study with these 2, neither it or the frrst study 
(Nagashhna et al, 2004; Nagashima et al, 2005) found an effect of pioglitazone on 
VLDL apo B ASR. However Nagashhna et al did find a reduction in triglyceride 
concentration with pioglitazone, an increase in VLDL triglyceride FCR and a trend 
towards an increase in VLDL apo B FCR (p = 0.052). There is some evidence from the 
second study (Robinson et al, 2004) that troglitazone may have a similar effect to 
rosiglitazone causing a decrease in VLDL apo B ASR but troglitazone had opposite 
effects on VLDL particle size to rosiglitazone and pioglitazone in the current study. A 
comparison of the results of these 3 studies is summarised in Table 36. 
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Table 36 Summary of studies on the effect ofTZDs on VLDL apo B metabolism 
Brackenridge Placebo 8.56 8.21 5.78 5.63 
Pioglitazone 30mg 5.19 6.64 4.09 4.29 
Rosiglitazone 8mg 10.04 7.86a 9.12 7.13 
Nagashima Pioglitazone 30- 29.8 32.6 3.92 4.53b 45mg 
Robinson Placebo 23.8 18.5 6.38 7.06 
Troglitazone 200mg 22.1 19.0 6.31 5.74 
Troglitazone 600mg 22.6 9.6c 9.17 5.78 
a p = 0.02, b p = 0.052, c p = 0.056 
The findings in the current study of reduced VLDL apo B ASR following treatment with 
rosiglitazone is in keeping with the results of another study performed in a hamster 
model of insulin resistance (Carpentier et al, 2002). This group used radiolabelled 
isotope (Triton WR-1339) to measure VLDL secretion rate and [2-3H]glycerol to 
measure clearance rates and found that rosiglitazone reduced secretion rate with no 
effect on clearance. Rosiglitazone was also associated with reduced expression of MTP. 
In contrast, a study in obese Zucker rats found an increase in triglyceride clearance rate 
but no reduction in secretion rate following treatment with rosiglitazone, however higher 
doses of rosiglitazone and treatment with a more potent TZD caused reductions in 
hepatic triglyceride secretion too (Oakes et al, 2001). When extrapolating these results to 
humans one must remember that rats have important differences in lipid metabolism, 
namely they secrete apo B48 and 1 00 from the liver and also impaired triglyceride 
clearance is the major mechanism accounting for their increased triglyceride levels 
rather than the increase in secretion seen in humans. However these studies in animal 
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models of insulin resistance seem to suppmt the action of rosiglitazone to reduce VLDL 
apoBASR. 
The effect of TZDs on lipoprotein metabolism can be compared with the effect of other 
interventions in subjects with type 2 diabetes and insulin resistance. Watts et al (Watts et 
al, 2003) con1pared the effect of statins and fibrates on lipoprotein 1netabolism in 11 
dyslipidaemic men with the metabolic syndrmne. Both atorvastatin and fenofibrate 
increased the FCR of VLDL, IDL and LDL apo B but had no effect on ASR. They 
suggest that the effect of fibrates may reflect hepatic activation of PP AR-a which 
increases expression ofLPL and decreases hepatic apo CIII synthesis. Another study has 
shown that following a 6 n1onth exercise program subjects with type 2 diabetes had a 
significant reduction in ASR of VLDL apo B (Almn et al, 2004). A significant 
improvement in insulin resistance as n1easured by HOMA was also found. There was no 
change in FCR ofVLDL apo B. 
In summary studies have found that TZDs can have different effects on lipoprotein 
metabolism. They can reduce hepatic VLDL apo B secretion possibly due to 
hnprovements in insulin sensitivity as demonstrated in the present work. In addition they 
may have a PP AR-a like action to increase VLDL triglyceride FCR possibly by 
increash1g LPL activity as seen in the study of Nagashima (Nagashima et al, 2004; 
Nagashima et al, 2005). This may not have occurred in the cunent work because there 
was no significant effect on baseline lipids and also VLDL apo B was studied rather than 
VLDL triglyceride. 
Problems with the study 
Some of the proble1ns with the study have already been alluded to. These include the 
excellent glycae1nic control and lack of dyslipidae1nia of participants at baseline. 
However as previously discussed there was no way of resolving these issues without 
jeopardising the study (by lack of recruitment) or without risking adversely affecting the 
health of subjects. 
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The tnethodology itself is a well-tested teclmique and there were few probletns 
associated with its use. Other investigators use glycerol to label triglyceride in addition 
to leucine to trace apo BlOO (Taskinen, 2003). However in general there has been good 
agreetnent between the rates of VLDL secretion calculated by these 2 tnethods. VLDL 
triglyceride/apo B ratio decreased significantly in the pioglitazone and the rosiglitazone 
group suggesting that VLDL particle size may have decreased. Because VLDLl and 
VLDL2 subclasses were not tneasured it is possible that a differential effect of the TZDs 
on VLDLl and VLDL2 production was missed. A problen1 that was encountered was 
with the modelling of the IDL data. Because the enrichment of IDL is very low the 
software used for the modelling can occasionally have difficulty with curve-fitting. This 
occurred for 2 studies (for subjects 2 and 5). Because data was analysed as paired studies 
this meant that their IDL data had to be discounted. 
Directions for future research 
The TZDs have wide-ranging effects on adipose tissue. With the current interest in 
adipose tissue as an endocrine organ and its role in insulin resistance this is the subject 
of 1nuch ongoing research. In addition the effect of TZDs on non-traditional 
cardiovascular risk factors is an area generating much excitetnent. Large studies are 
underway to investigate the possibility of a reduction in vascular morbidity and 
mortality following treatinent with TZDs (Charbonnel et al, 2004). However stnall 
studies such as this one can help us to elucidate mechanisms. 
Although we failed to demonstrate a reduction in traditional lipid parameters the 
reduction in VLDL triglyceride/apo B ratio with both TZDs and the change in LDL 
subfractions seen with rosiglitazone suggests that these drugs may be having subtle but 
itnpmtant effects which 1nay ultitnately be important in reducing cardiovascular risk. 
There is an increasing recognition that in type 2 diabetes there is over-secretion of large 
buoyant VLDLI which is linked to the dyslipidaemia of diabetes. The fact that both 
TZDs reduce VLDL particle size without significantly reducing triglyceride 
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concentration suggests that they n1ay be preferentially reducing the secretion ofVLDLl. 
This is an intriguing possibility that deserves further investigation. 
Another interesting area of research is the effect on liver fat of TZDs. It has been shown 
that pioglitazone reduces liver fat and this reduction is strongly correlated with an 
increase in adiponectin and improvement in hepatic and peripheral insulin sensitivity 
(Bajaj et al, 2004). Whether these changes are also associated with changes in VLDL 
secretion and if the effects of rosiglitazone are similar are further questions to be 
answered. The 2 studies by Bajaj in this area (Bajaj et al, 2003; Bajaj et al, 2004) did not 
use a control group for which they may be criticised. However an advantage of this 
approach is that if there is no placebo group then all the subjects recruited will receive 
active treattnent and therefore it means that subjects with higher HbAl c and 
dyslipidaemia can be recruited. It is then more likely that the study will find significant 
effects on these parameters. Another option is to use an active treatment as a control and 
this 1nethodology is being used in smaller studies looking at the mechanism behind the 
actions of TZDs. For instance pioglitazone has been compared with gliclazide and 
metfonnin in a study looking at their effect on lipoprotein subfractions (Lawrence et al, 
2004) and rosiglitazone has been compared with metformin in a study looking at liver 
fat content (Tiikkainen et al, 2004). 
Conclusions 
In conclusion this is the first time the 2 commercially available TZDs have been 
compared in a double-blinded placebo controlled study in patients with type 2 diabetes. 
The subjects in this study had better glycaetnic control and less dyslipidaemia than those 
in previous studies of TZDs. However it can be argued that since the importance of 
treating dyslipidaemia has been realised they were more reflective of patients seen today 
in clinic. Both drugs caused a significant reduction in HbAlc and FF As and a marked 
increase in adiponectin. However the effect on other lipid parameters was less than 
expected. Despite this we found a significant reduction in the secretion rate of VLDL 
apo B by the liver with rosiglitazone. This is the first thne this has been shown in 
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humans and is in agreement with the work of researchers using animal n1odels of insulin 
resistance. This differential effect 1nay reflect the improvetnents in insulin resistance 
seen in the rosiglitazone treated group. Both pioglitazone and rosiglitazone reduced 
VLDL particle size and rosiglitazone reduced LDL3 cholesterol and increased LDL2 
cholesterol which raises the intriguing possibility that they may reduce atherogenic risk. 
Much research is currently centred on treatment of the insulin resistance syndrome and 
non traditional cardiovascular risk factors. This work has suggested further lines of 
research particularly studying the effects of TZDs on hepatic. secretion of VLDLl and 
VLDL2. 
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